

# HEDIS<sup>®</sup> Measurement Year 2023 Aggregate Report *for* Child Health Plan *Plus*

February 2025

This report was produced by Health Services Advisory Group, Inc., for the Colorado Department of Health Care Policy & Financing





# **Table of Contents**

| 1. | Executive Summary  | 1-1  |
|----|--|------|
|    | Summary of Performance   | 1-1  |
|    | Limitations and Considerations   | 1-2  |
| 2. | Reader's Guide   |      |
| _• | Introduction   |      |
|    | CHP+ Health Plan Names   |      |
|    | Summary of MY 2023 Measures  |      |
|    | Data Collection Method   |      |
|    | Data Sources and Measure Audit Results   | 2-4  |
|    | Calculation of Statewide Averages  |      |
|    | Evaluating Measure Results   |      |
|    | National Benchmark Comparisons   | 2-5  |
|    | Trend Analysis   |      |
|    | Measure Changes Between CMS Core Set FFY 2023 and CMS Core Set FFY 2024              |      |
|    | Glossary   | 2-14 |
| 3. | Primary Care Access and Preventive Care  |      |
|    | Primary Care Access and Preventive Care  |      |
|    | Child and Adolescent Well-Care Visits—Total  | 3-2  |
|    | Childhood Immunization Status  | 3-3  |
|    | Chlamydia Screening in Women—16 to 20 Years  | 3-7  |
|    | Developmental Screening in the First Three Years of Life-Total                       | 3-8  |
|    | Immunizations for Adolescents—Combination 1  |      |
|    | Immunizations for Adolescents—Combination 2  | 3-10 |
|    | Lead Screening in Children   | 3-11 |
|    | Weight Assessment and Counseling for Nutrition and Physical Activity for             |      |
|    | Children/Adolescents— BMI Percentile—Total   | 3-12 |
|    | Weight Assessment and Counseling for Nutrition and Physical Activity for             |      |
|    | Children/Adolescents—Counseling for Nutrition—Total                                  | 3-13 |
|    | Weight Assessment and Counseling for Nutrition and Physical Activity for             |      |
|    | Children/Adolescents—Counseling for Physical Activity—Total                          | 3-14 |
|    | Well-Child Visits in the First 30 Months of Life—Well-Child Visits in the First 15   | 2.15 |
|    |  | 3-15 |
|    | Well-Child Visits in the First 30 Months of Life—Well-Child Visits for Age 15 Months | 2.10 |
|    | to 30 Months—Two or More Well-Child Visits   |      |
|    | Summary of Findings and Recommendations  |      |
| 4. | Maternal and Perinatal Health  |      |
|    | Maternal and Perinatal Health  |      |
|    | Contraceptive Care—All Women—MMEC—15 to 20 Years                                     |      |
|    | Contraceptive Care—All Women—LARC—15 to 20 Years                                     | 4-3  |



|    | Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—3 Days                         | 4-4         |
|----|--|-------------|
|    | Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—90 Days                        | 4-5         |
|    | Contraceptive Care—Postpartum Women—LARC—15 to 20 Years—3 Days                         |             |
|    | Contraceptive Care—Postpartum Women—LARC—15 to 20 Years—90 Days                        | 4-7         |
|    | Prenatal and Postpartum Care—Timeliness of Prenatal Care—Under Age 21                  | 4-8         |
|    | Prenatal and Postpartum Care—Postpartum Care—Under Age 21                              | 4-9         |
|    | Summary of Findings and Recommendations  | 4-10        |
| 5. | Care of Acute and Chronic Conditions   | 5-1         |
|    | Care of Acute and Chronic Conditions   | 5-1         |
|    | Asthma Medication Ratio—5 to 18 Years  |             |
|    | Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis-3 Months to 17 Ye | ears.5-3    |
|    | Summary of Findings and Recommendations  | 5-4         |
| 6. | Behavioral Health Care   | 6-1         |
|    | Behavioral Health Care   | 6-1         |
|    | Follow-Up After Emergency Department Visit for Mental Illness—7-Day Follow-Up—         |             |
|    | 6 to 17 Years  | 6-2         |
|    | Follow-Up After Emergency Department Visit for Mental Illness—30-Day Follow-Up—        |             |
|    | 6 to 17 Years  | 6-3         |
|    | Follow-Up After Emergency Department Visit for Substance Use—7-Day Follow-Up—          |             |
|    | 13 to 17 Years   | 6-4         |
|    | Follow-Up After Emergency Department Visit for Substance Use—30-Day Follow-Up—         |             |
|    | 13 to 17 Years   |             |
|    | Follow-Up After Hospitalization for Mental Illness—7-Day Follow-Up—6 to 17 Years       |             |
|    | Follow-Up After Hospitalization for Mental Illness—30-Day Follow-Up—6 to 17 Years      |             |
|    | Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase                | 6-8         |
|    | Follow-Up Care for Children Prescribed ADHD Medication—Continuation and                |             |
|    | Maintenance Phase  | 6-9         |
|    | Metabolic Monitoring for Children and Adolescents on Antipsychotics-                   |             |
|    | Blood Glucose Testing—Total  | 6-10        |
|    | Metabolic Monitoring for Children and Adolescents on Antipsychotics—                   | <i>(</i> 11 |
|    | Cholesterol Testing—Total  | 6-11        |
|    | Metabolic Monitoring for Children and Adolescents on Antipsychotics—                   | ( 10        |
|    | Blood Glucose and Cholesterol Testing—Total  |             |
|    | Screening for Depression and Follow-Up Plan—12 to 17 Years                             |             |
|    | Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Tot |             |
|    | Summary of Findings and Recommendations  |             |
| 7. | Use of Services  |             |
|    | Use of Services  |             |
|    | Ambulatory Care: ED Visits   |             |
|    | Summary of Findings and Recommendations  | 7-2         |
| 8. | Dental and Oral Health Services  |             |
|    | Dental and Oral Health Services  | 8-1         |



| Oral Evaluation, Dental Services—<1 Year  | 8-2   |
|---|---|
| Oral Evaluation, Dental Services—1 to 2 Years   | 8-3   |
| Oral Evaluation, Dental Services—3 to 5 Years   | 8-4   |
| Oral Evaluation, Dental Services—6 to 7 Years   | 8-5   |
| Oral Evaluation, Dental Services—8 to 9 Years   | 8-6   |
| Oral Evaluation, Dental Services—10 to 11 Years   | 8-7   |
| Oral Evaluation, Dental Services—12 to 14 Years   | 8-8   |
| Oral Evaluation, Dental Services—15 to 18 Years   | 8-9   |
| Oral Evaluation, Dental Services—19 to 20 Years   | 8-10  |
| Oral Evaluation, Dental Services—Total  | 8-11  |
| Sealant Receipt on Permanent First Molars—At Least One Sealant  | 8-12  |
| Sealant Receipt on Permanent First Molars—All Four Molars Sealed  | 8-13  |
| Topical Fluoride for Children—Dental Services—1 to 2 Years  | 8-14  |
| Topical Fluoride for Children—Dental Services—3 to 5 Years  | 8-15  |
| Topical Fluoride for Children—Dental Services—6 to 7 Years  | 8-16  |
| Topical Fluoride for Children—Dental Services—8 to 9 Years  | 8-17  |
| Topical Fluoride for Children—Dental Services—10 to 11 Years  |   |
| Topical Fluoride for Children—Dental Services—12 to 14 Years  | 8-19  |
| Topical Fluoride for Children—Dental Services—15 to 18 Years  | 8-20  |
| Topical Fluoride for Children—Dental Services—19 to 20 Years  | 8-21  |
| Topical Fluoride for Children—Dental Services—Total   | 8-22  |
| Summary of Findings and Recommendations   | 8-23  |
| Appendix A. Tabular Results for Measures by Health Plan   | A-1   |
| Primary Care Access and Preventive Care Measure Results   | A-1   |
| Maternal and Perinatal Health Performance Measure Results   | A-11  |
| Care of Acute and Chronic Conditions Performance Measure Results  | A-13  |
| Behavioral Health Care Performance Measure Results  | A-15  |
| Benavioral meanin Care remonnance measure Results   |   |
| Use of Services Measure Results   | A-20  |
| Use of Services Measure Results   |   |
|   | B-1   |
| Use of Services Measure Results<br>Appendix B. Trend Tables   | <b> B-1</b><br>B-1                                      |
| Use of Services Measure Results<br>Appendix B. Trend Tables<br>COA Trend Table  | <b>B-1</b><br>B-5                                       |
| Use of Services Measure Results<br>Appendix B. Trend Tables<br>COA Trend Table<br>DHMP Trend Table  | <b>B-1</b><br>B-1<br>B-5<br>B-8                         |
| Use of Services Measure Results<br>Appendix B. Trend Tables<br>COA Trend Table<br>DHMP Trend Table<br>Kaiser Trend Table  | <b>B-1</b><br>B-1<br>B-5<br>B-8<br>B-12                 |
| Use of Services Measure Results<br>Appendix B. Trend Tables<br>COA Trend Table<br>DHMP Trend Table<br>Kaiser Trend Table<br>RMHP Trend Table  | <b>B-1</b><br>B-1<br>B-5<br>B-8<br>B-12<br>B-15         |
| Use of Services Measure Results<br>Appendix B. Trend Tables<br>COA Trend Table<br>DHMP Trend Table<br>Kaiser Trend Table<br>RMHP Trend Table<br>DentaQuest Trend Table  | <b>B-1</b><br>B-1<br>B-5<br>B-8<br>B-12<br>B-15<br>B-16 |
| Use of Services Measure Results<br>Appendix B. Trend Tables<br>COA Trend Table<br>DHMP Trend Table<br>Kaiser Trend Table<br>RMHP Trend Table<br>DentaQuest Trend Table<br>Colorado CHP+ Weighted Averages Trend Table | B-1<br>B-1<br>B-5<br>B-8<br>B-12<br>B-15<br>B-16<br>C-1 |



## **1. Executive Summary**

The Child Health Plan *Plus* (CHP+) program is administered by Colorado's Department of Health Care Policy & Financing (the Department). Colorado's four CHP+ managed care organizations (MCOs) in fiscal year (FY) 2023–2024 included Colorado Access (COA), Denver Health Medical Plan (DHMP), Kaiser Permanente Colorado (Kaiser), and Rocky Mountain Health Plans (RMHP). DentaQuest is the Colorado dental program and provides dental benefits to pregnant woman and children enrolled in the CHP+ program.

In FY 2023–2024, each CHP+ health plan underwent a National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS<sup>®</sup>)<sup>1</sup> Compliance Audit<sup>TM,2</sup> through a licensed HEDIS audit organization in order to verify the processes used to report valid HEDIS rates. All CHP+ health plans submitted final measure rates and audit results to Health Services Advisory Group, Inc. (HSAG), the Department's external quality review organization (EQRO). HSAG examined the measures among the following domains of care: Primary Care Access and Preventive Care, Maternal and Perinatal Health, Care of Acute and Chronic Conditions, Behavioral Health Care, Use of Services, and Dental and Oral Health Services. Please see Appendix C for additional information on NCQA's Information Systems (IS) standards<sup>3</sup> and the audit findings for the CHP+ health plans. This report documents the results of HSAG's analysis and recommendations for improvement, where appropriate.

# **Summary of Performance**

Figure 1-1 shows the Colorado CHP+ program's performance on the measurement year (MY) 2023 performance measure indicators that were comparable to NCQA's Quality Compass<sup>®,4</sup> national Medicaid health maintenance organization (HMO) percentiles for HEDIS MY 2022 (referred to throughout this report as percentiles). The bars represent the number of CHP+ statewide weighted averages that fell into each national Medicaid percentile range. The percentile range shows how the CHP+ statewide weighted average ranked nationally. Measures under the Use of Services domain are considered utilization-based measures rather than performance measures; therefore, they are not included in this figure.

<sup>&</sup>lt;sup>1</sup> HEDIS<sup>®</sup> is a registered trademark of the NCQA.

<sup>&</sup>lt;sup>2</sup> NCQA HEDIS Compliance Audit<sup>TM</sup> is a trademark of the NCQA.

<sup>&</sup>lt;sup>3</sup> National Committee for Quality Assurance. *HEDIS Compliance Audit Standards, Policies and Procedures, Volume 5.* Washington D.C.

<sup>&</sup>lt;sup>4</sup> Quality Compass<sup>®</sup> is a registered trademark of the NCQA.






Figure 1-1—Colorado CHP+ Weighted Averages for HEDIS Measure Comparisons

The Colorado CHP+ weighted averages indicated improved performance statewide compared to national standards, as 11 of 26 (42.31 percent) measure rates fell below the 50th percentile.

# **Limitations and Considerations**

- Since all MY 2023 measures were reported using the administrative methodology according to the Department's direction, the CHP+ health plans that were able to obtain supplemental data or capture more complete data will generally report higher rates when using the administrative methodology. As a result, the rates presented in this report for measures with a hybrid option may be more representative of data completeness rather than a measure of performance.
- National HEDIS percentiles are not available for the Children's Health Insurance Program (CHIP) population; therefore, comparison of the CHP+ MCOs' rates to Medicaid percentiles should be interpreted with caution.



# Introduction

The State of Colorado offers its residents a low-cost health insurance plan for qualified children ages 18 and younger and pregnant women ages 19 and older through its CHP+ program, also known as CHIP. As of the end of FY 2023–2024, Colorado's CHP+ enrollment was 101,943 children and pregnant women. The CHP+ services are coordinated through four MCOs and DentaQuest, a CHP+ prepaid ambulatory health plan (PAHP). Medical services covered by Colorado's CHP+ program include primary care, emergency/urgent care, hospital services, dental care, prescriptions, immunizations, maternity care, and mental/behavioral health care.

To evaluate performance levels and to provide an objective, comparative review of the Colorado CHP+ health plans' quality-of-care outcomes and key performance measure rates, the Department required its health plans to report results following NCQA's HEDIS protocols. The Department selected performance measures from the Centers for Medicare & Medicaid Services (CMS) Child Core Set to evaluate the health plans' performance and for public reporting. For MY 2023, the Department required that the health plans report all measures using the administrative methodology. This report includes rates calculated using only administrative data. Therefore, caution should be exercised when comparing results for measures with a hybrid option to national benchmarks, which were established using administrative and/or medical record review data.

The reader's guide is designed to provide supplemental information to the reader that may aid in the interpretation and use of the results presented in this report.

# **CHP+ Health Plan Names**

Table 2-1 presents the CHP+ health plans discussed within this report and their corresponding abbreviations.

| CHP+ Health Plan Name       | Abbreviation |
|-----------------------------|--------------|
| Colorado Access             | СОА          |
| Denver Health Medical Plan  | DHMP         |
| Kaiser Permanente Colorado  | Kaiser       |
| Rocky Mountain Health Plans | RMHP         |
| DentaQuest                  | DentaQuest   |

#### Table 2-1—MY 2023 CHP+ Health Plan Names and Abbreviations



## Summary of MY 2023 Measures

Within this report, HSAG presents the CHP+ health plans and statewide performance on CMS Core Set measures selected by the Department for MY 2023, which use the Federal Fiscal Year (FFY) 2024 CMS Core Set of Adult and Children's Health Care Quality Measures. The measures selected by the Department were grouped into the following domains of care: Primary Care Access and Preventive Care, Maternal and Perinatal Health, Care of Acute and Chronic Conditions, Behavioral Health Care, Use of Services, and Dental and Oral Health Services. While performance is reported primarily at the measure indicator level, grouping these measures into domains encourages the health plans and the Department to consider the measures as a whole rather than in isolation and to develop the strategic changes required to improve overall performance.

Table 2-2 shows the selected MY 2023 measures and measure indicators that are presented within this report as well as the corresponding domains of care. Additional measure indicator rates are displayed within the appendices for more granular definitions of health plan performance for select measures. For example, the *Total* rates for the *Child and Adolescent Well-Care Visits* measure indicators are displayed in Section 3 and Appendix D of this report to provide an overall understanding of plan and statewide performance associated with child and adolescent well-care visits. *Child and Adolescent Well-Care Visits* rates for *3 to 11 Years*, *12 to 17 Years*, and *18 to 21 Years* are presented along with the *Total* rates in the appendices.

| Performance Measures   |
|--|
| Primary Care Access and Preventive Care  |
| Child and Adolescent Well-Care Visits (WCV-CH)   |
| Childhood Immunization Status—Combinations 3, 7, and 10 (CIS-CH)   |
| Chlamydia Screening in Women—16 to 20 Years (CHL-CH)   |
| Developmental Screening in the First Three Years of Life (DEV-CH)  |
| Immunizations for Adolescents—Combination 1 and Combination 2 (IMA-CH)   |
| Lead Screening in Children (LSC-CH)  |
| Screening for Depression and Follow-Up Plan—12 to 17 Years (CDF-CH)  |
| Weight Assessment and Counseling for Nutrition and Physical Activity for<br>Children/Adolescents—Body Mass Index (BMI) Percentile—Total, Counseling for Nutrition—<br>Total, and Counseling for Physical Activity—Total (WCC-CH) |
| Well-Child Visits in the First 30 Months of Life—Well-Child Visits in the First 15 Months of Life—Six or More Well-Child Visits and Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits (W30-CH)      |



#### Performance Measures

#### **Maternal and Perinatal Health**

Contraceptive Care—All Women—Most or Moderately Effective Contraception (MMEC)—15 to 20 Years and Long-Acting Reversible Contraception (LARC)—15 to 20 Years (CCW-CH)

Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—3 Days and 15 to 20 Years—90 Days, and LARC—15 to 20 Years—3 Days and 15 to 20 Years—90 Days (CCP-CH)

Prenatal and Postpartum Care—Timeliness of Prenatal Care—Under Age 21 and Postpartum Care—Under Age 21 (PPC-CH)

**Care of Acute and Chronic Conditions** 

Asthma Medication Ratio—5 to 18 Years (AMR-CH)

*Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—3 Months to 17 Years (AAB-CH)* 

**Behavioral Health Care** 

*Follow-Up After Emergency Department Visit for Mental Illness*—7-Day Follow-Up—6 to17 Years and 30-Day Follow-Up—6 to17 Years (FUM-CH)

Follow-Up After Emergency Department Visit for Substance Use—7-Day Follow-Up—13 to17 Years and 30-Day Follow-Up—13 to17 Years (FUA-CH)

Follow-Up After Hospitalization for Mental Illness—7-Day Follow-Up—6 to17 Years and 30-Day Follow-Up—6 to17 Years (FUH-CH)

Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication—Initiation Phase and Continuation and Maintenance Phase (ADD-CH)

Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose Testing—Total, Cholesterol Testing—Total, and Blood Glucose and Cholesterol Testing—Total (APM-CH)

*Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total (APP-CH)* 

**Use of Services** 

Ambulatory Care: Emergency Department (ED) Visits (AMB-CH)

**Dental and Oral Health Services** 

Oral Evaluation, Dental Services (OEV-CH)

Topical Fluoride for Children (TFL-CH)

Sealant Receipt on Permanent First Molars (SFM-CH)

Of note, CMS Core Set technical measure descriptions are included throughout this report, which include age requirements for inclusion in the measure. In some instances, the CMS Core Set technical measure definition includes individuals who would not be eligible for the CHP+ program (i.e., some measures apply to adults who are age 18 and older; however, the CHP+ program is limited to individuals



who are in the month of their 19th birthday or younger). Therefore, the measure results actually reflect a more limited age group than the CMS Core Set technical specification definition.

# **Data Collection Method**

According to the Department's guidance, all measure rates presented in this report for the health plans are based on administrative data only. The administrative method requires that the health plans identify the eligible population (i.e., the denominator) using administrative data, derived from claims and encounters. In addition, the numerator(s), or services provided to the members in the eligible population, are derived solely using administrative and supplemental data collected during the reporting year. Supplemental data include immunization registry data, medical record review data from the prior year, etc. Medical records collected during the current year cannot be used to retrieve information. When using the administrative method, the entire eligible population becomes the denominator, and sampling is not allowed. In contrast, the hybrid method extracts a systematic sample of members and utilizes data from the medical record, along with administrative and supplemental data. The hybrid method generally produces higher rates because the completeness of documentation in the medical record exceeds what is typically captured in administrative data; however, the medical record review component of the hybrid method is considered more labor intensive. The data collection or calculation methods (i.e., administrative, hybrid) for each measure are described in detail by CMS in the *FFY 2024 Child Resource Manual and Technical Specifications*.<sup>5</sup>

# **Data Sources and Measure Audit Results**

Health plan-specific performance displayed in this report was based on data elements obtained from the custom rate reporting templates produced by HSAG. Prior to HSAG's receipt of the health plans' custom rate reporting templates, all the health plans were required by the Department to have their MY 2023 results examined and verified through an NCQA HEDIS Compliance Audit.

Through the audit process, each measure indicator rate reported by a health plan was assigned an NCQA-defined audit result. MY 2023 measure indicator rates received one of seven predefined audit results: *Reportable (R), Small Denominator (NA), Biased Rate (BR), No Benefit (NB), Not Required (NQ), Not Reported (NR)*, and *Unaudited (UN)*. The audit results are defined in the Glossary section.

Please see Appendix C for additional information on NCQA's IS standards and the audit findings for the CHP+ health plans.

<sup>&</sup>lt;sup>5</sup> Centers for Medicare & Medicaid Services. FFY 2024 Child Resource Manual and Technical Specifications. Available at: <u>https://www.medicaid.gov/medicaid/quality-of-care/performance-measurement/adult-and-child-health-care-quality-measures/child-core-set-reporting-resources/index.html</u>. Accessed on: Oct 8, 2024.



# **Calculation of Statewide Averages**

To calculate the statewide weighted averages, HSAG collected the audited results, numerator, denominator, rate, audit designation, and eligible population data elements reported in the files submitted by the four CHP+ MCOs for all measures. Given that the MCOs varied in membership size and demographic configuration, the statewide rate for a measure was the average rate weighted by each MCOs' eligible population for the measure. Weighting the rates by the eligible population sizes ensured that the rate for an MCO with 125,000 members, for example, had a greater impact on the overall Colorado CHP+ weighted average rate than the rate for an MCO with only 10,000 members. For the MCOs with rates reported as *NA* due to small denominators, the numerators, denominators, and eligible populations were still included in the calculations of the statewide weighted average. However, MCO rates reported as *BR*, *NB*, *NQ*, *NR*, or *UN* were excluded from the statewide weighted average calculation.

# **Evaluating Measure Results**

#### National Benchmark Comparisons

#### **Benchmark Data**

MY 2023 health plan rates and the statewide weighted average rates were compared to the corresponding national HEDIS benchmarks, where applicable. For comparative purposes, HSAG used the most recent data available from NCQA at the time of the production of this report to evaluate the MY 2023 rates: NCQA's Quality Compass national Medicaid HMO percentiles for HEDIS MY 2022.

For some measures for which lower rates indicate better performance (e.g., *Ambulatory Care—ED Visits*), HSAG inverted the percentiles to be consistently applied to these measures as with the other measures. For example, the 10th percentile (a lower rate) was inverted to become the 90th percentile, indicating better performance.

Since national percentiles are not available specifically for the CHIP population, the CHP+ health plan rates as well as the Colorado CHP+ statewide weighted averages were compared to the national percentiles, which were composed of performance from all Medicaid plans. Therefore, comparisons of Colorado's CHP+ population measure indicator rates to the benchmarks should be interpreted with caution.

Additionally, benchmarking data (i.e., NCQA Quality Compass) are the proprietary intellectual property of NCQA; therefore, this report does not display any actual percentile values. As a result, rate comparisons to benchmarks are illustrated within this report using proxy displays.

#### **Figure Interpretation**

For each performance measure indicator presented in this report, the horizontal bar graph figure positioned on the right side of the page presents each health plan's performance against the HEDIS MY 2022 Quality Compass benchmarks, Colorado CHP+ weighted average (i.e., the bar shaded darker



blue) as well as the 50th percentile (i.e., the bar shaded gray), and the high (i.e., the bar shaded green) and low (i.e., the bar shaded red) performance levels.

For most performance measures, the high-performance level (HPL) corresponds to the 90th percentile and the low performance level (LPL) corresponds to the 25th percentile. For measures in which lower rates indicate better performance, the 10th percentile (rather than the 90th percentile) and the 75th percentile (rather than the 25th percentile) are considered the HPL and LPL, respectively. An example of the horizontal bar graph figure for one measure is shown in Figure 2-1.




Figure 2-1—Sample Horizontal Bar Graph Figure

#### **Percentile Rankings and Star Ratings**

In addition to illustrating health plan-specific and statewide performance via side-by-side comparisons to national percentiles, benchmark comparisons are denoted within this report using the percentile ranking performance levels and star ratings defined in Table 2-3.

| Star Rating | Percentile<br>Ranking | Performance Level   |
|-------------|-----------------------|---|
| ****        | <u>&gt;</u> 90th      | At or above the 90th percentile                               |
| ****        | 75th-89th             | At or above the 75th percentile but below the 90th percentile |
| ***         | 50th-74th             | At or above the 50th percentile but below the 75th percentile |
| **          | 25th-49th             | At or above the 25th percentile but below the 50th percentile |
| *           | 10th-24th             | At or above the 10th percentile but below the 25th percentile |
|             | <10th                 | Below the 10th percentile                                     |

#### Table 2-3—HEDIS Measures Percentile Ranking Performance Levels



Some measures in the Use of Services domain are designed to capture the frequency of services provided. Higher or lower rates in this domain do not necessarily indicate better or worse performance. These rates and the associated percentile rankings are provided for information only.

Of note, health plan-specific and statewide rates were rounded to the second decimal place before performance levels were determined. As HSAG assigned percentile rankings and star ratings, an em dash (—) was presented to indicate when the measure did not have an applicable benchmark; therefore, the performance levels for these measures were not presented in this report.

## **Trend Analysis**

In addition to the percentile ranking and star rating results, HSAG also compared MY 2023 Colorado CHP+ weighted averages and health plan-specific rates to the corresponding MY 2022 rates. HSAG also evaluated the extent of changes observed in the rates between years. Year-over-year performance comparisons are based on the Chi-square test of statistical significance with a p value <0.05. However, caution should be exercised when interpreting results of the significance testing, given that statistically significant changes may not necessarily be clinically significant. To limit the impact of this, a change will not be considered statistically significant unless the change was at least 3 percentage points. Note that statistical testing could not be performed on the utilization-based measures under the Use of Services domain given that variances were not available in the custom reporting templates for HSAG to use for statistical testing.

In general, results from statistical significance testing provide information on whether a change in the rate may suggest improvement or decline in performance. Throughout the report, references to "significant" changes in performance are noted; these instances refer to statistically significant differences between performance from MY 2022 to MY 2023. At the statewide level, if the number of health plans reporting *NR* or *BR* differs vastly from year to year, the statewide performance may not represent all of the contracted health plans, and any changes observed across years may need to take this factor into consideration. Nonetheless, changes (regardless of whether they are significant) could be related to the following factors independent of any effective interventions designed to improve the quality of care:

- Substantial changes in measure specifications where NCQA recommends a break in trending.
- Substantial changes in membership composition within the health plan.

Similarly, caution should be exercised when comparing rates calculated administratively to national benchmarks that were calculated using the hybrid methodology.



#### **Figure Interpretation**

Within Appendix A and Appendix B of this report, performance measure indicator rates and results of significance testing between MY 2022 and MY 2023 are presented in tabular format. MY 2023 rates shaded green with one caret (^) indicate a significant improvement in performance from the previous year. MY 2023 rates shaded red with two carets (^^) indicate a significant decline in performance from the previous year.

For each performance measure indicator presented in this report, the vertical bar graph figure positioned on the left side of the page presents the MY 2021, MY 2022, and MY 2023 Colorado CHP+ weighted averages, with significance testing performed between the MY 2022 and MY 2023 weighted averages. Within these figures, MY 2023 rates with one caret (^) indicate a significant improvement in performance from MY 2022. MY 2023 rates with two carets (^^) indicate a significant decline in performance from MY 2022. An example of the vertical bar graph figure for measure indicators reported is shown in Figure 2-2.




Figure 2-2—Sample Vertical Bar Graph Figure



# Measure Changes Between CMS Core Set FFY 2023 and CMS Core Set FFY 2024

The following is a list of measures with technical specification changes that CMS announced for FFY 2024.<sup>6,7</sup> These changes may have an effect on the MY 2023 rates that are presented in this report. The list of measure changes is presented verbatim, and HSAG only made minor formatting updates.

## **Overall Changes**

- Updated the reporting year to FFY 2024, and data collection time frame to 2023.
- Updated specifications, value set codes, copyright, and table source information to *HEDIS Measurement Year (MY) 2023 Volume 2* for all HEDIS measures.
- Updated specifications, value set codes, and copyright information to correspond to calendar year 2023 for non-HEDIS measures.
- Updated references to exclusions throughout specifications. For HEDIS measures, exclusions are now distinguished by whether supplemental and medical record data may be used to identify them; supplemental and medical record data may be used for "required exclusions" but not "exclusions."
- Updated guidance related to mandatory reporting of the behavioral health measures in the Adult Core Set beginning in FFY 2024.
- Clarified that Child Core Set reporting is mandatory beginning with FFY 2024 reporting and states are required to adhere to technical specifications and reporting guidance issued by CMS.
- Clarified that all measure-eligible beneficiaries must be included in state reporting.
- Clarified that for each Child Core Set measure reported to CMS, states should calculate and report separate rates for the Medicaid population (inclusive of CHIP-funded Medicaid expansion) and the separate CHIP population (for states with a separate CHIP).
- Clarified that a visit results in a stay when the visit date of service occurs on the day prior to the admission date or any time during the admission (admission date through discharge date). This guidance applies to the following HEDIS measures in the Child Core Set: *AAB-CH, ADD-CH, AMB-CH, AMR-CH, CPC-CH, FUA-CH, FUH-CH,* and *FUM-CH*.
- Clarified that beneficiaries who died any time during the measurement year are a required exclusion. This guidance applies to the following HEDIS measures in the Child Core Set: *AAB-CH, ADD-CH, AMR-CH, APM-CH, APP-CH, CHL-CH, CIS-CH, CPC-CH, FUA-CH, FUH-CH, FUM-CH, IMA-CH, LSC-CH, PPC2-CH, SFM-CH, W30-CH, WCC-CH,* and *WCV-CH*.

<sup>&</sup>lt;sup>6</sup> Centers for Medicare & Medicaid Services. *Summary of Updates to the Adult Core Set Measures FFY 2024 Technical Specifications and Resource Manual*. February 2023.

<sup>&</sup>lt;sup>7</sup> Centers for Medicare & Medicaid Services. Summary of Updates to the Child Core Set Measures FFY 2024 Technical Specifications and Resource Manual. February 2023.



## Ambulatory Care: Emergency Department (ED) Visits

- Clarified in Guidance for Reporting that for the purpose of Core Set reporting, states should report this measure as a rate per 1,000 beneficiary months.
- Clarified guidance in the Numerator for visits that result in an inpatient stay.

## Asthma Medication Ratio: Ages 5 to 18

- Clarified the required exclusions for the measure.
- Removed Dyphylline Guaifenesin Medications List from the Asthma Controller Medications list.

# Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Ages 3 Months to 17 Years

- Updated Step 1 of "Event/diagnosis" and the corresponding value sets to clarify that states should identify all beneficiaries who had an outpatient visit, ED visit, observation visit, telephone visit, e-visit, or virtual check-in during the intake period, with a diagnosis of acute bronchitis/bronchiolitis.
- Updated Step 3 of "Event/diagnosis" and the corresponding value sets to clarify that states should remove episode dates where the beneficiary had a claim/encounter with any diagnosis for a comorbid condition during the 12 months prior to or on the episode date.

## **Childhood Immunization Status**

- Added anaphylaxis as numerator compliant for the following vaccines: IPV, MMR, VZV, pneumococcal conjugate, hepatitis A, and influenza. Anaphylaxis was previously included for DTaP, HiB, and rotavirus.
- Removed seropositive test results from the numerator criteria in the hybrid specification.

## Chlamydia Screening in Women Ages 16 to 20

- Revised the optional exclusion for pregnancy test to be in Step 2 of the "Event/diagnosis" criteria.
- Removed Mestranol-norethindrone from the Contraceptive Medications list.

## Contraceptive Care—All Women

- Updated the value set directory including:
  - Codes indicating sterilization for non-contraceptive reasons.
  - Codes indicating a pregnancy.
  - Codes used to identify provision of a most or moderately effective contraceptive (MMEC) method.



- Codes used to identify use of a long-acting reversible contraception (LARC) method.

#### Contraceptive Care—Postpartum Women

- Updated the value set directory including:
  - Codes used to identify provision of a most or moderately effective contraceptive method.
  - Codes used to identify use of a long-acting reversible contraception method.

## Follow-Up After Emergency Department Visit for Mental Illness

• In the "Event/diagnosis" section, replaced the reference to Mental Illness Value Set, Intentional Self-Harm Value Set with Mental Illness and Intentional Self-Harm Value Set.

## Follow-Up After Emergency Department Visit for Substance Use

- Added eligible population instructions for ED visits followed by residential treatment.
- In the Benefit section, clarified that beneficiaries with withdrawal management, as well as detoxification-only chemical dependency benefits, do not meet the criteria.

## Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity (ADHD) Medication

- Added instructions for calculating covered days.
- Added instructions for identifying same or different drugs.
- Replaced "discharge date" with "admission date" in Step 4 of the "Event/diagnosis" in both Rate 1 and Rate 2.
- Modified medication lists to make them compatible with digital measure formatting.
- Removed the bullet in the notes with guidance for beneficiaries with multiple overlapping prescriptions. This guidance is now included in the 'covered days' definition.

## Immunizations for Adolescents

• Updated the hybrid specification numerator criteria for meningococcal, HPV, and Tdap.

## Lead Screening in Children

• Revised the hybrid denominator to indicate that states can reduce the sample based on the prior year's rate (in addition to the current year's administrative rate).



## Metabolic Monitoring for Children and Adolescents on Antipsychotics

• In the "Event/diagnosis" section, replaced the reference to Antipsychotic Medications List, Antipsychotic Combination Medications List, Prochlorperazine Medications List with APM Antipsychotic Medications List.

## **Oral Evaluation, Dental Services**

- Added Guidance for Reporting to clarify which rates are subject mandatory reporting:
  - For FFY 2024 Child Core Set reporting, the following rate is required: Total ages <1 to 20.
- Clarified in the numerator that the oral evaluation must be "comprehensive or periodic."
- Clarified data quality considerations.

## Prenatal and Postpartum Care: Under Age 21

- Added Guidance for Reporting:
  - For the purpose of Child Core Set reporting, both the prenatal and postpartum care rates are reported for beneficiaries under age 21 as of the delivery date. The Adult Core Set measure is reported for beneficiaries age 21 and older as of the delivery date.
  - States that use the hybrid methodology will need to draw separate samples by age, in order to submit results for the Child Core Set (under age 21) and Adult Core Set (age 21 and over).
- Revised measure specifications to include both *Timeliness of Prenatal Care* and *Postpartum Care* rates for Child Core Set reporting.
- Added age in "eligible population" section to clarify that the Child Core Set measure applies to beneficiaries under age 21 as of the date of delivery.
- Replaced all references to "women" with "beneficiary" throughout the measure specification.
- Clarified continuous enrollment requirements for Step 2 of the *Timeliness of Prenatal Care* numerator.

## Screening for Depression and Follow-Up Plan

- Moved code tables (Table CDF-A through Table CDF-F) to a value set directory, which is linked in the technical specifications; updated codes in tables.
- Updated terminology to refer to "qualifying" encounters rather than "eligible" encounters.
- Added additional guidance for beneficiaries with multiple qualifying encounters.
- Updated the Follow-up Plan language with examples of follow-up provider type.



## Sealant Receipt on Permanent First Molars

• Updated the "Exclusions" section to clarify that a beneficiary is excluded if they have a restorative code that includes occlusal tooth surface alone OR in combination with any other surface codes.

## **Topical Fluoride for Children**

- Added Guidance for Reporting to clarify which rates are subject to mandatory reporting:
  - For FFY 2024 Child Core Set reporting, the following three rates are required: (1) Dental or oral health services: Total ages 1 through 20; (2) Dental services: Total ages 1 through 20; and (3) Oral health services: Total ages 1 through 20.
- Clarified data quality considerations.

## Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents

- Revised the optional exclusion for pregnant beneficiaries to be a required exclusion.
- Replaced the reference to "female beneficiaries" with "beneficiaries" in the required exclusions.



# Glossary

Table 2-4 provides definitions of terms, abbreviations, and acronyms used through this report.

| Term              | Description  |
|-------------------|--|
| ADHD              | Attention-deficit/hyperactivity disorder.  |
| Audit Result      | The HEDIS auditor's final determination, based on audit findings, of the appropriateness of the health plan to publicly report its HEDIS measure rates. Each measure indicator rate included in the HEDIS audit receives an audit result of <i>Reportable (R)</i> , <i>Small Denominator (NA)</i> , <i>Biased Rate (BR)</i> , <i>No Benefit (NB)</i> , <i>Not Required (NQ)</i> , <i>Not Reported (NR)</i> , and <i>Unaudited (UN)</i> . |
| BMI               | Body mass index.   |
| BR                | Biased Rate: indicates that the health plan's reported rate was invalid; therefore, the rate was not presented.  |
| CHIP              | Children's Health Insurance Program.   |
| CHP+              | Child Health Plan Plus, Colorado's program implementing the CHIP.  |
| CMS               | Centers for Medicare & Medicaid Services.  |
| COVID-19          | Coronavirus disease 2019.  |
| Data Completeness | The degree to which occurring services/diagnoses appear in the health plan's administrative data systems.  |
| Denominator       | The number of members who meet all criteria specified in a measure for<br>inclusion in the eligible population. When using the administrative method,<br>the entire eligible population becomes the denominator. When using the<br>hybrid method, a sample of the eligible population becomes the denominator.   |
| DTaP              | Diphtheria, tetanus, and pertussis.  |
| ED                | Emergency department.  |
| Electronic Data   | Data that are maintained in a computer environment versus a paper environment.   |
| Encounter Data    | Billing data received from a capitated provider. (Although the health plan<br>does not reimburse the provider for each encounter, submission of encounter<br>data allows the health plan to collect the data for future HEDIS reporting.)  |
| EOC               | Effectiveness of care.   |
| EQRO              | External quality review organization.  |
| Exclusions        | Conditions outlined in HEDIS measure specifications that describe when a member should not be included in the denominator.   |

| Table 2-4—Definition of | Terms Used in | <b>Tables and Graphs</b> |
|-------------------------|---------------|--------------------------|
|-------------------------|---------------|--------------------------|



| Term               | Description  |
|--------------------|--|
| Final Audit Report | Following the health plan's completion of any corrective actions, an auditor completes the final audit report, documenting all final findings and results of the HEDIS audit. The final audit report includes a summary report, IS capabilities assessment, medical record review validation findings, measure results, and the auditor's audit opinion (the final audit statement). |
| Flu                | Influenza.   |
| FFY                | Federal fiscal year.   |
| FY                 | Fiscal year.   |
| HEDIS              | The Healthcare Effectiveness Data and Information Set (HEDIS), developed<br>and maintained by NCQA, is a set of performance measures used to assess the<br>quality of care provided by managed healthcare organizations.   |
| HEDIS Repository   | The data warehouse where all data used for HEDIS reporting are stored.   |
| НерА               | Hepatitis A.   |
| HepB               | Hepatitis B.   |
| HiB                | Haemophilus influenza type B.  |
| HIV                | Human immunodeficiency virus.  |
| НМО                | Health maintenance organization.   |
| HPL                | High performance level. (For most performance measures, the Department defined the HPL as the most recent 90th percentile. For measures such as <i>Ambulatory Care—ED Visits</i> , in which lower rates indicate better performance, the 10th percentile [rather than the 90th percentile] is considered the HPL.)   |
| HPV                | Human papillomavirus.  |
| HSAG               | Health Services Advisory Group, Inc., the Department's external quality review organization.   |
| Hybrid Measures    | Measures that can be reported using the hybrid method (i.e., combination of claims/encounter data and medical record review data).   |
| IDSS               | The Interactive Data Submission System, a tool used to submit data to NCQA.  |
| IPV                | Inactivated polio virus.   |
| IS                 | Information Systems; automated systems for collecting, processing, and transmitting data.  |
| IS Standards       | Information Systems (IS) standards; an NCQA-defined set of standards that measure how an organization collects, stores, analyzes, and reports medical, customer service, member, practitioner, and vendor data. <sup>8</sup>   |

<sup>&</sup>lt;sup>8</sup> National Committee for Quality Assurance. HEDIS Compliance Audit Standards, Policies and Procedures, Volume 5. Washington D.C.



| Term                    | Description   |
|-------------------------|---|
| LARC                    | Long-acting reversible contraception.   |
| LPL                     | Low performance level. (For most performance measures, the Department defined the LPL as the most recent 25th national Medicaid percentile. For measures such as <i>Ambulatory Care—ED Visits</i> , in which lower rates indicate better performance, the 75th percentile [rather than the 25th percentile] is considered the LPL.)   |
| Material Bias           | For most measures reported as a rate, any error that causes $a \pm 5$ percent difference in the reported rate is considered materially biased. For non-rate measures, any error that causes $a \pm 10$ percent difference in the reported rate or calculation is considered materially biased.  |
| МСО                     | Managed care organization.  |
| MMEC                    | Most or moderately effective contraception.   |
| Medicaid<br>Percentiles | The NCQA national percentiles for each HEDIS measure for the Medicaid product line used to compare the health plan's performance and assess the reliability of the health plan's HEDIS rates.   |
| MMR                     | Measles, mumps, and rubella.  |
| MY                      | Measurement year.   |
| NA                      | <ul> <li>Small Denominator; indicates that the health plan followed the specifications, but the denominator was too small (&lt;30) to report a valid rate, resulting in an NA designation.</li> <li>For EOC and EOC-like measures, when the denominator is fewer than 30.</li> <li>For utilization measures that count member months, when the denominator is fewer than 360 member months.</li> <li>For all risk-adjusted utilization measures, when the denominator is fewer than 150.</li> </ul> |
| NB                      | No Benefit; indicates that the required benefit to calculate the measure was not offered.   |
| NCQA                    | The National Committee for Quality Assurance (NCQA) is a not-for-profit<br>organization that assesses, through accreditation reviews and standardized<br>measures, the quality of care provided by managed healthcare delivery<br>systems; reports results of those assessments to employers, consumers, public<br>purchasers, and regulators; and ultimately seeks to improve the healthcare<br>provided within the managed care industry.   |
| NR                      | Not Reported; indicates that the health plan chose not to report the required HEDIS measure indicator rate. This designation was assigned to rates during previous reporting years to indicate one of the following designations: the health plan chose not to report the required measure indicator rate, or the health plan's reported rate was invalid.  |
| Numerator               | The number of members in the denominator who received all the services as specified in the measure.   |



| Term            | Description   |
|-----------------|---|
| NQ              | Not Required; indicates that the health plan was not required to report this measure.   |
| OB/GYN          | Obstetrician/Gynecologist.  |
| РАНР            | Prepaid ambulatory health plan.   |
| РСР             | Primary care practitioner.  |
| PCV             | Pneumococcal conjugate.   |
| PHE             | Public health emergency.  |
| РОР             | Eligible population.  |
| PID             | Pelvic inflammatory disease.  |
| Provider Data   | Electronic files containing information about physicians such as type of physician, specialty, reimbursement arrangement, and office location.  |
| Quality Compass | NCQA Quality Compass benchmark.   |
| R               | Reportable.   |
| RV              | Rotavirus.  |
| Software Vendor | A third party, with source code certified by NCQA, that contracts with the<br>health plan to write source code for HEDIS measures. (For the measures to be<br>certified, the vendor must submit programming codes associated with the<br>measure to NCQA for automated testing of program logic, and a minimum<br>percentage of the measures must receive a "Pass" or "Pass With<br>Qualifications" designation.) |
| SUD             | Substance use disorder.   |
| The Department  | The Colorado Department of Health Care Policy & Financing.  |
| Tdap            | Tetanus, diphtheria, and pertussis.   |
| UN              | Unaudited; indicates that the organization chose to report a measure that is not required to be audited.  |
| VZV             | Varicella zoster virus (chicken pox).   |



## 3. Primary Care Access and Preventive Care

# **Primary Care Access and Preventive Care**

The following section provides a detailed analysis of the four Colorado CHP+ MCOs' performance within the Primary Care Access and Preventive Care domain. The Primary Care Access and Preventive Care domain encompasses the following measures/indicators:


- Child and Adolescent Well-Care Visits—Total
- Childhood Immunization Status—Combinations 3, 7, and 10
- Chlamydia Screening in Women—16 to 20 Years
- Developmental Screening in the First Three Years of Life—Total
- Immunizations for Adolescents—Combination 1 and Combination 2
- Lead Screening in Children
- Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— BMI Percentile—Total, Counseling for Nutrition—Total, and Counseling for Physical Activity— Total
- Well-Child Visits in the First 30 Months of Life—Well-Child Visits in the First 15 Months of Life— Six or More Well-Child Visits and Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits

Please see the "Reader's Guide" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendix A and Appendix B.




#### Child and Adolescent Well-Care Visits—Total

*Child and Adolescent Well-Care Visits—Total* measures the percentage of children ages 3 to 21 years who had at least one comprehensive well-care visit with a primary care practitioner (PCP) or an obstetrician/gynecologist (OB/GYN) during the measurement year.



*One caret* (^) *indicates a statistically significant improvement in performance from MY 2022 to MY 2023.* 

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.



The Colorado CHP+ weighted average and DHMP's, Kaiser's, and COA's rates were above the 50th percentile but below the HPL. RMHP's rate fell below the LPL. MCO performance varied by approximately 10 percentage points.



## **Childhood Immunization Status**

*Childhood Immunization Status* measures the percentage of members 2 years of age who received the following vaccinations on or before their second birthday. Table 3-1 displays the different antigens associated with various combinations.


| Combination    | Four<br>DTaP | Three<br>IPV | One<br>MMR   | Three<br>HiB | Three<br>HepB | One<br>VZV | Four<br>PCV | One<br>HepA | Two or<br>Three<br>RV | Two<br>Flu |
|----------------|--------------|--------------|--------------|--------------|---------------|------------|-------------|-------------|-----------------------|------------|
| Combination 3  | ~            | ~            | $\checkmark$ | ~            | ~             | ~          | ~           |             |                       |            |
| Combination 7  | ~            | ~            | ~            | ~            | ~             | ~          | ~           | ~           | ~                     |            |
| Combination 10 | ~            | ~            | ~            | ~            | ~             | ~          | ~           | ~           | ~                     | ✓          |

Acronyms: DTaP—diphtheria, tetanus toxoids, and acellular pertussis; flu—influenza; HepA—hepatitis A; HepB—hepatitis B; HiB—haemophilus influenza type B; IPV—inactivated polio virus; MMR—measles, mumps, and rubella; PCV—pneumococcal conjugate; RV—rotavirus; VZV—varicella zoster virus (chicken pox)




#### **Childhood Immunization Status—Combination 3**

*Childhood Immunization Status—Combination 3* measures the percentage of members 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, and four PCV.



*One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.* 

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.



*Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.* 


DHMP's rate exceeded the HPL. The Colorado CHP+ weighted average and COA's and RMHP's rates were above the 50th percentile but below HPL. Kaiser's rate fell below the LPL. MCO performance varied by approximately 24 percentage points.






#### **Childhood Immunization Status—Combination 7**

*Childhood Immunization Status—Combination 7* measures the percentage of members 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, one HepA, and two or three RV.



One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.

DHMP's rate exceeded the HPL. The Colorado CHP+ weighted average and COA's and RMHP's rates were above the 50th percentile but below the HPL. Kaiser's rate was above the LPL but below 50th percentile. MCO performance varied by approximately 20 percentage points.




#### **Childhood Immunization Status—Combination 10**

*Childhood Immunization Status—Combination 10* measures the percentage of members 2 years of age who received the following vaccines by their second birthday: four DTaP, three IPV, one MMR, three HiB, three HepB, one VZV, four PCV, one HepA, two or three RV, and two flu.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.

DHMP's rate exceeded the HPL. The Colorado CHP+ weighted average and COA's, Kaiser's, and RMHP's rates were above the 50th percentile but below the HPL. There are no rates below the LPL. MCO performance varied by approximately 14 percentage points.




#### Chlamydia Screening in Women—16 to 20 Years

*Chlamydia Screening in Women—16 to 20 Years* measures the percentage of women ages 16 to 20 years who were identified as sexually active and who had at least one test for chlamydia during the measurement year.



One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




DHMP's rate exceeded the HPL. The Colorado CHP+ weighted average and COA's, Kaiser's, and RMHP's rates fell below the LPL. MCO performance varied by approximately 48 percentage points.




## Developmental Screening in the First Three Years of Life—Total

Developmental Screening in the First Three Years of Life—Total measures the percentage of children screened for risk of developmental, behavioral, and social delays using a standardized screening tool in the 12 months preceding or on their first, second, or third birthday.



*One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.* 

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




*Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.* 

MCO performance varied by approximately 19 percentage points.




#### Immunizations for Adolescents—Combination 1

*Immunizations for Adolescents—Combination 1* measures the percentage of members 13 years of age who had the following vaccines by their 13th birthday: one dose of meningococcal vaccine and one Tdap vaccine.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.

Kaiser's rate was above the LPL but below the 50th percentile. The Colorado CHP+ weighted average and COA's, DHMP's, and RMHP's rates fell below the LPL. MCO performance varied by approximately 11 percentage points.




#### Immunizations for Adolescents—Combination 2

*Immunizations for Adolescents—Combination 2* measures the percentage of members 13 years of age who had the following vaccines by their 13th birthday: one dose of meningococcal vaccine, one Tdap vaccine, and completed the HPV vaccine series.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.


The Colorado CHP+ weighted average and DHMP's and Kaiser's rates were above the 50th percentile but below the HPL. COA's rate was above the LPL but below the 50th percentile. RMHP's rate fell below the LPL. MCO performance varied by approximately 12 percentage points.




#### Lead Screening in Children

*Lead Screening in Children* measures the percentage of members 2 years of age who had one or more capillary or venous lead blood test for lead poisoning by their second birthday





The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




The Colorado CHP+ weighted average and DHMP's, COA's, RMHP's, and Kaiser's rates fell below the LPL. MCO performance varied by approximately 37 percentage points.




## Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— BMI Percentile—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile—Total measures the percentage of members ages 3 to 17 years who had an outpatient visit with a PCP or OB/GYN and had evidence of BMI percentile documentation during the measurement year.



One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.

Kaiser's rate exceeded the HPL. DHMP's rate fell below the 50th percentile but was above the LPL. The Colorado CHP+ weighted average and COA's and RMHP's rates fell below the LPL. MCO performance varied by approximately 76 percentage points.




## Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Nutrition—Total

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Nutrition— Total measures the percentage of members ages 3 to 17 years who had an outpatient visit with a PCP or OB/GYN and received counseling for nutrition during the measurement year.



*One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.* 

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.

Kaiser's rate exceeded the HPL. DHMP's rate was above the 50th percentile but below the HPL. The Colorado CHP+ weighted average and COA's and RMHP's rates fell below the LPL. MCO performance varied by approximately 69 percentage points.




#### Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Physical Activity—Total

*Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—Counseling for Physical Activity—Total* measures the percentage of members ages 3 to 17 years who had an outpatient visit with a PCP or OB/GYN and received counseling for physical activity during the measurement year.



One caret (^) indicates a statistically significant improvement in performance from MY 2022to MY 2023.

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.

Kaiser's rate exceeded the HPL. DHMP's rate was above the 50th percentile but below the HPL. The Colorado CHP+ weighted average and RMHP's and COA's rates fell below the LPL. MCO performance varied by approximately 76 percentage points.




# *Well-Child Visits in the First 30 Months of Life—Well-Child Visits in the First 15 Months of Life—Six or More Well-Child Visits*

Well-Child Visits in the First 30 Months of Life—Well-Child Visits in the First 15 Months of Life—Six or More Well-Child Visits measures the percentage of members who turned 15 months of age during the measurement year and who received six or more well-child visits on different dates of service with a PCP upon or before turning 15 months of age.



One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




The Colorado CHP+ weighted average and RMHP's, COA's, and DHMP's rates were above the 50th percentile but fell below the HPL. Kaiser's rate fell below the LPL. MCO performance varied by approximately 16 percentage points.




# *Well-Child Visits in the First 30 Months of Life—Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits*

Well-Child Visits in the First 30 Months of Life—Well-Child Visits for Age 15 Months to 30 Months—Two or More Well-Child Visits measures the percentage of members who turned 30 months of age during the measurement year and who received two or more well-child visits on different dates of service with a PCP between the child turning 15 months of age plus one day and the child turning 30 months of age.



*One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.* 

The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.



The Colorado CHP+ weighted average and RMHP's and COA's rates were above the 50th percentile but below the HPL. Kaiser's rate was above the LPL but below the 50th percentile. DHMP's rate fell below the LPL. MCO performance varied by approximately 13 percentage points.



#### Summary of Findings and Recommendations

Table 3-2 presents the MCOs' performance ratings for each measure in the Primary Care Access and Preventive Care domain. Performance ratings were assigned across five categories (from  $\star$  representing *Poor Performance* to  $\star\star\star\star\star$  representing *Excellent Performance*).

| Performance Measures  | DHMP             | RMHP              | COA            | Kaiser         |
|---|------------------|-------------------|----------------|----------------|
| Child and Adolescent Well-Care Visits <sup>H</sup>                                |                  | 1                 | 1              | N              |
| Total   | ***              | **                | ***            | ***            |
| Childhood Immunization Status <sup>H</sup>  |                  | 1                 |                | <b>I</b>       |
| Combination 3   | ****             | ***               | ****           | *              |
| Combination 7   | ****             | ***               | ****           | **             |
| Combination 10  | ****             | ***               | ****           | ****           |
| Chlamydia Screening in Women <sup>H</sup>   | L.               | 1                 | _1             |                |
| 16 to 20 Years  | ****             | *                 | *              | *              |
| Developmental Screening in the First Three Yea                                    | rs of Life       | 1                 |                | <b>I</b>       |
| Total   |                  |                   |                |                |
| Immunizations for Adolescents <sup>H</sup>  | L.               | 1                 | _1             |                |
| Combination 1   | *                | *                 | *              | **             |
| Combination 2   | ***              | *                 | **             | ***            |
| Lead Screening in Children <sup>H</sup>   |                  | 1                 |                | <b>I</b>       |
| Lead Screening in Children  | *                | *                 | *              | *              |
| Screening for Depression and Follow-Up Plan                                       |                  | 1                 |                |                |
| 12 to 17 Years  | _                |                   |                |                |
| Weight Assessment and Counseling for Nutrition                                    | n and Physical A | ctivity for Child | ren/Adolescent | s <sup>H</sup> |
| BMI Percentile—Total  | **               | *                 | *              | *****          |
| Counseling for Nutrition—Total  | ****             | *                 | *              | *****          |
| Counseling for Physical Activity—Total  | ****             | *                 | *              | *****          |
| Well-Child Visits in the First 30 Months of Life <sup>k</sup>                     | I                | 1                 | 1              |                |
| Well-Child Visits in the First 15 Months of                                       | ***              | ****              | ***            | _              |
| Life—Six or More Well-Child Visits  | ***              | ****              | ***            | *              |
| Well-Child Visits for Age 15 Months to 30<br>Months—Two or More Well-Child Visits | *                | ***               | ***            | **             |

Table 3-2—Primary Care Access and Preventive Care: Measure-Specific Performance Ratings

<sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that the denominator was too small to report the rate or there was no benchmark for comparison.



Table 3-3 presents a summary of the MCOs' overall performance for the measures in the Primary Care Access and Preventive Care domain. The table shows the number of measures falling into each performance rating.

| Health Plan Name | ***** | **** | *** | ** | * |
|------------------|-------|------|-----|----|---|
| DHMP             | 4     | 2    | 3   | 1  | 3 |
| RMHP             | 0     | 1    | 4   | 1  | 7 |
| COA              | 0     | 3    | 3   | 1  | 6 |
| Kaiser           | 3     | 1    | 2   | 3  | 4 |

## Table 3-3—Primary Care Access and Preventative Care: MCO-Specific Count of Measures by Performance Rating

All four MCOs reported HEDIS measure rates below the 25th percentile for the *Lead Screening in Children* measure. Additionally, three of the four MCOs reported rates below the 25th percentile for the *Chlamydia Screening in Women—16 to 20 Years* measure. This suggests significant room for improvement in ensuring comprehensive screening occurs for this population. The MCOs and the Department should identify the factors contributing to the low rates for preventive screenings for children and adolescents (e.g., barriers to accessing care, provider billing issues, administrative data source challenges). Untreated chlamydia infections can lead to serious and irreversible complications, including PID, infertility, and increased risk of becoming infected with HIV. Screening is important, as approximately 75 percent of chlamydia infections in women and 95 percent of infections in men are asymptomatic. This results in delayed medical care and treatment.<sup>9</sup>

Of note, three of four (75 percent) MCOs reported rates at or above the 50th percentile for all three *Childhood Immunization Status* measure indicators again this year, with DHMP and COA reporting rates at or above the 75th percentile for all three measure indicators. Three of four (75 percent) MCOs reported HEDIS measure rates above the 50th percentile for the *Well-Child Visits in the First 15 Months of Life—Six or More Well-Child Visits* and *Child and Adolescent Well-Care Visits—Total* measures, which was a significant improvement from MY 2022.

<sup>&</sup>lt;sup>9</sup> Meyers, D.S., H. Halvorson, S. Luckhaupt. 2007. "Screening for Chlamydial Infection: An Evidence Update for the U.S. Preventive Services Task Force." Ann Intern Med 147(2):135–42.



## 4. Maternal and Perinatal Health

## **Maternal and Perinatal Health**

The following section provides a detailed analysis of the Colorado CHP+ MCOs' performance for the Maternal and Perinatal Health domain. The Maternal and Perinatal Health domain encompasses the following measures:


- Contraceptive Care—All Women—MMEC—15 to 20 Years and LARC—15 to 20 Years
- Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—3 Days and 15 to 20 Years— 90 Days, and LARC—15 to 20 Years—3 Days and 15 to 20 Years—90 Days
- Prenatal and Postpartum Care—Timeliness of Prenatal Care—Under Age 21 and Postpartum Care—Under Age 21

Please see the "Reader's Guide" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendix A and Appendix B.




#### Contraceptive Care—All Women—MMEC—15 to 20 Years

*Contraceptive Care—All Women—MMEC—15 to 20 Years* measures the percentage of women ages 15 to 20 years who were provided an MMEC.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




MCO performance varied by approximately 5 percentage points.




#### Contraceptive Care—All Women—LARC—15 to 20 Years

*Contraceptive Care—All Women—LARC—15 to 20 Years* measures the percentage of women ages 15 to 20 years who were provided an LARC.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.





MCO performance varied by approximately 2 percentage points.




#### *Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—3 Days*

*Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—3 Days* measures the percentage of women ages 15 to 20 years who were provided an MMEC within three days of delivery.





None of the MCOs had a reportable rate for this indicator.




None of the MCOs had a reportable rate for this indicator.




#### Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—90 Days

*Contraceptive Care—Postpartum Women—MMEC—15 to 20 Years—90 Days* measures the percentage of women ages 15 to 20 years who were provided an MMEC within 90 days of delivery.



NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

None of the MCOs had a reportable rate for this indicator.




None of the MCOs had a reportable rate for this indicator.




#### *Contraceptive Care—Postpartum Women—LARC—15 to 20 Years—3 Days*

*Contraceptive Care—Postpartum Women—LARC—15 to 20 Years—3 Days* measures the percentage of women ages 15 to 20 years who were provided an LARC within three days of delivery.



NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

None of the MCOs had a reportable rate for this indicator.




None of the MCOs had a reportable rate for this indicator.




#### *Contraceptive Care—Postpartum Women—LARC—15 to 20 Years—90 Days*

*Contraceptive Care—Postpartum Women—LARC—15 to 20 Years—90 Days* measures the percentage of women ages 15 to 20 years who were provided an LARC within 90 days of delivery.



NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

None of the MCOs had a reportable rate for this indicator




None of the MCOs had a reportable rate for this indicator




#### Prenatal and Postpartum Care—Timeliness of Prenatal Care—Under Age 21

*Prenatal and Postpartum Care—Timeliness of Prenatal Care—Under Age 21* measures the percentage of deliveries of live births that received a prenatal care visit in the first trimester, on the enrollment start date, or within 42 days of enrollment in the MCO. The measure is documented for beneficiaries under 21 years of age at the time of delivery.



Please note that this measure could not be compared to national benchmarks due to a break in trending.




Caution should be exercised when comparing administrative-only rates to national benchmarks that were calculated using the administrative and/or hybrid methodology.

MCO performance varied by approximately 25 percentage points.




#### Prenatal and Postpartum Care—Postpartum Care—Under Age 21

*Prenatal and Postpartum Care—Postpartum Care—Under Age 21* measures the percentage of deliveries of live births that received postpartum care visit in the first trimester, on the enrollment start date, or within 42 days of enrollment in the MCO. The measure is documented for beneficiaries under 21 years of age at the time of delivery.



Please note that this measure could not be compared to national benchmarks due to a break in trending, and it is the first year being reported so it cannot be compared to prior years.



MCO performance varied by approximately 33 percentage points.



#### Summary of Findings and Recommendations

Table 4-1 presents the MCOs' performance ratings for each measure in the Maternal and Perinatal Health domain. Performance ratings were assigned across five categories (from  $\star$  representing *Poor Performance* to  $\star \star \star \star \star$  representing *Excellent Performance*).

| Performance Measures                              | DHMP | RMHP | COA | Kaiser |
|---|------|------|-----|--------|
| Contraceptive Care—All Women                      | l.   |      |     | 1      |
| MMEC—15 to 20 Years                               |      |      |     |        |
| LARC–15 to 20 Years                               |      | _    |     |        |
| Contraceptive Care—Postpartum Women <sup>SA</sup> |      |      |     |        |
| MMEC—15 to 20 Years—3 Days                        |      |      |     |        |
| MMEC—15 to 20 Years—90 Days                       |      | _    |     |        |
| LARC—15 to 20 Years—3 Days                        |      | _    |     |        |
| LARC—15 to 20 Years—90 Days                       |      |      |     |        |
| Prenatal and Postpartum Care <sup>H</sup>         |      |      |     |        |
| Timeliness of Prenatal Care—Under Age 21          |      |      |     |        |
| Postpartum Care—Under Age 21                      |      |      |     |        |

#### Table 4-1—Maternal and Perinatal Health: Measure-Specific Performance Rating

<sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— Indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending.

This symbol may also indicate that the denominator was too small to report the rate or there was no benchmark for comparison.

Table 4-2 presents a summary of the MCOs' overall performance for the measures in the Maternal and Perinatal Health domain with the number of measures falling into each performance rating.

| Health Plan Name | ***** | **** | *** | ** | * |
|------------------|-------|------|-----|----|---|
| DHMP             | 0     | 0    | 0   | 0  | 0 |
| RMHP             | 0     | 0    | 0   | 0  | 0 |
| СОА              | 0     | 0    | 0   | 0  | 0 |
| Kaiser           | 0     | 0    | 0   | 0  | 0 |

Despite not being able to compare performance measure rates to NCQA benchmarks for applicable measures (i.e., *Prenatal and Postpartum Care—Under Age 21)* within the Maternal and Perinatal Health domain, the MCOs still have opportunities to improve access to prenatal and postpartum care visits for beneficiaries under 21 years of age. Studies indicate that as many as 60 percent of all pregnancy-related deaths could be prevented if women had better access to healthcare, received better quality of care, and



made changes in their health and lifestyle habits.<sup>10</sup> Timely and adequate prenatal and postpartum care can set the stage for the long-term health and well-being of new mothers and their infants.<sup>11</sup> HSAG recommends the MCOs consider leveraging opportunities to host campaigns and/or conduct member outreach activities to engage members in the importance of timely prenatal and postpartum care. HSAG also recommends the MCOs consider exploring available community programs or providing care management support services such as appointment and transportation scheduling, pregnancy and parenting education, and pregnancy monitoring.

<sup>&</sup>lt;sup>10</sup> Building U.S. Capacity to Review and Prevent Maternal Deaths. (2018). Report From Nine Maternal Mortality Review Committees. Available at: <u>https://www.cdcfoundation.org/sites/default/files/files/ReportfromNineMMRCs.pdf</u>. Accessed on: Oct 11, 2024.

<sup>&</sup>lt;sup>11</sup> American College of Obstetricians and Gynecologists (ACOG). (2018). Optimizing Postpartum Care. ACOG Committee Opinion No. 736. Obstet Gynecol, 131:140-150.



### 5. Care of Acute and Chronic Conditions

## **Care of Acute and Chronic Conditions**

The following section provides a detailed analysis of the Colorado CHP+ MCOs' performance for the Care of Acute and Chronic Conditions domain. The Care of Acute and Chronic Conditions domain encompasses the following measures/indicators:


- Asthma Medication Ratio—5 to 18 Years
- Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—3 Months to 17 Years

Please see the "Reader's Guide" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendix A and Appendix B.




#### Asthma Medication Ratio—5 to 18 Years

*Asthma Medication Ratio*—5 to 18 Years measures the percentage of children and adolescents ages 5 to 18 years who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

MCO performance varied by approximately 7 percentage points.




#### Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—3 Months to 17 Years

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—3 Months to 17 Years measures the percentage of children and adolescents ages 3 months to 17 years with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.



Kaiser's and RMHP's rates exceeded the HPL. The Colorado CHP+ weighted average and COA's rate were above the 50th percentile but below the HPL. DHMP did not have a reportable rate. MCO performance varied by approximately 25 percentage points.



#### Summary of Findings and Recommendations

Table 4-1 presents the MCOs' performance ratings for each measure in the Care of Acute and Chronic Conditions domain. Performance ratings were assigned across five categories (from  $\star$  representing *Poor Performance* to  $\star \star \star \star \star$  representing *Excellent Performance*).

#### Table 5-1—Care of Acute and Chronic Conditions: Measure-Specific Performance Ratings

| Performance Measures  | DHMP | RMHP | COA | Kaiser |
|---|------|------|-----|--------|
| Asthma Medication Ratio   |      |      |     |        |
| 5 to 18 Years   |      |      |     |        |
| Avoidance of Antibiotic Treatment for Acute<br>Bronchitis/Bronchiolitis |      |      |     |        |
| 3 Months to 17 Years  |      | **** | *** | ****   |

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that the denominator was too small to report the rate or there was no benchmark for comparison.

Table 5-2 presents a summary of the MCOs' overall performance for measures in the Care of Acute and Chronic Conditions domain.

#### Table 5-2—Care of Acute and Chronic Conditions: MCO-Specific Count of Measures by Performance Rating

| Health Plan Name | ***** | **** | *** | ** | * |
|------------------|-------|------|-----|----|---|
| DHMP             | 0     | 0    | 0   | 0  | 0 |
| RMHP             | 1     | 0    | 0   | 0  | 0 |
| СОА              | 0     | 0    | 1   | 0  | 0 |
| Kaiser           | 1     | 0    | 0   | 0  | 0 |

Three of four (75 percent) MCOs reported a HEDIS measure rate above the 50th percentile for *Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—3 Months to 17 Years*, while two of four (50 percent) MCOs reported a rate above the 90th percentile.



## **Behavioral Health Care**

The following section provides a detailed analysis of the Colorado CHP+ MCOs' performance for the Behavioral Health Care domain. The Behavioral Health Care domain encompasses the following measures/indicators:


- Follow-Up After Emergency Department Visit for Mental Illness—7-Day Follow-Up—6 to 17 Years and 30-Day Follow-Up—6 to 17 Years
- Follow-Up After Emergency Department Visit for Substance Use—7-Day Follow-Up—13 to 17 Years and 30-Day Follow-Up—13 to 17 Years
- Follow-Up After Hospitalization for Mental Illness—7-Day Follow-Up—6 to 17 Years and 30-Day Follow-Up—6 to 17 Years
- Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase and Continuation and Maintenance Phase
- Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose Testing— Total, Cholesterol Testing—Total, and Blood Glucose and Cholesterol Testing—Total
- Screening for Depression and Follow-Up Plan—12 to 17 Years
- Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total

Please see the "Reader's Guide" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendix A and Appendix B.




#### Follow-Up After Emergency Department Visit for Mental Illness—7-Day Follow-Up—6 to 17 Years

*Follow-Up After Emergency Department Visit for Mental Illness*—7-*Day Follow-Up*—6 to 17 Years measures the percentage of ED visits for members ages 6 to 17 years with a principal diagnosis of mental illness or intentional self-harm and who had a follow-up visit for mental illness within seven days of the ED visit during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate exceeded the HPL.




#### Follow-Up After Emergency Department Visit for Mental Illness—30-Day Follow-Up—6 to 17 Years

*Follow-Up After Emergency Department Visit for Mental Illness*—30-Day Follow-Up—6 to 17 Years measures the percentage of ED visits for members ages 6 to 17 years with a principal diagnosis of mental illness or intentional self-harm and who had a follow-up visit for mental illness within 30 days of the ED visit during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate fell slightly below the HPL but above the 50th percentile.




#### Follow-Up After Emergency Department Visit for Substance Use-7-Day Follow-Up-13 to 17 Years

*Follow-Up After Emergency Department Visit for Substance Use*—7-*Day Follow-Up*—13 to 17 Years measures the percentage of ED visits for members ages 13 to 17 years with a principal diagnosis of SUD, or any diagnosis of drug overdose, for which there was follow-up within seven days of the ED visit during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, which was above the 50th percentile but below the HPL.




#### *Follow-Up After Emergency Department Visit for Substance Use*—30-Day Follow-Up—13 to 17 Years

*Follow-Up After Emergency Department Visit for Substance Use*—30-Day Follow-Up—13 to 17 Years measures the percentage of ED visits for members ages 13 to 17 years with a principal diagnosis of SUD, or any diagnosis of drug overdose, for which there was follow-up within 30 days of the ED visit during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.


Only COA had a reportable rate, which was above the 50th percentile and Colorado CHP+ weighted average but below the HPL.




#### Follow-Up After Hospitalization for Mental Illness—7-Day Follow-Up—6 to 17 Years

*Follow-Up After Hospitalization for Mental Illness*—7-*Day Follow-Up*—6 to 17 Years measures the percentage of discharges for members ages 6 to 17 years who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider within seven days after discharge during the measurement year.





The Colorado CHP+ weighted average significantly improved from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate fell above the 50th percentile but below the HPL.




#### *Follow-Up After Hospitalization for Mental Illness*—30-Day Follow-Up—6 to 17 Years

*Follow-Up After Hospitalization for Mental Illness*—30-Day Follow-Up—6 to 17 Years measures the percentage of discharges for members ages 6 to 17 years who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider within 30 days after discharge during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small ( $\leq$ 30) to report a valid rate.

Only COA had a reportable rate, and the rate was above the 50th percentile and Colorado CHP+ weighted average but below the HPL.




#### Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase

*Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase* measures the percentage of children ages 6 to 12 years with an ambulatory prescription dispensed for ADHD medication who had one follow-up visit with a practitioner with prescribing authority during the 30-day initiation phase during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small ( $\leq$ 30) to report a valid rate.

RMHP's rate exceeded the HPL. The Colorado CHP+ weighted average and COA's rate were above the LPL but below the 50th percentile. DHMP and Kaiser did not have reportable rates. MCO performance varied by approximately 18 percentage points.




#### Follow-Up Care for Children Prescribed ADHD Medication—Continuation and Maintenance Phase

*Follow-Up Care for Children Prescribed ADHD Medication—Continuation and Maintenance Phase* measures the percentage of children ages 6 to 12 years with an ambulatory prescription dispensed for ADHD medication who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (nine months) after the initiation phase during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate fell below the LPL.




#### Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose Testing—Total

*Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose Testing—Total* measures the percentage of children and adolescents ages 1 to 17 years who had two or more antipsychotic prescriptions and who received blood glucose testing during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate was above the LPL but below the HPL and the 50th percentile.




#### Metabolic Monitoring for Children and Adolescents on Antipsychotics—Cholesterol Testing—Total

*Metabolic Monitoring for Children and Adolescents on Antipsychotics—Cholesterol Testing—Total* measures the percentage of children and adolescents ages 1 to 17 years who had two or more antipsychotic prescriptions and who received cholesterol testing during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate fell below the LPL.




# Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose and Cholesterol Testing—Total

*Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose and Cholesterol Testing—Total* measures the percentage of children and adolescents ages 1 to 17 years who had two or more antipsychotic prescriptions and who received blood glucose and cholesterol testing during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.




NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate fell below the LPL.




#### Screening for Depression and Follow-Up Plan-12 to 17 Years

Screening for Depression and Follow-Up Plan—12 to 17 Years measures the percentage of children and adolescents ages 12 to 17 years screened for depression on the date of the encounter or 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool and, if positive, had a follow-up plan documented on the date of the eligible encounter during the measurement year.



One caret (^) indicates a statistically significant improvement in performance from MY 2022 to MY 2023.

The Colorado CHP+ weighted average weighted average significantly improved from MY 2022 to MY 2023.




MCO performance varied by approximately 23 percentage points.




#### Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total

*Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total* measures the percentage of children and adolescents ages 1 to 17 years who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment during the measurement year.



The Colorado CHP+ weighted average did not demonstrate a significant change from MY 2022 to MY 2023.



NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

Only COA had a reportable rate, and the rate exceeded the HPL.



#### Summary of Findings and Recommendations

Table 3-1 presents the MCOs' performance ratings for each measure in the Behavioral Health Care domain. Performance ratings were assigned across five categories (from  $\star$  representing *Poor Performance* to  $\star \star \star \star \star$  representing *Excellent Performance*).

| Table 6-1—Behavioral Health Care: Measure-Specific Performance Ratings |
|--|
|--|

| Performance Measures  | DHMP                       | RMHP             | СОА   | Kaiser |
|---|----------------------------|------------------|-------|--------|
| Follow-Up After Emergency Department Visit for Su               | ubstance Use <sup>H</sup>  | l                |       |        |
| 7-Day Follow-Up—13 to 17 Years                                  |                            |                  | ***   |        |
| 30-Day Follow-Up—13 to 17 Years                                 |                            |                  | ****  |        |
| Follow-Up After Emergency Department Visit for M                | ental Illness <sup>H</sup> |                  |       |        |
| 7-Day Follow-Up—6 to 17 Years                                   |                            |                  | ****  |        |
| 30-Day Follow-Up—6 to 17 Years                                  |                            |                  | ****  |        |
| Follow-Up After Hospitalization for Mental Illness <sup>H</sup> |                            |                  |       |        |
| 7-Day Follow-Up—6 to 17 Years                                   |                            |                  | ****  |        |
| 30-Day Follow-Up—6 to 17 Years                                  |                            |                  | ***   |        |
| Follow-Up Care for Children Prescribed ADHD Me                  | dication <sup>H</sup>      |                  |       |        |
| Initiation Phase  |                            | ****             | **    |        |
| Continuation and Maintenance Phase                              |                            |                  | *     |        |
| Metabolic Monitoring for Children and Adolescents               | on Antipsychoti            | ics <sup>H</sup> | · · · |        |
| Blood Glucose Testing—Total                                     |                            |                  | **    |        |
| Cholesterol Testing—Total                                       |                            |                  | *     |        |
| Blood Glucose and Cholesterol Testing—Total                     |                            |                  | *     |        |
| Use of First-Line Psychosocial Care for Children an             | d Adolescents o            | n Antipsychotic  | es s  |        |
| Total   |                            |                  | ****  |        |

<sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

—indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that the denominator was too small to report the rate or there was no benchmark for comparison.



Table 6-2 presents a summary of the MCOs' overall performance for measures in the Behavioral Health Care domain.

| Health Plan Name | ***** | **** | *** | ** | * |
|------------------|-------|------|-----|----|---|
| DHMP             | 0     | 0    | 0   | 0  | 0 |
| RMHP             | 1     | 0    | 0   | 0  | 0 |
| COA              | 2     | 3    | 2   | 2  | 3 |
| Kaiser           | 0     | 0    | 0   | 0  | 0 |

Table 6-2—Behavioral Health Care: MCO-Specific Count of Measures by Performance Rating

While only COA had reportable rates for the *Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose Testing—Total, Cholesterol Testing—Total,* and *Blood Glucose and Cholesterol Testing—Total* measure indicators, the rates fell below the 50th percentile for one measure indicator and below the 25th percentile for two measure indicators. These rates suggest COA has room for improvement to ensure better health outcomes for children and adolescents on antipsychotics. Antipsychotic prescribing for children and adolescents has increased rapidly in recent decades.<sup>12</sup> These medications can elevate a child's risk for developing serious metabolic health complications<sup>13</sup> associated with poor cardiometabolic outcomes in adulthood.<sup>14</sup> The MCOs and the Department should identify the key drivers contributing to the low rates (e.g., barriers to standing lab orders, provider billing issues, gaps in administrative data sources). Additionally, the MCOs and the Department should consider ongoing education and/or one-on-one discussion with provider organizations on the importance of annual metabolic monitoring for patients on antipsychotics.

Of note, COA's reported HEDIS rates for the *Follow-Up After Emergency Department Visit for Mental Illness*—7-Day Follow-Up—6 to 17 Years and 30-Day Follow-Up—6 to 17 Years and Follow-Up After Emergency Department Visit for Substance Use—7-Day Follow-Up—13 to 17 Years and 30-Day Follow-Up—13 to 17 Years measure indicators ranked above the 75th percentile. RMHP's reported HEDIS measure rate was above the 90th percentile for the Follow-Up Care for Children Prescribed ADHD Medication—Initiation Phase measure indicator.

<sup>&</sup>lt;sup>12</sup> Patten, S.B., W. Waheed, L. Bresee. 2012. "A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents." Canadian Journal of Psychiatry 57:717–21.

<sup>&</sup>lt;sup>13</sup> Correll, C. U., P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra. 2009. "Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents." Journal of the American Medical Association.

<sup>&</sup>lt;sup>14</sup> Srinivasan, S.R., L. Myers, G.S. Berenson. January 2002. "Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study." Diabetes 51(1):204–9.



# **Use of Services**

Within the Use of Services domain, HEDIS methodology requires that the rate be derived using only the administrative method. The Use of Services domain encompasses the following measure:

• Ambulatory Care: ED Visits

All MCOs were required to report this measure in MY 2023. The MCOs' member months served as an eligible population proxy and were used when calculating the Colorado CHP+ weighted average.

Rates displayed in the Use of Services domain are for informational purposes only; the rates do not indicate the quality and timeliness of, or access to, care and services. Therefore, exercise caution in connecting these data to the efficacy of the program, as many factors influence these data. HSAG recommends that MCOs review the Use of Services results to identify whether a rate is higher or lower than expected. Additional focused analyses related to the Use of Services domain may help to identify key drivers associated with the utilization patterns.

Please see the "Reader's Guide" section for guidance on interpreting the tables presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendix A and Appendix B.



#### Ambulatory Care: ED Visits

The *Ambulatory Care* measure summarizes use of ambulatory care for *ED Visits*. In this section, the results for the total age group are presented.

#### Results

Table 7-1 shows ED visits per 1,000 member months for ambulatory care for all ages.

| Health Plan Name                  | ED Visits |
|-----------------------------------|-----------|
| DHMP                              | 22.37     |
| RMHP                              | 16.76     |
| COA                               | 28.95     |
| Kaiser                            | 20.83     |
| MY 2023 Medicaid Weighted Average | 26.21     |
| MY 2022 Medicaid Weighted Average | 22.19     |
| MY 2021 Medicaid Weighted Average | 17.54     |

 Table 7-1—Ambulatory Care: ED Visits per 1,000 Member Months for Total Age Group

For the *ED Visits* measure indicator, MCO performance varied, ranging from 20.83 ED visits per 1,000 member months to 28.95 ED visits per 1,000 member months. The rates for the four MCOs vary, indicating differences in patterns of ED use.

#### Summary of Findings and Recommendations

Reported rates for the MCOs and CHP+ weighted averages for the Use of Services domain did not consider the characteristics of the population; therefore, HSAG was not able to draw formal conclusions regarding performance based on the reported utilization results. Nonetheless, combined with other performance metrics, the utilization results provide additional information that the MCOs may use to assess barriers or patterns of utilization when evaluating potential performance improvement interventions.



## 8. Dental and Oral Health Services

# **Dental and Oral Health Services**

The following section provides a detailed analysis of the Colorado CHP+ dental PAHP's performance for the Dental and Oral Health Services domain. The Dental and Oral Health Services domain encompasses the following measures/indicators:


- Oral Evaluation, Dental Services
- Sealant Receipt on Permanent First Molars—At Least One Sealant and All Four Molars Sealed
- Topical Fluoride for Children

Please see the "Reader's Guide" section for guidance on interpreting the figures presented within this section. For reference, additional analyses for each measure indicator are displayed in Appendix A and Appendix B.



#### Oral Evaluation, Dental Services—<1 Year


*Oral Evaluation, Dental Services*—<*1 Year* measures the percentage of children under 1 year of age who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—1 to 2 Years


*Oral Evaluation, Dental Services—1 to 2 Years* measures the percentage of children ages 1 to 2 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—3 to 5 Years


*Oral Evaluation, Dental Services—3 to 5 Years* measures the percentage of children ages 3 to 5 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—6 to 7 Years


*Oral Evaluation, Dental Services—6 to 7 Years* measures the percentage of children ages 6 to 7 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—8 to 9 Years


*Oral Evaluation, Dental Services*— 8 to 9 Years measures the percentage of children ages 8 to 9 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—10 to 11 Years


*Oral Evaluation, Dental Services—10 to 11 Years* measures the percentage of children ages 10 to 11 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—12 to 14 Years


*Oral Evaluation, Dental Services*—12 to 14 Years measures the percentage of children ages 12 to 14 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—15 to 18 Years


*Oral Evaluation, Dental Services*—15 to 18 Years measures the percentage of children ages 15 to 18 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—19 to 20 Years


*Oral Evaluation, Dental Services—19 to 20 Years* measures the percentage of children ages 19 to 20 years who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Oral Evaluation, Dental Services—Total


*Oral Evaluation, Dental Services—Total* measures the percentage of children under 21 years of age who received a comprehensive or periodic oral evaluation during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Sealant Receipt on Permanent First Molars—At Least One Sealant


Sealant Receipt on Permanent First Molars—At Least One Sealant measures the percentage of enrolled children who have received at least one sealant on permanent first molars during the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Sealant Receipt on Permanent First Molars—All Four Molars Sealed


Sealant Receipt on Permanent First Molars—All Four Molars Sealed measures the percentage of enrolled children who have received sealants on all four permanent first molars. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Topical Fluoride for Children—Dental Services—1 to 2 Years


*Topical Fluoride for Children—Dental Services—1 to 2 Years* measures the percentage of enrolled children ages 1 to 2 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Topical Fluoride for Children—Dental Services—3 to 5 Years


*Topical Fluoride for Children—Dental Services—3 to 5 Years* measures the percentage of enrolled children ages 3 to 5 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Topical Fluoride for Children—Dental Services—6 to 7 Years


*Topical Fluoride for Children—Dental Services—6 to 7 Years* measures the percentage of enrolled children ages 6 to 7 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Topical Fluoride for Children—Dental Services—8 to 9 Years


*Topical Fluoride for Children—Dental Services—8 to 9 Years* measures the percentage of enrolled children ages 8 to 9 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### *Topical Fluoride for Children—Dental Services—10 to 11 Years*


*Topical Fluoride for Children—Dental Services—10 to 11 Years* measures the percentage of enrolled children ages 10 to 11 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### *Topical Fluoride for Children—Dental Services—12 to 14 Years*


*Topical Fluoride for Children—Dental Services—12 to 14 Years* measures the percentage of enrolled children ages 12 to 14 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### *Topical Fluoride for Children—Dental Services—15 to 18 Years*

*Topical Fluoride for Children—Dental Services—15 to 18 Years* measures the percentage of enrolled children ages 15 to 18 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.




DENTAL AND ORAL HEALTH SERVICES



#### *Topical Fluoride for Children—Dental Services—19 to 20 Years*


*Topical Fluoride for Children—Dental Services—19 to 20 Years* measures the percentage of enrolled children ages 19 to 20 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





#### Topical Fluoride for Children—Dental Services—Total

*Topical Fluoride for Children—Dental Services—Total* measures the percentage of enrolled children ages 1 to 20 years who received at least two topical fluoride applications as: (1) dental or oral health services, (2) dental services, and (3) oral health services within the measurement year. Given there are no established benchmarks, HSAG was unable to make rate comparisons to benchmarks.





### Summary of Findings and Recommendations

Table 8-1 presents the DentaQuest performance ratings for each measure in the Dental and Oral Health Services domain.

| Performance Measures                      | HEDIS MY<br>2021<br>Rate | HEDIS MY<br>2022<br>Rate | HEDIS MY<br>2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| Dental and Oral Health Services           |                          |                          |                          |                       |
| Oral Evaluation, Dental Services          |                          |                          |                          |                       |
| <1 Year                                   |                          | 3.85%                    | 3.68%                    |                       |
| 1 to 2 Years                              |                          | 24.60%                   | 25.37%                   |                       |
| 3 to 5 Years                              |                          | 38.64%                   | 39.40%                   |                       |
| 6 to 7 Years                              |                          | 44.73%                   | 45.76%                   |                       |
| 8 to 9 Years                              |                          | 45.51%                   | 45.25%                   |                       |
| 10 to 11 Years                            |                          | 43.72%                   | 45.45%                   |                       |
| 12 to 14 Years                            |                          | 41.78%                   | 41.67%                   |                       |
| 15 to 18 Years                            |                          | 32.58%                   | 33.16%                   |                       |
| 19 to 20 Years                            |                          | 22.83%                   | 21.53%                   |                       |
| Total                                     |                          | 38.25%                   | 38.61%                   |                       |
| Sealant Receipt on Permanent First Molars | L                        |                          |                          |                       |
| At Least One Sealant                      | 24.49%                   | 43.06%                   | 54.28%                   |                       |
| All Four Molars Sealed                    | 14.30%                   | 29.27%                   | 40.60%                   |                       |
| Topical Fluoride for Children             |                          |                          |                          |                       |
| Dental Services—1 to 2 Years              |                          | 21.39%                   | 19.31%                   |                       |
| Dental Services—3 to 5 Years              |                          | 26.41%                   | 24.63%                   |                       |
| Dental Services—6 to 7 Years              |                          | 28.90%                   | 25.17%                   |                       |
| Dental Services—8 to 9 Years              |                          | 30.16%                   | 26.49%                   |                       |
| Dental Services—10 to 11 Years            |                          | 28.06%                   | 24.47%                   |                       |
| Dental Services—12 to 14 Years            |                          | 24.04%                   | 21.41%                   |                       |
| Dental Services—15 to 18 Years            |                          | 17.67%                   | 15.87%                   |                       |
| Dental Services—19 to 20 Years            |                          | 7.14%                    | 4.91%                    |                       |
| Dental Services—Total                     |                          | 24.19%                   | 21.37%                   |                       |

 Table 8-1—Dental and Oral Health Services: Measure-Specific Performance Ratings

— indicates that a percentile ranking was not determined because there was a break in trending or there was no benchmark for comparison.

Reported rates for DentaQuest could not be compared to national benchmarks because there were no established benchmarks for comparison; therefore, HSAG was not able to draw formal conclusions regarding performance based on MY 2023 reported results. Nonetheless, the DentaQuest results provide additional information that may be used to assess quality improvement interventions.



## Appendix A. Tabular Results for Measures by Health Plan

Appendix A presents tables showing results for the measures by health plan. Where applicable, the results provided for each measure include the eligible population and rate for each health plan as well as MY 2021, MY 2022, and MY 2023 Colorado CHP+ weighted averages. Yellow shading with one caret (^) indicates the MY 2023 health plan-specific rate or Colorado CHP+ weighted average ranked at or above the 50th percentile when compared to MY 2022 National Medicaid Quality Compass benchmarks. Comparisons of Colorado's CHP+ population measure indicator rates to the national Medicaid benchmarks should be interpreted with caution, as previously discussed in the body of this report.

# **Primary Care Access and Preventive Care Measure Results**

| CHP+ Plan                              | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| Child and Adolescent Well-Care Visits  |                        |         |
| 3 to 11 Years <sup>H</sup>             |                        |         |
| СОА                                    | 11,099                 | 53.13%  |
| DHMP                                   | 1,276                  | 61.05%^ |
| Kaiser                                 | 1,647                  | 57.01%^ |
| RMHP                                   | 1,550                  | 47.61%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 53.64%  |
| MY 2022 Colorado CHP+ Weighted Average |                        | 47.20%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 51.70%  |
| 12 to 17 Years <sup>H</sup>            |                        |         |
| СОА                                    | 8,557                  | 45.17%  |
| DHMP                                   | 1,116                  | 51.79%^ |
| Kaiser                                 | 1,361                  | 47.91%  |
| RMHP                                   | 1,316                  | 42.48%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 45.78%  |
| MY 2022 Colorado CHP+ Weighted Average |                        | 40.79%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 43.73%  |
| 18 to 21 Years <sup>H</sup>            |                        |         |
| СОА                                    | NA                     | NA      |
| DHMP                                   | 261                    | 35.63%^ |
| Kaiser                                 | 230                    | 27.39%^ |
| RMHP                                   | 191                    | 32.46%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 31.96%^ |

 Table A-1—Primary Care Access and Preventive Care Measure Results—MCO-Specific Rates

 and Colorado CHP+ Weighted Averages



| CHP+ Plan                              | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| MY 2022 Colorado CHP+ Weighted Average |                        | 23.90%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 28.36%^ |
| Total <sup>H</sup>                     |                        |         |
| СОА                                    | 19,656                 | 49.66%^ |
| DHMP                                   | 2,653                  | 54.66%^ |
| Kaiser                                 | 3,238                  | 51.08%^ |
| RMHP                                   | 3,057                  | 44.46%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 49.73%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 42.88%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 46.98%  |
| Childhood Immunization Status          |                        |         |
| DTaP <sup>H</sup>                      |                        |         |
| СОА                                    | 890                    | 76.63%^ |
| DHMP                                   | 56                     | 85.71%^ |
| Kaiser                                 | 96                     | 66.67%  |
| RMHP                                   | 104                    | 72.12%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 75.39%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 68.49%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 68.97%  |
| IPV <sup>#</sup>                       |                        |         |
| СОА                                    | 890                    | 88.99%^ |
| DHMP                                   | 56                     | 94.64%  |
| Kaiser                                 | 96                     | 76.04%  |
| RMHP                                   | 104                    | 90.38%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 86.74%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 81.75%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 81.54%  |
| MMR <sup>H</sup>                       |                        |         |
| СОА                                    | 890                    | 87.08%^ |
| DHMP                                   | 56                     | 94.64%^ |
| Kaiser                                 | 96                     | 77.08%  |
| RMHP                                   | 104                    | 88.46%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 86.47%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 81.39%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 82.96%  |
| HiB <sup>H</sup>                       |                        |         |
| СОА                                    | 890                    | 87.53%^ |
| DHMP                                   | 56                     | 94.64%  |



| CHP+ Plan                              | Eligible<br>Population | Rate            |
|--|------------------------|-----------------|
| Kaiser                                 | 96                     | 78.13%          |
| RMHP                                   | 104                    | 85.58%          |
| MY 2023 Colorado CHP+ Weighted Average |                        | 85.69%^         |
| MY 2022 Colorado CHP+ Weighted Average |                        | 80.90%          |
| MY 2021 Colorado CHP+ Weighted Average |                        | 82.35%          |
| Hepatitis B <sup>H</sup>               |                        |                 |
| COA                                    | 890                    | 88.43%^         |
| DHMP                                   | 56                     | 96.43%          |
| Kaiser                                 | 96                     | 77.08%          |
| RMHP                                   | 104                    | 87.50%          |
| MY 2023 Colorado CHP+ Weighted Average |                        | 86.56%          |
| MY 2022 Colorado CHP+ Weighted Average |                        | 78.35%          |
| MY 2021 Colorado CHP+ Weighted Average |                        | 81.24%          |
| VZV <sup>H</sup>                       |                        |                 |
| СОА                                    | 890                    | 87.64%^         |
| DHMP                                   | 56                     | 94.64%^         |
| Kaiser                                 | 96                     | 77.08%          |
| RMHP                                   | 104                    | 86.54%^         |
| MY 2023 Colorado CHP+ Weighted Average |                        | 86.74%^         |
| MY 2022 Colorado CHP+ Weighted Average |                        | 81.27%          |
| MY 2021 Colorado CHP+ Weighted Average |                        | 81.95%          |
| Hepatitis A <sup>H</sup>               |                        |                 |
| COA                                    | 890                    | 85.51%^         |
| DHMP                                   | 56                     | 92.86%^         |
| Kaiser                                 | 96                     | 80.21%          |
| RMHP                                   | 104                    | 77.88%          |
| MY 2023 Colorado CHP+ Weighted Average |                        | <b>84.47%</b> ^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 79.32%          |
| MY 2021 Colorado CHP+ Weighted Average |                        | 80.02%          |
| Pneumococcal Conjugate <sup>H</sup>    |                        |                 |
| COA                                    | 890                    | 79.33%^         |
| DHMP                                   | 56                     | 91.07%          |
| Kaiser                                 | 96                     | 69.79%          |
| RMHP                                   | 104                    | 74.04%^         |
| MY 2023 Colorado CHP+ Weighted Average |                        | 76.44%^         |
| MY 2022 Colorado CHP+ Weighted Average |                        | 72.51%^         |
| MY 2021 Colorado CHP+ Weighted Average |                        | 74.54%^         |



| CHP+ Plan                              | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| Rotavirus <sup>H</sup>                 |                        |         |
| СОА                                    | 890                    | 76.97%^ |
| DHMP                                   | 56                     | 89.29%  |
| Kaiser                                 | 96                     | 71.88%^ |
| RMHP                                   | 104                    | 79.81%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 74.78%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 70.44%^ |
| MY 2021 Colorado CHP+ Weighted Average |                        | 70.99%^ |
| Influenza <sup>H</sup>                 |                        |         |
| СОА                                    | 890                    | 52.25%^ |
| DHMP                                   | 56                     | 58.93%  |
| Kaiser                                 | 96                     | 55.21%^ |
| RMHP                                   | 104                    | 45.19%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 51.13%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 51.70%^ |
| MY 2021 Colorado CHP+ Weighted Average |                        | 63.29%^ |
| Combination 3 <sup>H</sup>             |                        |         |
| СОА                                    | 890                    | 71.01%^ |
| DHMP                                   | 56                     | 83.93%^ |
| Kaiser                                 | 96                     | 58.33%  |
| RMHP                                   | 104                    | 65.38%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 69.90%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 61.19%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 64.91%^ |
| Combination 7 <sup>H</sup>             |                        |         |
| СОА                                    | 890                    | 64.61%^ |
| DHMP                                   | 56                     | 76.79%^ |
| Kaiser                                 | 96                     | 55.21%  |
| RMHP                                   | 104                    | 60.58%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 63.87%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 55.84%^ |
| MY 2021 Colorado CHP+ Weighted Average |                        | 57.91%^ |
| Combination 10 <sup>H</sup>            |                        |         |
| СОА                                    | 890                    | 42.58%^ |
| DHMP                                   | 56                     | 53.57%^ |
| Kaiser                                 | 96                     | 39.58%^ |
| RMHP                                   | 104                    | 38.46%^ |
| MY 2023 Colorado CHP+ Weighted Average |                        | 42.32%^ |



| CHP+ Plan  | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| MY 2022 Colorado CHP+ Weighted Average                   |                        | 39.54%^ |
| MY 2021 Colorado CHP+ Weighted Average                   |                        | 48.48%^ |
| Chlamydia Screening in Women                             |                        |         |
| 16 to 20 Years <sup>H</sup>                              |                        |         |
| COA  | 775                    | 38.71%  |
| DHMP   | 161                    | 76.40%^ |
| Kaiser   | 114                    | 35.96%  |
| RMHP   | 107                    | 28.04%  |
| MY 2023 Colorado CHP+ Weighted Average                   |                        | 42.70%  |
| MY 2022 Colorado CHP+ Weighted Average                   |                        | 31.44%  |
| MY 2021 Colorado CHP+ Weighted Average                   |                        | 36.58%  |
| Developmental Screening in the First Three Years of Life |                        |         |
| 1 Year <sup>SA</sup>                                     |                        |         |
| СОА  | 831                    | 68.95%  |
| DHMP   | 87                     | 62.07%  |
| Kaiser   | 71                     | 56.34%  |
| RMHP   | 124                    | 54.03%  |
| MY 2023 Colorado CHP+ Weighted Average                   |                        | 65.95%  |
| MY 2022 Colorado CHP+ Weighted Average                   |                        | 48.58%  |
| MY 2021 Colorado CHP+ Weighted Average                   |                        | 66.21%  |
| 2 Years <sup>SA</sup>                                    |                        |         |
| СОА  | 1,096                  | 71.35%  |
| DHMP   | 106                    | 70.75%  |
| Kaiser   | 96                     | 80.21%  |
| RMHP   | 104                    | 59.62%  |
| MY 2023 Colorado CHP+ Weighted Average                   |                        | 71.04%  |
| MY 2022 Colorado CHP+ Weighted Average                   |                        | 44.82%  |
| MY 2021 Colorado CHP+ Weighted Average                   |                        | 64.80%  |
| 3 Years <sup>SA</sup>                                    |                        |         |
| СОА  | 1,193                  | 57.33%  |
| DHMP   | 96                     | 66.67%  |
| Kaiser   | 88                     | 79.55%  |
| RMHP   | 109                    | 49.54%  |
| MY 2023 Colorado CHP+ Weighted Average                   |                        | 58.68%  |
| MY 2022 Colorado CHP+ Weighted Average                   |                        | 27.99%  |
| MY 2021 Colorado CHP+ Weighted Average                   |                        | 48.87%  |



| CHP+ Plan                              | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| <i>Total</i> <sup>SA</sup>             |                        |         |
| СОА                                    | 3,120                  | 65.35%  |
| DHMP                                   | 289                    | 66.78%  |
| Kaiser                                 | 255                    | 73.33%  |
| RMHP                                   | 337                    | 54.30%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 65.03%  |
| MY 2022 Colorado CHP+ Weighted Average |                        | 37.84%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 57.54%  |
| Immunizations for Adolescents          |                        |         |
| <i>Meningococcal<sup>H</sup></i>       |                        |         |
| СОА                                    | 1,390                  | 69.93%  |
| DHMP                                   | 115                    | 78.26%  |
| Kaiser                                 | 243                    | 75.31%  |
| RMHP                                   | 292                    | 67.01%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 69.75%  |
| MY 2022 Colorado CHP+ Weighted Average |                        | 72.27%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 74.26%  |
| Tdap <sup>H</sup>                      |                        |         |
| COA                                    | 1,390                  | 80.22%  |
| DHMP                                   | 115                    | 87.83%  |
| Kaiser                                 | 243                    | 85.19%^ |
| RMHP                                   | 292                    | 81.79%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 80.34%  |
| MY 2022 Colorado CHP+ Weighted Average |                        | 82.94%  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 82.09%  |
| HPV <sup>H</sup>                       |                        |         |
| СОА                                    | 1,390                  | 36.98%^ |
| DHMP                                   | 115                    | 50.43%^ |
| Kaiser                                 | 243                    | 42.39%^ |
| RMHP                                   | 292                    | 32.65%  |
| MY 2023 Colorado CHP+ Weighted Average |                        | 37.11%^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 35.53%^ |
| MY 2021 Colorado CHP+ Weighted Average |                        | 39.50%^ |
| Combination 1 <sup>H</sup>             |                        |         |
| СОА                                    | 1,390                  | 68.92%  |
| DHMP                                   | 115                    | 78.26%  |
| Kaiser                                 | 243                    | 75.31%  |
| RMHP                                   | 292                    | 66.67%  |



| CHP+ Plan  | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| MY 2023 Colorado CHP+ Weighted Average                     |                        | 69.02%  |
| MY 2022 Colorado CHP+ Weighted Average                     |                        | 71.47%  |
| MY 2021 Colorado CHP+ Weighted Average                     |                        | 73.38%  |
| Combination 2 <sup>H</sup>                                 |                        |         |
| СОА  | 1,390                  | 34.24%  |
| DHMP   | 115                    | 49.57%^ |
| Kaiser   | 243                    | 40.74%^ |
| RMHP   | 292                    | 29.90%  |
| MY 2023 Colorado CHP+ Weighted Average                     |                        | 34.56%^ |
| MY 2022 Colorado CHP+ Weighted Average                     |                        | 33.30%  |
| MY 2021 Colorado CHP+ Weighted Average                     |                        | 37.06%^ |
| Lead Screening in Children                                 |                        |         |
| Lead Screening in Children <sup>H</sup>                    |                        |         |
| СОА  | 550                    | 43.64%  |
| DHMP   | 56                     | 46.43%  |
| Kaiser   | 95                     | 9.47%   |
| RMHP   | 104                    | 37.50%  |
| MY 2023 Colorado CHP+ Weighted Average                     |                        | 39.01%  |
| MY 2022 Colorado CHP+ Weighted Average                     |                        | 29.78%  |
| MY 2021 Colorado CHP+ Weighted Average                     |                        |         |
| Screening for Depression and Follow-Up Plan                |                        |         |
| 12 to 17 Years <sup>H</sup>                                |                        |         |
| СОА  | 5,132                  | 24.75%  |
| DHMP   | 1,651                  | 25.80%  |
| Kaiser   | 1,307                  | 2.83%   |
| RMHP   | 1,927                  | 10.12%  |
| MY 2023 Colorado CHP+ Weighted Average                     |                        | 19.25%  |
| MY 2022 Colorado CHP+ Weighted Average                     |                        | 13.41%  |
| MY 2021 Colorado CHP+ Weighted Average                     |                        | 6.81%   |
| Weight Assessment and Counseling for Nutrition and Physic. | al Activity for        |         |
| Children/Adolescents                                       |                        |         |
| BMI Percentile—3 to 11 Years <sup>H</sup>                  |                        |         |
| СОА  | 7,919                  | 17.40%  |
| DHMP   | 835                    | 94.64%  |
| Kaiser   | 1,173                  | 95.23%^ |
| RMHP   | 986                    | 85.97%  |
| MY 2023 Colorado CHP+ Weighted Average                     |                        | 30.16%  |
| MY 2022 Colorado CHP+ Weighted Average                     |                        | 26.56%  |
| MY 2021 Colorado CHP+ Weighted Average                     |                        | 24.90%  |



| CHP+ Plan  | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| BMI Percentile—12 to 17 Years <sup>H</sup>           | _                      |         |
| COA  | 5,682                  | 21.77%  |
| DHMP   | 681                    | 91.44%  |
| Kaiser   | 875                    | 92.46%^ |
| RMHP   | 801                    | 87.37%  |
| MY 2023 Colorado CHP+ Weighted Average               |                        | 33.66%  |
| MY 2022 Colorado CHP+ Weighted Average               |                        | 30.37%  |
| MY 2021 Colorado CHP+ Weighted Average               |                        | 29.07%  |
| BMI Percentile—Total <sup>H</sup>                    |                        |         |
| СОА  | 13,601                 | 19.23%  |
| DHMP   | 1,516                  | 93.19%  |
| Kaiser   | 2,048                  | 94.04%^ |
| RMHP   | 1,787                  | 86.62%  |
| MY 2023 Colorado CHP+ Weighted Average               |                        | 31.64%  |
| MY 2022 Colorado CHP+ Weighted Average               |                        | 28.21%  |
| MY 2021 Colorado CHP+ Weighted Average               |                        | 26.61%  |
| Counseling for Nutrition—3 to 11 Years <sup>H</sup>  |                        |         |
| COA  | 7,919                  | 27.39%  |
| DHMP   | 835                    | 87.05%^ |
| Kaiser   | 1,173                  | 95.14%^ |
| RMHP   | 986                    | 79.19%  |
| MY 2023 Colorado CHP+ Weighted Average               |                        | 38.71%  |
| MY 2022 Colorado CHP+ Weighted Average               |                        | 29.85%  |
| MY 2021 Colorado CHP+ Weighted Average               |                        | 26.83%  |
| Counseling for Nutrition—12 to 17 Years <sup>H</sup> |                        |         |
| COA  | 5,682                  | 23.27%  |
| DHMP   | 681                    | 81.28%^ |
| Kaiser   | 875                    | 92.46%^ |
| RMHP   | 801                    | 75.26%  |
| MY 2023 Colorado CHP+ Weighted Average               |                        | 35.03%  |
| MY 2022 Colorado CHP+ Weighted Average               |                        | 29.52%  |
| MY 2021 Colorado CHP+ Weighted Average               |                        | 26.80%  |
| Counseling for Nutrition—Total <sup>H</sup>          |                        | ·       |
| COA  | 13,601                 | 25.67%  |
| DHMP   | 1,516                  | 84.43%^ |
| Kaiser   | 2,048                  | 93.99%^ |
| RMHP   | 1,787                  | 77.37   |
| MY 2023 Colorado CHP+ Weighted Average               |                        | 37.15%  |



| CHP+ Plan  | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| MY 2022 Colorado CHP+ Weighted Average                       |                        | 29.71%  |
| MY 2021 Colorado CHP+ Weighted Average                       |                        | 26.82%  |
| Counseling for Physical Activity—3 to 11 Years <sup>H</sup>  |                        |         |
| COA  | 7,919                  | 19.31%  |
| DHMP   | 835                    | 84.38%^ |
| Kaiser   | 1,173                  | 95.06%^ |
| RMHP   | 986                    | 78.28%  |
| MY 2023 Colorado CHP+ Weighted Average                       |                        | 32.26%  |
| MY 2022 Colorado CHP+ Weighted Average                       |                        | 23.69%  |
| MY 2021 Colorado CHP+ Weighted Average                       |                        | 20.44%  |
| Counseling for Physical Activity—12 to 17 Years <sup>H</sup> |                        | •       |
| COA  | 5,682                  | 18.39%  |
| DHMP   | 681                    | 81.28%^ |
| Kaiser   | 875                    | 92.91%^ |
| RMHP   | 801                    | 80.00%  |
| MY 2023 Colorado CHP+ Weighted Average                       |                        | 31.32%  |
| MY 2022 Colorado CHP+ Weighted Average                       |                        | 26.77%  |
| MY 2021 Colorado CHP+ Weighted Average                       |                        | 23.36%  |
| Counseling for Physical Activity—Total <sup>H</sup>          |                        |         |
| COA  | 13,601                 | 18.93%  |
| DHMP   | 1,516                  | 82.97%^ |
| Kaiser   | 2,048                  | 94.14%^ |
| RMHP   | 1,787                  | 79.08%  |
| MY 2023 Colorado CHP+ Weighted Average                       |                        | 31.86%  |
| MY 2022 Colorado CHP+ Weighted Average                       |                        | 25.03%  |
| MY 2021 Colorado CHP+ Weighted Average                       |                        | 21.63%  |
| Well-Child Visits in the First 30 Months of Life             |                        |         |
| Well-Child Visits in the First 15 Months of Life—Six or More | e Visits <sup>H</sup>  |         |
| COA  | 728                    | 62.64%^ |
| DHMP   | 40                     | 60.00%^ |
| Kaiser   | 64                     | 50.00%  |
| RMHP   | 77                     | 66.23%^ |
| MY 2023 Colorado CHP+ Weighted Average                       |                        | 61.94%^ |
| MY 2022 Colorado CHP+ Weighted Average                       |                        | 46.06%  |
| MY 2021 Colorado CHP+ Weighted Average                       |                        | 47.60%  |



| CHP+ Plan  | Eligible<br>Population | Rate            |
|--|------------------------|-----------------|
| Well-Child Visits for Age 15 to 30 Months of Life—Two or Mon | re Visits <sup>H</sup> |                 |
| СОА  | 952                    | 68.70%^         |
| DHMP   | 35                     | 57.14%          |
| Kaiser   | 85                     | 62.35%          |
| RMHP   | 129                    | 70.54%^         |
| MY 2023 Colorado CHP+ Weighted Average                       |                        | <b>68.11%</b> ^ |
| MY 2022 Colorado CHP+ Weighted Average                       |                        | 59.14%          |
| MY 2021 Colorado CHP+ Weighted Average                       |                        | 63.58%          |

NA (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate.

<sup>H</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that the rate was not reported.

Yellow shading with one caret (^) indicates the rate was at or above the 50th percentile.



# Maternal and Perinatal Health Performance Measure Results

| CHP+ Plan                                 | Eligible<br>Population | Rate   |
|---|------------------------|--------|
| Contraceptive Care—All Women              |                        |        |
| MMEC—15 to 20 Years <sup>SA</sup>         |                        |        |
| COA                                       | 2,840                  | 17.46% |
| DHMP                                      | 400                    | 18.75% |
| Kaiser                                    | 463                    | 17.93% |
| RMHP                                      | 397                    | 22.42% |
| MY 2023 Colorado CHP+ Weighted Average    |                        | 18.12% |
| MY 2022 Colorado CHP+ Weighted Average    |                        | 16.87% |
| MY 2021 Colorado CHP+ Weighted Average    |                        | 24.39% |
| LARC—15 to 20 Years <sup>SA</sup>         |                        |        |
| COA                                       | 2,840                  | 3.06%  |
| DHMP                                      | 400                    | 5.50%  |
| Kaiser                                    | 463                    | 4.10%  |
| RMHP                                      | 397                    | 5.04%  |
| MY 2023 Colorado CHP+ Weighted Average    |                        | 3.61%  |
| MY 2022 Colorado CHP+ Weighted Average    |                        | 3.19%  |
| MY 2021 Colorado CHP+ Weighted Average    |                        | 5.49%  |
| Contraceptive Care—Postpartum Women       |                        |        |
| MMEC—15 to 20 Years—3 Days <sup>SA</sup>  |                        |        |
| COA                                       | 13                     | NA     |
| DHMP                                      | 1                      | NA     |
| Kaiser                                    | 1                      | NA     |
| RMHP                                      | 3                      | NA     |
| MY 2023 Colorado CHP+ Weighted Average    |                        | NA     |
| MY 2022 Colorado CHP+ Weighted Average    |                        | 0.00%  |
| MY 2021 Colorado CHP+ Weighted Average    |                        |        |
| MMEC—15 to 20 Years—90 Days <sup>SA</sup> |                        |        |
| COA                                       | 13                     | NA     |
| DHMP                                      | 1                      | NA     |
| Kaiser                                    | 1                      | NA     |
| RMHP                                      | 3                      | NA     |
| MY 2023 Colorado CHP+ Weighted Average    |                        | NA     |
| MY 2022 Colorado CHP+ Weighted Average    |                        | 64.86% |
| MY 2021 Colorado CHP+ Weighted Average    |                        |        |

# Table A-2—Maternal and Perinatal Health Performance Measure Results— MCO-Specific Rates and Colorado CHP+ Weighted Averages



| CHP+ Plan   | Eligible<br>Population | Rate   |
|---|------------------------|--------|
| LARC—15 to 20 Years—3 Days <sup>SA</sup>              |                        |        |
| COA   | 13                     | NA     |
| DHMP  | 1                      | NA     |
| Kaiser  | 1                      | NA     |
| RMHP  | 3                      | NA     |
| MY 2023 Colorado CHP+ Weighted Average                |                        | NA     |
| MY 2022 Colorado CHP+ Weighted Average                |                        | 2.70%  |
| MY 2021 Colorado CHP+ Weighted Average                |                        |        |
| LARC—15–20 Years—90 Days <sup>SA</sup>                |                        |        |
| СОА   | 13                     | NA     |
| DHMP  | 1                      | NA     |
| Kaiser  | 1                      | NA     |
| RMHP  | 3                      | NA     |
| MY 2023 Colorado CHP+ Weighted Average                |                        | NA     |
| MY 2022 Colorado CHP+ Weighted Average                |                        | 35.14% |
| MY 2021 Colorado CHP+ Weighted Average                |                        |        |
| Prenatal and Postpartum Care                          |                        |        |
| Timeliness of Prenatal Care—Under Age 21 <sup>H</sup> |                        |        |
| СОА   | 19                     | NA     |
| DHMP  | 1                      | NA     |
| Kaiser  | 50                     | 80.00% |
| RMHP  | 72                     | 54.17% |
| MY 2023 Colorado CHP+ Weighted Average                |                        | 59.86% |
| MY 2022 Colorado CHP+ Weighted Average                |                        | NA     |
| MY 2021 Colorado CHP+ Weighted Average                |                        | NA     |
| Postpartum Care—Under Age 21 <sup>H</sup>             |                        |        |
| COA   | 19                     | NA     |
| DHMP  | 1                      | NA     |
| Kaiser  | 50                     | 84.00% |
| RMHP  | 72                     | 51.39% |
| MY 2023 Colorado CHP+ Weighted Average                |                        | 61.97% |
| MY 2022 Colorado CHP+ Weighted Average                |                        | NA     |
| MY 2021 Colorado CHP+ Weighted Average                |                        | NA     |

<sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

 $^{SA}$  indicates that the measure could only be compared to the statewide average.

-indicates that the rate was not reported.



### **Care of Acute and Chronic Conditions Performance Measure Results**

# Table A-3—Care of Acute and Chronic Conditions Performance Measure Results—MCO-Specific Rates and Colorado CHP+ Weighted Averages

| CHP+ Plan   | Eligible<br>Population | Rate     |
|---|------------------------|----------|
| Asthma Medication Ratio                                       | 1                      | 1        |
| 5 to 11 Years <sup>H</sup>                                    |                        |          |
| СОА   | 156                    | 73.72%   |
| DHMP  | 19                     | NA       |
| Kaiser  | 14                     | NA       |
| RMHP  | 7                      | NA       |
| MY 2023 Colorado CHP+ Weighted Average                        |                        | 75.00%   |
| MY 2022 Colorado CHP+ Weighted Average                        |                        | 67.95%   |
| MY 2021 Colorado CHP+ Weighted Average                        |                        | 70.80%^  |
| 12 to 18 Years <sup>H</sup>                                   |                        |          |
| СОА   | 128                    | 59.38%   |
| DHMP  | 11                     | NA       |
| Kaiser  | 11                     | NA       |
| RMHP  | 10                     | NA       |
| MY 2023 Colorado CHP+ Weighted Average                        |                        | 59.38%   |
| MY 2022 Colorado CHP+ Weighted Average                        |                        | 55.22%   |
| MY 2021 Colorado CHP+ Weighted Average                        |                        | 82.33%^  |
| 5 to 18 Years <sup>SA</sup>                                   |                        |          |
| COA   | 284                    | 67.25%   |
| DHMP  | 30                     | 60.00%   |
| Kaiser  | 25                     | NA       |
| RMHP  | 17                     | NA       |
| MY 2023 Colorado CHP+ Weighted Average                        |                        | 67.98%   |
| MY 2022 Colorado CHP+ Weighted Average                        |                        | 61.64%   |
| MY 2021 Colorado CHP+ Weighted Average                        |                        | 76.42%   |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronch | hiolitis               |          |
| 3 Months to 17 Years <sup>H</sup>                             |                        |          |
| СОА   | 304                    | 75.00%^  |
| DHMP  | 12                     | NA       |
| Kaiser  | 36                     | 100.00%^ |
| RMHP  | 62                     | 87.10%^  |

| CHP+ Plan                              | Eligible<br>Population | Rate            |
|--|------------------------|-----------------|
| MY 2023 Colorado CHP+ Weighted Average |                        | <b>79.47%</b> ^ |
| MY 2022 Colorado CHP+ Weighted Average |                        | 82.81%^         |
| MY 2021 Colorado CHP+ Weighted Average |                        |                 |

<sup>H</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that the rate was not reported.

Yellow shading with one caret (^) indicates the rate was at or above the 50th percentile.



#### **Behavioral Health Care Performance Measure Results**

# Table A-4—Behavioral Health Care Performance Measure Results—MCO-Specific Rates and Colorado CHP+ Weighted Averages

| CHP+ Plan  | Eligible<br>Population | Rate            |
|--|------------------------|-----------------|
| Follow-Up After Emergency Department Visit for Mental Illness  |                        |                 |
| 7-Day Follow-Up—6 to 17 Years                                  |                        |                 |
| СОА  | 81                     | 75.31%^         |
| DHMP   | 7                      | NA              |
| Kaiser   | 16                     | NA              |
| RMHP   | 16                     | NA              |
| MY 2023 Colorado CHP+ Weighted Average                         |                        | 65.83%^         |
| MY 2022 Colorado CHP+ Weighted Average                         |                        | 58.54%^         |
| MY 2021 Colorado CHP+ Weighted Average                         |                        | —               |
| 30-Day Follow-Up—6 to 17 Years                                 |                        |                 |
| СОА  | 81                     | 83.95%^         |
| DHMP   | 7                      | NA              |
| Kaiser   | 16                     | NA              |
| RMHP   | 16                     | NA              |
| MY 2023 Colorado CHP+ Weighted Average                         |                        | 77.50%^         |
| MY 2022 Colorado CHP+ Weighted Average                         |                        | 71.95%^         |
| MY 2021 Colorado CHP+ Weighted Average                         |                        | —               |
| Follow-Up After Emergency Department Visit for Substance Use D | isorder                |                 |
| 7-Day Follow-Up—13 to 17 Years                                 |                        |                 |
| СОА  | 36                     | 22.22%^         |
| DHMP   | 2                      | NA              |
| Kaiser   | 5                      | NA              |
| RMHP   | 4                      | NA              |
| MY 2023 Colorado CHP+ Weighted Average                         |                        | <b>23.40%</b> ^ |
| MY 2022 Colorado CHP+ Weighted Average                         |                        | <b>26.83%</b> ^ |
| MY 2021 Colorado CHP+ Weighted Average                         |                        |                 |
| 30-Day Follow-Up—13 to 17 Years                                |                        |                 |
| СОА  | 36                     | 41.67%^         |
| DHMP   | 2                      | NA              |
| Kaiser   | 5                      | NA              |
| RMHP   | 4                      | NA              |
| MY 2023 Colorado CHP+ Weighted Average                         |                        | <b>40.43%</b> ^ |
| MY 2022 Colorado CHP+ Weighted Average                         |                        | 31.71%          |
| MY 2021 Colorado CHP+ Weighted Average                         |                        |                 |



| CHP+ Plan   | Eligible<br>Population | Rate    |
|---|------------------------|---------|
| Follow-Up After Hospitalization for Mental Illness            |                        |         |
| 7-Day Follow-Up-6 to 17 Years <sup>H</sup>                    |                        |         |
| СОА   | 161                    | 55.28%^ |
| DHMP  | 9                      | NA      |
| Kaiser  | 19                     | NA      |
| RMHP  | 22                     | NA      |
| MY 2023 Colorado CHP+ Weighted Average                        |                        | 56.40%^ |
| MY 2022 Colorado CHP+ Weighted Average                        |                        | 40.36%  |
| MY 2021 Colorado CHP+ Weighted Average                        |                        | 41.15%  |
| 30-Day Follow-Up—6 to 17 Years <sup>H</sup>                   |                        |         |
| СОА   | 161                    | 76.40%^ |
| DHMP  | 9                      | NA      |
| Kaiser  | 19                     | NA      |
| RMHP  | 22                     | NA      |
| MY 2023 Colorado CHP+ Weighted Average                        |                        | 71.56%  |
| MY 2022 Colorado CHP+ Weighted Average                        |                        | 75.90%^ |
| MY 2021 Colorado CHP+ Weighted Average                        |                        | 58.85%  |
| Follow-Up Care for Children Prescribed ADHD Medication        |                        |         |
| Initiation Phase <sup>H</sup>                                 |                        |         |
| СОА   | 193                    | 41.45%  |
| DHMP  | 4                      | NA      |
| Kaiser  | 19                     | NA      |
| RMHP  | 32                     | 59.38%^ |
| MY 2023 Colorado CHP+ Weighted Average                        |                        | 43.55%  |
| MY 2022 Colorado CHP+ Weighted Average                        |                        | 38.64%  |
| MY 2021 Colorado CHP+ Weighted Average                        |                        | 32.05%  |
| Continuation and Maintenance Phase <sup>H</sup>               |                        |         |
| СОА   | 65                     | 44.62%  |
| DHMP  | 1                      | NA      |
| Kaiser  | 7                      | NA      |
| RMHP  | 14                     | NA      |
| MY 2023 Colorado CHP+ Weighted Average                        |                        | 49.43%  |
| MY 2022 Colorado CHP+ Weighted Average                        |                        | 53.33%  |
| MY 2021 Colorado CHP+ Weighted Average                        |                        | 40.79%  |
| Metabolic Monitoring for Children and Adolescents on Antipsyc | chotics                |         |
| Blood Glucose Testing—1 to 11 Years <sup>H</sup>              |                        |         |
| COA   | 16                     | NA      |
| DHMP  | 1                      | NA      |



| CHP+ Plan  | Eligible<br>Population | Rate    |
|--|------------------------|---------|
| Kaiser   | 1                      | NA      |
| RMHP   | 2                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average           |                        | NA      |
| MY 2022 Colorado CHP+ Weighted Average           |                        | 41.94%  |
| MY 2021 Colorado CHP+ Weighted Average           |                        | NA      |
| Blood Glucose Testing—12 to 17 Year <sup>H</sup> |                        |         |
| СОА  | 86                     | 58.14%  |
| DHMP   | 1                      | NA      |
| Kaiser   | 4                      | NA      |
| RMHP   | 7                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average           |                        | 61.22%^ |
| MY 2022 Colorado CHP+ Weighted Average           |                        | 53.91%  |
| MY 2021 Colorado CHP+ Weighted Average           |                        | 56.45%  |
| Blood Glucose Testing—Total <sup>H</sup>         |                        |         |
| СОА  | 102                    | 54.90%  |
| DHMP   | 2                      | NA      |
| Kaiser   | 5                      | NA      |
| RMHP   | 9                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average           |                        | 56.78%^ |
| MY 2022 Colorado CHP+ Weighted Average           |                        | 51.57%  |
| MY 2021 Colorado CHP+ Weighted Average           |                        | 53.02%  |
| Cholesterol Testing—1 to 11 Years <sup>H</sup>   |                        |         |
| СОА  | 16                     | NA      |
| DHMP   | 1                      | NA      |
| Kaiser   | 1                      | NA      |
| RMHP   | 2                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average           |                        | NA      |
| MY 2022 Colorado CHP+ Weighted Average           |                        | 35.48%  |
| MY 2021 Colorado CHP+ Weighted Average           |                        | NA      |
| Cholesterol Testing—12 to 17 Years <sup>H</sup>  |                        |         |
| СОА  | 86                     | 27.91%  |
| DHMP   | 1                      | NA      |
| Kaiser   | 4                      | NA      |
| RMHP   | 7                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average           |                        | 31.63%  |
| MY 2022 Colorado CHP+ Weighted Average           |                        | 26.56%  |
| MY 2021 Colorado CHP+ Weighted Average           |                        | 29.84%  |



| CHP+ Plan   | Eligible<br>Population | Rate    |
|---|------------------------|---------|
| Cholesterol Testing—Total <sup>H</sup>                            |                        |         |
| СОА   | 102                    | 28.43%  |
| DHMP  | 2                      | NA      |
| Kaiser  | 5                      | NA      |
| RMHP  | 9                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average                            |                        | 30.51%  |
| MY 2022 Colorado CHP+ Weighted Average                            |                        | 28.30%  |
| MY 2021 Colorado CHP+ Weighted Average                            |                        | 28.86%  |
| Blood Glucose and Cholesterol Testing—1 to 11 Years <sup>H</sup>  |                        |         |
| СОА   | 16                     | NA      |
| DHMP  | 1                      | NA      |
| Kaiser  | 1                      | NA      |
| RMHP  | 2                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average                            |                        | NA      |
| MY 2022 Colorado CHP+ Weighted Average                            |                        | 35.48%^ |
| MY 2021 Colorado CHP+ Weighted Average                            |                        | NA      |
| Blood Glucose and Cholesterol Testing—12 to 17 Years <sup>H</sup> |                        |         |
| СОА   | 86                     | 26.74%  |
| DHMP  | 1                      | NA      |
| Kaiser  | 4                      | NA      |
| RMHP  | 7                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average                            |                        | 30.61%  |
| MY 2022 Colorado CHP+ Weighted Average                            |                        | 25.78%  |
| MY 2021 Colorado CHP+ Weighted Average                            |                        | 29.84%  |
| Blood Glucose and Cholesterol Testing—Total <sup>H</sup>          |                        |         |
| СОА   | 102                    | 27.45%  |
| DHMP  | 2                      | NA      |
| Kaiser  | 5                      | NA      |
| RMHP  | 9                      | NA      |
| MY 2023 Colorado CHP+ Weighted Average                            |                        | 29.66%  |
| MY 2022 Colorado CHP+ Weighted Average                            |                        | 27.67%  |
| MY 2021 Colorado CHP+ Weighted Average                            |                        | 28.86%  |
| Use of First-Line Psychosocial Care for Children and Adolescents  | on Antipsych           | otics   |
| 1 to 11 Years   |                        |         |
| СОА   | 14                     | NA      |
| DHMP  | 0                      | NA      |
| Kaiser  | 0                      | NA      |
| RMHP  | 2                      | NA      |



| CHP+ Plan                              | Eligible<br>Population | Rate            |
|--|------------------------|-----------------|
| MY 2023 Colorado CHP+ Weighted Average |                        | NA              |
| MY 2022 Colorado CHP+ Weighted Average |                        | NA              |
| MY 2021 Colorado CHP+ Weighted Average |                        | NA              |
| 12 to 17 Years <sup>H</sup>            |                        |                 |
| COA                                    | 67                     | 76.12%^         |
| DHMP                                   | 1                      | NA              |
| Kaiser                                 | 2                      | NA              |
| RMHP                                   | 5                      | NA              |
| MY 2023 Colorado CHP+ Weighted Average |                        | 72.00%^         |
| MY 2022 Colorado CHP+ Weighted Average |                        | <b>68.25%</b> ^ |
| MY 2021 Colorado CHP+ Weighted Average |                        | <b>69.49%</b> ^ |
| Total <sup>H</sup>                     |                        |                 |
| СОА                                    | 81                     | 76.54%^         |
| DHMP                                   | 1                      | NA              |
| Kaiser                                 | 2                      | NA              |
| RMHP                                   | 7                      | NA              |
| MY 2023 Colorado CHP+ Weighted Average |                        | 71.43%^         |
| MY 2022 Colorado CHP+ Weighted Average |                        | 66.67%^         |
| MY 2021 Colorado CHP+ Weighted Average |                        | 71.01%^         |

<sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

*— indicates that the rate was not reported.* 

Yellow shading with one caret (^) indicates the rate was at or above the 50th percentile.



#### **Use of Services Measure Results**

#### Table A-5—Use of Services Measure Results—MCO-Specific Rates and Colorado CHP+ Weighted Averages

| CHP+ Plan                              | Eligible<br>Population | Rate   |
|--|------------------------|--------|
| Ambulatory Care: ED Visits             |                        |        |
| <1 Year <sup>SA</sup>                  |                        |        |
| COA                                    | 11,428                 | 59.42% |
| DHMP                                   | 1,189                  | 56.35% |
| Kaiser                                 | 1,596                  | 50.75% |
| RMHP                                   | 1,918                  | 26.07% |
| MY 2023 Colorado CHP+ Weighted Average |                        | 54.37% |
| MY 2022 Colorado CHP+ Weighted Average |                        | 51.67% |
| MY 2021 Colorado CHP+ Weighted Average |                        | 40.98% |
| 1 to 9 Years <sup>SA</sup>             |                        |        |
| COA                                    | 212,838                | 33.45% |
| DHMP                                   | 18,180                 | 28.77% |
| Kaiser                                 | 27,122                 | 26.77% |
| RMHP                                   | 35,919                 | 17.32% |
| MY 2023 Colorado CHP+ Weighted Average |                        | 30.57% |
| MY 2022 Colorado CHP+ Weighted Average |                        | 24.90% |
| MY 2021 Colorado CHP+ Weighted Average |                        | 18.12% |
| 10 to 19 Years <sup>SA</sup>           |                        |        |
| COA                                    | 254,083                | 23.82% |
| DHMP                                   | 24,895                 | 16.07% |
| Kaiser                                 | 36,613                 | 15.13% |
| RMHP                                   | 46,108                 | 15.94% |
| MY 2023 Colorado CHP+ Weighted Average |                        | 21.40  |
| MY 2022 Colorado CHP+ Weighted Average |                        | 19.01  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 16.24  |
| 0 to 19 Years <sup>H</sup>             |                        |        |
| COA                                    | 478,349                | 28.95% |
| DHMP                                   | 44,264                 | 22.37% |
| Kaiser                                 | 65,331                 | 20.83% |
| RMHP                                   | 83,945                 | 16.76% |
| MY 2023 Colorado CHP+ Weighted Average |                        | 26.21  |
| MY 2022 Colorado CHP+ Weighted Average |                        | 22.19  |
| MY 2021 Colorado CHP+ Weighted Average |                        | 17.54  |

<sup>H</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks. <sup>SA</sup> indicates that the measure could only be compared to the statewide average.



#### **Appendix B. Trend Tables**

Appendix B includes trend tables for the health plans and the Colorado CHP+ weighted averages. Where applicable, measure rates for MY 2021, MY 2022, and MY 2023 are presented.

MY 2022 to MY 2023 performance comparisons are based on the Chi-square test of statistical significance with a *p* value <0.05. Rates shaded green with one caret (^) indicate a statistically significant improvement in performance from the previous year. Rates shaded red with two carets (^^) indicate a statistically significant decline in performance from the previous year.

For measures in the Use of Services domain, statistical tests across years were not performed because variances were not provided in the Interactive Data Submission System (IDSS) files; differences in rates were reported without statistical test results. In addition, higher or lower rates did not necessarily denote better or worse performance. Rates are not risk adjusted; therefore, the percentile ranking should be interpreted with caution and may not accurately reflect better or worse performance.

## **COA Trend Table**

| Performance Measures                    | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| Primary Care Access and Preventive Care |                          |                          |                          |                       |
| Child and Adolescent Well-Care Visits   |                          |                          |                          |                       |
| 3 to 11 Years <sup>H</sup>              | 52.84%                   | 46.40%                   | 53.13%^                  | 25th-49th             |
| 12 to 17 Years <sup>H</sup>             | 44.86%                   | 39.27%                   | 45.17%^                  | 25th-49th             |
| 18 to 21 Years <sup>H</sup>             | 28.87%                   | 23.29%                   | NA                       |                       |
| <i>Total</i> <sup>H</sup>               | 48.16%                   | 41.86%                   | 49.66%^                  | 50th-74th             |
| Childhood Immunization Status           | I                        |                          |                          |                       |
| $DTaP^{H}$                              | 70.61%                   | 66.42%                   | 76.63%^                  | 75th-89th             |
| IPV <sup>H</sup>                        | 84.19%                   | 80.81%                   | 88.99%^                  | 50th-74th             |
| MMR <sup>H</sup>                        | 83.55%                   | 80.07%                   | 87.08%^                  | 50th-74th             |
| HiB <sup>H</sup>                        | 84.03%                   | 79.70%                   | 87.53%^                  | 75th-89th             |
| Hepatitis B <sup>H</sup>                | 83.71%                   | 75.28%                   | 88.43%^                  | 50th-74th             |
| VZV <sup>H</sup>                        | 82.43%                   | 79.52%                   | 87.64%^                  | 75th-89th             |
| Hepatitis $A^H$                         | 79.87%                   | 78.23%                   | 85.51%^                  | 75th-89th             |
| Pneumococcal Conjugate <sup>H</sup>     | 76.52%                   | 70.48%                   | 79.33%^                  | 75th-89th             |
| <i>Rotavirus<sup>H</sup></i>            | 72.04%                   | 68.82%                   | 76.97%^                  | 75th-89th             |
| Influenza <sup>H</sup>                  | 62.30%                   | 51.48%                   | 52.25%                   | 75th-89th             |
| Combination 3 <sup>H</sup>              | 65.97%                   | 57.93%                   | 71.01%^                  | 75th-89th             |
| Combination 7 <sup>H</sup>              | 57.35%                   | 52.58%                   | 64.61%^                  | 75th-89th             |

#### Table B-1—COA Trend Table



| Performance Measures   | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|--|--------------------------|--------------------------|--------------------------|-----------------------|
| Combination 10 <sup>H</sup>  | 46.81%                   | 37.64%                   | 42.58%                   | 75th-89th             |
| Chlamydia Screening in Women   |                          |                          |                          |                       |
| 16 to 20 Years <sup>H</sup>  | 34.66%                   | 29.07%                   | 38.71%^                  | 10th-24th             |
| Developmental Screening in the First Three Years of Life                                       |                          |                          |                          |                       |
| 1 Year <sup>SA</sup>   |                          | 48.04%                   | 68.95%^                  | BTSA                  |
| 2 Years <sup>SA</sup>  |                          | 38.65%                   | 71.35%^                  | BTSA                  |
| 3 Years <sup>SA</sup>  |                          | 23.06%                   | 57.33%^                  | WTSA                  |
| <i>Total<sup>SA</sup></i>  |                          | 33.36%                   | 65.35%^                  | BTSA                  |
| Immunizations for Adolescents  |                          |                          |                          |                       |
| Meningococcal <sup>H</sup>   | 77.26%                   | 72.57%                   | 69.93%                   | 10th-24th             |
| $Tdap^{H}$   | 85.20%                   | 82.00%                   | 80.22%                   | 10th-24th             |
| $HPV^{H}$  | 40.39%                   | 35.45%                   | 36.98%                   | 50th-74th             |
| Combination $1^H$  | 76.45%                   | 71.79%                   | 68.92%                   | 10th-24th             |
| Combination 2 <sup>H</sup>   | 37.74%                   | 33.31%                   | 34.24%                   | 25th-49th             |
| Lead Screening in Children   |                          |                          |                          |                       |
| Lead Screening in Children <sup>H</sup>  |                          | 30.88%                   | 43.64%^                  | 10th-24th             |
| Screening for Depression and Follow-Up Plan  |                          |                          |                          |                       |
| 12 to 17 Years <sup>H</sup>  |                          | 14.47%                   | 24.75%^                  | BTSA                  |
| Weight Assessment and Counseling for Nutrition and Physical                                    | Activity for             | Children/Add             | olescents                |                       |
| BMI Percentile—3 to 11 Years <sup>H</sup>  | 14.74%                   | 16.27%                   | 17.40%                   | <10th                 |
| BMI Percentile—12 to 17 Years <sup>H</sup>   | 18.65%                   | 20.09%                   | 21.77%                   | <10th                 |
| BMI Percentile—Total <sup>H</sup>  | 16.32%                   | 17.90%                   | 19.23%                   | <10th                 |
| Counseling for Nutrition—3 to 11 Years <sup>H</sup>  | 13.78%                   | 19.07%                   | 27.39%^                  | <10th                 |
| Counseling for Nutrition—12 to 17 Years <sup>H</sup>   | 14.12%                   | 18.24%                   | 23.27%^                  | <10th                 |
| Counseling for Nutrition—Total <sup>H</sup>  | 13.92%                   | 18.71%                   | 25.67%^                  | <10th                 |
| Counseling for Physical Activity—3 to 11 Years <sup>H</sup>                                    | 8.44%                    | 12.05%                   | 19.31%^                  | <10th                 |
| Counseling for Physical Activity—12 to 17 Years <sup>H</sup>                                   | 10.73%                   | 14.74%                   | 18.39%^                  | <10th                 |
| Counseling for Physical Activity—Total <sup>H</sup>  | 9.37%                    | 13.20%                   | 18.93%^                  | <10th                 |
| Well-Child Visits in the First 30 Months of Life   |                          |                          | <u> </u>                 |                       |
| Well-Child Visits in the First 15 Months of Life—Six or<br>More Well-Child Visits <sup>H</sup> | 61.19%                   | 52.51%                   | 62.64%^                  | 50th-74th             |
| Well-Child Visits for Age 15 Months to 30 Months—Two or<br>More Well-Child Visits <sup>H</sup> | 65.48%                   | 55.06%                   | 68.70%^                  | 50th-74th             |
| Maternal and Perinatal Health  |                          |                          |                          |                       |
| Contraceptive Care—All Women   |                          |                          |                          |                       |
| MMEC-15 to 20 Years <sup>SA</sup>  |                          | 16.44%                   | 17.46%                   | WTSA                  |
| LARC—15 to 20 Years <sup>SA</sup>  |                          | 2.86%                    | 3.06%                    | WTSA                  |



| Performance Measures  | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| Contraceptive Care—Postpartum Women                               |                          |                          |                          |                       |
| MMEC—15 to 20 Years—3 Days <sup>SA</sup>                          |                          | NA                       | NA                       |                       |
| MMEC—15 to 20 Years—90 Days <sup>SA</sup>                         |                          | NA                       | NA                       |                       |
| LARC-15 to 20 Years-3 Days <sup>SA</sup>                          |                          | NA                       | NA                       |                       |
| LARC—15 to 20 Years—90 Days <sup>SA</sup>                         |                          | NA                       | NA                       |                       |
| Prenatal and Postpartum Care                                      |                          |                          |                          |                       |
| <i>Timeliness of Prenatal Care—Under Age 21<sup>H</sup></i>       |                          |                          | NA                       |                       |
| Postpartum Care—Under Age 21 <sup>H</sup>                         |                          |                          | NA                       |                       |
| Care of Acute and Chronic Conditions                              |                          |                          |                          |                       |
| Asthma Medication Ratio   |                          |                          |                          |                       |
| 5 to 11 Years <sup>H</sup>  | 81.98%                   | 65.26%                   | 73.72%                   | 25th-49th             |
| 12 to 18 Years <sup>H</sup>                                       | 68.97%                   | 51.09%                   | 59.38%                   | 10th-24th             |
| 5 to 18 Years <sup>SA</sup>                                       | 75.29%                   | 58.29%                   | 67.25%^                  | WTSA                  |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronc      | hiolitis                 | •<br>•                   |                          |                       |
| 3 Months to 17 Years <sup>H</sup>                                 |                          | 81.48%                   | 75.00%                   | 50th-74th             |
| Behavioral Health Care  |                          |                          |                          |                       |
| Follow-Up After Emergency Department Visit for Mental Illne       | ess                      |                          |                          |                       |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>                        |                          | 76.27%                   | 75.31%                   | ≥90th                 |
| 30-Day Follow-Up—6 to 17 Years <sup>H</sup>                       |                          | 86.44%                   | 83.95%                   | 75th-89th             |
| Follow-Up After Emergency Department Visit for Substance U        | lse                      |                          |                          |                       |
| 7-Day Follow-Up—13 to 17 Years <sup>H</sup>                       |                          | 22.58%                   | 22.22%                   | 50th-74th             |
| <i>30-Day Follow-Up—13 to 17 Years<sup>H</sup></i>                |                          | 29.03%                   | 41.67%                   | 75th-89th             |
| Follow-Up After Hospitalization for Mental Illness                |                          |                          |                          |                       |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>                        | 36.42%                   | 30.08%                   | 55.28%^                  | 75th-89th             |
| <i>30-Day Follow-Up—6 to 17 Years<sup>H</sup></i>                 | 54.91%                   | 72.36%                   | 76.40%                   | 50th-74th             |
| Follow-Up Care for Children Prescribed ADHD Medication            |                          |                          |                          |                       |
| Initiation Phase <sup>H</sup>                                     | 29.03%                   | 36.62%                   | 41.45%                   | 25th-49th             |
| Continuation and Maintenance Phase <sup>H</sup>                   | 38.60%                   | 52.83%                   | 44.62%                   | 10th-24th             |
| Metabolic Monitoring for Children and Adolescents on Antips       | ychotics                 |                          |                          |                       |
| Blood Glucose Testing—1 to 11 Years <sup>H</sup>                  | NA                       | NA                       | NA                       |                       |
| Blood Glucose Testing—12 to 17 Years <sup>H</sup>                 | 53.33%                   | 48.48%                   | 58.14%                   | 25th-49th             |
| Blood Glucose Testing—Total <sup>H</sup>                          | 50.00%                   | 47.62%                   | 54.90%                   | 25th-49th             |
| Cholesterol Testing—1 to 11 Years <sup>H</sup>                    | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—12 to 17 Years <sup>H</sup>                   | 27.78%                   | 21.21%                   | 27.91%                   | 10th-24th             |
| Cholesterol Testing—Total <sup>H</sup>                            | 27.19%                   | 24.60%                   | 28.43%                   | 10th-24th             |
| Blood Glucose and Cholesterol Testing—1 to 11 Years <sup>H</sup>  |                          | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—12 to 17 Years <sup>H</sup> |                          | 20.20%                   | 26.74%                   | <10th                 |



| Performance Measures  | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| Blood Glucose and Cholesterol Testing—Total <sup>H</sup>    | 27.19%                   | 23.81%                   | 27.45%                   | 10th-24th             |
| Use of First-Line Psychosocial Care for Children and Adoles | scents on Antip          | osychotics               |                          |                       |
| 1 to 11 Years <sup>H</sup>                                  | NA                       | NA                       | NA                       |                       |
| 12 to 17 Years <sup>H</sup>                                 | 71.43%                   | 67.35%                   | 76.12%                   | ≥90th                 |
| Total <sup>H</sup>  | 72.00%                   | 64.41%                   | 76.54%                   | ≥90th                 |
| Use of Services   |                          |                          |                          |                       |
| Ambulatory Care: ED Visits                                  |                          |                          |                          |                       |
| <1 Year <sup>SA</sup>                                       | 46.19                    | 52.91                    | 59.42                    |                       |
| 1 to 9 Years <sup>SA</sup>                                  | 20.02                    | 26.61                    | 33.45                    |                       |
| 10 to 19 Years <sup>SA</sup>                                | 17.63                    | 21.04                    | 23.82                    |                       |
| 0 to 19 Years <sup>H</sup>                                  | 19.23                    | 24.09                    | 28.95                    |                       |

<sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that there was no benchmark for comparison.

BTSA indicates the reported rate was better than the statewide average.

WTSA indicates the reported rate was worse than the statewide average.

Rates shaded green with one caret (^) indicate a statistically significant improvement in performance from the previous year.



### **DHMP Trend Table**

| Table B-2—DHMP 1   |         |         |                  |            |
|--|---------|---------|------------------|------------|
|  | HEDIS   | HEDIS   | HEDIS            | Percentile |
| Performance Measures                                     | MY 2021 | MY 2022 | MY 2023          | Ranking    |
|  | Rate    | Rate    | Rate             |            |
| Primary Care Access and Preventive Care                  |         |         |                  |            |
| Child and Adolescent Well-Care Visits                    |         |         |                  |            |
| 3 to 11 Years <sup>H</sup>                               | 52.41%  | 46.24%  | 61.05%^          | 50th-74th  |
| 12 to 17 Years <sup>H</sup>                              | 46.37%  | 44.11%  | 51.79%^          | 50th-74th  |
| 18 to 21 Years <sup>H</sup>                              | 25.43%  | 28.88%  | 35.63%           | 75th-89th  |
| Total <sup>H</sup>                                       | 47.87%  | 43.71%  | 54.66%^          | 50th-74th  |
| Childhood Immunization Status                            |         |         |                  |            |
| $DTaP^{H}$   | 60.00%  | 81.58%  | 80.36%           | ≥90th      |
| $IPV^{H}$  | 68.00%  | 86.84%  | <b>67.86%</b> ^^ | <10th      |
| MMR <sup>H</sup>   | 78.00%  | 84.21%  | 91.07%           | ≥90th      |
| HiB <sup>H</sup>   | 74.00%  | 84.21%  | 73.21%           | <10th      |
| Hepatitis $B^H$  | 58.00%  | 89.47%  | 76.79%           | 10th-24th  |
| VZV <sup>H</sup>   | 76.00%  | 81.58%  | 91.07%           | ≥90th      |
| Hepatitis $A^H$  | 78.00%  | 81.58%  | 89.29%           | ≥90th      |
| Pneumococcal Conjugate <sup>H</sup>                      | 64.00%  | 81.58%  | 48.21%^^         | <10th      |
| Rotavirus <sup>H</sup>                                   | 54.00%  | 73.68%  | 42.86%^^         | <10th      |
| Influenza <sup>H</sup>                                   | 60.00%  | 55.26%  | 37.50%           | 25th-49th  |
| Combination 3 <sup>H</sup>                               | 52.00%  | 78.95%  | 82.14%           | ≥90th      |
| Combination 7 <sup>H</sup>                               | 48.00%  | 68.42%  | 75.00%           | ≥90th      |
| Combination $10^{H}$                                     | 44.00%  | 52.63%  | 51.79%           | ≥90th      |
| Chlamydia Screening in Women                             |         |         |                  |            |
| 16 to 20 Years <sup>H</sup>                              | 38.33%  | 42.31%  | 76.40%^          | ≥90th      |
| Developmental Screening in the First Three Years of Life |         |         |                  |            |
| 1 Year <sup>SA</sup>                                     |         | NA      | 62.07%           | WTSA       |
| 2 Years <sup>SA</sup>                                    |         | 75.00%  | 70.75%           | WTSA       |
| 3 Years <sup>SA</sup>                                    |         | 41.07%  | 66.67%^          | BTSA       |
| <i>Total</i> <sup>SA</sup>                               |         | 55.12%  | 66.78%^          | BTSA       |
| Immunizations for Adolescents                            |         |         |                  |            |
| Meningococcal <sup>H</sup>                               | 66.10%  | 83.45%  | 66.96%^^         | <10th      |
| Tdap <sup>H</sup>  | 66.10%  | 83.45%  | 72.17%^^         | <10th      |
| HPV <sup>H</sup>   | 43.50%  | 46.76%  | 41.74%           | 50th-74th  |
| Combination 1 <sup>H</sup>                               | 64.97%  | 82.73%  | 67.83%^^         | 10th-24th  |
| Combination 2 <sup>H</sup>                               | 42.94%  | 46.76%  | 40.87%           | 50th-74th  |
| Lead Screening in Children                               | i       |         |                  |            |
| Lead Screening in Children <sup>H</sup>                  |         | 61.54%  | 46.43%           | 10th-24th  |
|  |         |         |                  |            |

#### Table B-2—DHMP Trend Table



| Performance Measures   | HEDIS<br>MY 2021 | HEDIS<br>MY 2022 | HEDIS<br>MY 2023 | Percentile |
|--|------------------|------------------|------------------|------------|
| Performance Measures   | Rate             | Rate             | Rate             | Ranking    |
| Screening for Depression and Follow-Up Plan  | nate             | Nate             | nate             |            |
| 12 to 17 Years <sup>H</sup>  |                  | 33.60%           | 25.80%^^         | BTSA       |
| Weight Assessment and Counseling for Nutrition and Physical A                                  | Chivity for Cl   |                  |                  |            |
| BMI Percentile—3 to 11 Years <sup>H</sup>  | 71.28%           | 65.34%           | 75.81%^          | 25th-49th  |
| BMI Percentile—12 to 17 Years <sup>H</sup>   | 73.94%           | 63.89%           | 73.57%^          | 25th-49th  |
| BMI Percentile—Total <sup>H</sup>  | 72.47%           | 64.65%           | 74.80%^          | 25th-49th  |
| Counseling for Nutrition—3 to 11 Years <sup>H</sup>  | 79.22%           | 72.31%           | 81.68%^          | 75th-89th  |
| Counseling for Nutrition—12 to 17 Years <sup>H</sup>   | 75.89%           | 67.40%           | 73.86%^          | 50th-74th  |
| Counseling for Nutrition—Total <sup>H</sup>  | 77.72%           | 69.97%           | 78.17%^          | 75th-89th  |
| Counseling for Physical Activity—3 to 11 Years <sup>H</sup>                                    | 78.50%           | 70.92%           | 80.60%^          | 75th-89th  |
| Counseling for Physical Activity—12 to 17 Years <sup>H</sup>                                   | 75.89%           | 67.18%           | 73.27%^          | 50th-74th  |
| Counseling for Physical Activity—Total <sup>H</sup>  | 77.33%           | 69.13%           | 77.31%^          | 75th-89th  |
| Well-Child Visits in the First 30 Months of Life   |                  | l                |                  |            |
| Well-Child Visits in the First 15 Months of Life—Six or More<br>Well-Child Visits <sup>H</sup> | 50.00%           | NA               | 60.00%           | 50th–74th  |
| Well-Child Visits for Age 15 Months to 30 Months—Two or<br>More Well-Child Visits <sup>H</sup> | 63.29%           | 63.89%           | 57.14%           | <10th      |
| Maternal and Perinatal Health  |                  |                  |                  |            |
| Contraceptive Care—All Women   |                  |                  |                  |            |
| MMEC-15 to 20 Years <sup>SA</sup>  |                  | 9.32%            | 18.75%^          | BTSA       |
| LARC–15 to 20 Years <sup>SA</sup>  |                  | 1.43%            | 5.50%^           | BTSA       |
| Contraceptive Care—Postpartum Women  |                  |                  |                  |            |
| MMEC—15 to 20 Years—3 Days <sup>SA</sup>   |                  | NA               | NA               |            |
| MMEC—15 to 20 Years—90 Days <sup>SA</sup>  |                  | NA               | NA               |            |
| LARC-15 to 20 Years-3 Days <sup>SA</sup>   |                  | NA               | NA               |            |
| LARC—15 to 20 Years—90 Days <sup>SA</sup>  |                  | NA               | NA               |            |
| Prenatal and Postpartum Care   |                  | •                |                  |            |
| <i>Timeliness of Prenatal Care—Under Age 21<sup>H</sup></i>                                    |                  |                  | NA               |            |
| Postpartum Care—Under Age 21 <sup>H</sup>  |                  |                  | NA               |            |
| Care of Acute and Chronic Conditions   |                  |                  |                  |            |
| Asthma Medication Ratio  |                  |                  | 1                |            |
| 5 to 11 Years <sup>H</sup>   | NA               | NA               | NA               |            |
| 12 to 18 Years <sup>H</sup>  | NA               | NA               | NA               |            |
| 5 to 18 Years <sup>8A</sup>  | NA               | NA               | 60.00%           | WTSA       |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronch                                  | iolitis          | [                |                  |            |
| 3 Months to 17 Years <sup>H</sup>  |                  | NA               | NA               |            |
| Behavioral Health Care   |                  |                  |                  |            |
| Follow-Up After Emergency Department Visit for Mental Illness                                  | 5                | [                |                  |            |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>   |                  | NA               | NA               | —          |



| Performance Measures  | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| <i>30-Day Follow-Up</i> —6 to 17 Years <sup>H</sup>               |                          | NA                       | NA                       |                       |
| Follow-Up After Emergency Department Visit for Substance U        | se                       |                          |                          |                       |
| 7-Day Follow-Up—13 to 17 Years <sup>H</sup>                       |                          | NA                       | NA                       |                       |
| <i>30-Day Follow-Up—13 to 17 Years<sup>H</sup></i>                |                          | NA                       | NA                       |                       |
| Follow-Up After Hospitalization for Mental Illness                |                          |                          |                          |                       |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>                        | NA                       | NA                       | NA                       |                       |
| <i>30-Day Follow-Up</i> —6 to 17 Years <sup>H</sup>               | NA                       | NA                       | NA                       |                       |
| Follow-Up Care for Children Prescribed ADHD Medication            |                          |                          |                          |                       |
| Initiation Phase <sup>H</sup>                                     | NA                       | NA                       | NA                       |                       |
| Continuation and Maintenance Phase <sup>H</sup>                   | NA                       | NA                       | NA                       |                       |
| Metabolic Monitoring for Children and Adolescents on Antipsy      | vchotics                 |                          |                          |                       |
| Blood Glucose Testing—1 to 11 Years <sup>H</sup>                  |                          | NA                       | NA                       |                       |
| Blood Glucose Testing—12 to 17 Years <sup>H</sup>                 | NA                       | NA                       | NA                       |                       |
| Blood Glucose Testing—Total <sup>H</sup>                          | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—1 to 11 Years <sup>H</sup>                    |                          | NA                       | NA                       |                       |
| Cholesterol Testing—12 to 17 Years <sup>H</sup>                   | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—Total <sup>H</sup>                            | NA                       | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—1 to 11 Years <sup>H</sup>  |                          | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—12 to 17 Years <sup>H</sup> |                          | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—Total <sup>H</sup>          | NA                       | NA                       | NA                       |                       |
| Use of First-Line Psychosocial Care for Children and Adolesce     | ents on Antipsy          | vchotics                 |                          |                       |
| 1 to 11 Years <sup>H</sup>  |                          | NA                       | NA                       |                       |
| 12 to 17 Years <sup>H</sup>                                       |                          | NA                       | NA                       |                       |
| Total <sup>H</sup>  |                          | NA                       | NA                       |                       |
| Use of Services   |                          | <u> </u>                 | <u> </u>                 | <u> </u>              |
| Ambulatory Care: ED Visits  |                          |                          |                          |                       |
| <1 Year <sup>SA</sup>   | 34.29                    | 60.57                    | 56.35                    |                       |
| 1 to 9 Years <sup>SA</sup>  | 14.97                    | 25.11                    | 28.77                    |                       |
| 10 to 19 Years <sup><math>SA</math></sup>                         | 11.40                    | 11.61                    | 16.07                    |                       |
| 0 to 19 Years <sup>H</sup>  | 13.31                    | 18.25                    | 22.37                    |                       |

*NA* (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate. <sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that there was no benchmark for comparison.

BTSA indicates the reported rate was better than the statewide average.

WTSA indicates the reported rate was worse than the statewide average.

Rates shaded green with one caret ( $^{\circ}$ ) indicate a statistically significant improvement in performance from the previous year. Rates shaded red with two carets ( $^{\circ}$ ) indicate a statistically significant decline in performance from the previous year.



## **Kaiser Trend Table**

| Performance Measures                                     | HEDIS<br>MY 2021 | HEDIS<br>MY 2022 | HEDIS<br>MY 2023 | Percentile<br>Ranking |
|--|------------------|------------------|------------------|-----------------------|
|  | Rate             | Rate             | Rate             |                       |
| Primary Care Access and Preventive Care                  |                  |                  |                  |                       |
| Child and Adolescent Well-Care Visits                    |                  |                  |                  |                       |
| 3 to 11 Years <sup>H</sup>                               | 48.51%           | 46.98%           | 57.01%^          | 50th-74th             |
| 12 to 17 Years <sup>H</sup>                              | 41.81%           | 40.83%           | 47.91%^          | 25th-49th             |
| 18 to 21 Years <sup>H</sup>                              | 30.16%           | 26.69%           | 27.39%           | 50th-74th             |
| Total <sup>H</sup>                                       | 44.27%           | 42.70%           | 51.08%^          | 50th-74th             |
| Childhood Immunization Status                            |                  |                  | 1                |                       |
| $DTaP^{H}$   | 78.90%           | 71.88%           | 66.67%           | 25th-49th             |
| $IPV^{H}$  | 92.66%           | 85.42%           | 76.04%           | <10th                 |
| $MMR^{H}$  | 89.91%           | 84.38%           | 77.08%           | <10th                 |
| HiB <sup>H</sup>   | 91.74%           | 84.38%           | 78.13%           | 10th-24th             |
| Hepatitis B <sup>H</sup>                                 | 94.50%           | 88.54%           | 77.08%^^         | 10th-24th             |
| VZV <sup>H</sup>   | 88.99%           | 85.42%           | 77.08%           | <10th                 |
| Hepatitis $A^{H}$  | 90.83%           | 86.46%           | 80.21%           | 25th-49th             |
| Pneumococcal Conjugate <sup>H</sup>                      | 84.40%           | 78.13%           | 69.79%           | 25th-49th             |
| <i>Rotavirus<sup>H</sup></i>                             | 78.90%           | 72.92%           | 71.88%           | 50th-74th             |
| Influenza <sup>H</sup>                                   | 72.48%           | 60.42%           | 55.21%           | ≥90th                 |
| Combination $3^{H}$                                      | 77.06%           | 67.71%           | 58.33%           | 10th-24th             |
| Combination 7 <sup>H</sup>                               | 69.72%           | 60.42%           | 55.21%           | 25th-49th             |
| Combination $10^{H}$                                     | 56.88%           | 47.92%           | 39.58%           | 75th-89th             |
| Chlamydia Screening in Women                             |                  |                  |                  |                       |
| 16 to 20 Years <sup>H</sup>                              | 47.12%           | 38.61%           | 35.96%           | <10th                 |
| Developmental Screening in the First Three Years of Life |                  |                  |                  |                       |
| 1 Year <sup>SA</sup>                                     | <u> </u>         | 35.21%           | 56.34%^          | WTSA                  |
| 2 Years <sup>SA</sup>                                    |                  | 77.08%           | 80.21%           | BTSA                  |
| 3 Years <sup>SA</sup>                                    |                  | 65.09%           | 79.55%^          | BTSA                  |
| Total <sup>SA</sup>                                      |                  | 61.54%           | 73.33%^          | BTSA                  |
| mmunizations for Adolescents                             |                  | 01.01/0          | 13.3370          | 210/1                 |
| Meningococcal <sup>H</sup>                               | 81.02%           | 80.28%           | 75.31%           | 25th-49th             |
| Tdap <sup>H</sup>  | 87.35%           | 85.21%           | 85.19%           | 50th-74th             |
| $HPV^{H}$  | 43.67%           | 44.37%           | 42.39%           | 75th-89th             |

Table B-3—Kaiser Trend Table



| Performance Measures   | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|--|--------------------------|--------------------------|--------------------------|-----------------------|
| Combination $I^H$  | 80.12%                   | 79.58%                   | 75.31%                   | 25th-49th             |
| Combination $2^{H}$  | 42.47%                   | 43.31%                   | 40.74%                   | 50th-74th             |
| Lead Screening in Children   |                          |                          |                          |                       |
| Lead Screening in Children <sup>H</sup>  | _                        | 2.08%                    | 9.47%^                   | <10th                 |
| Screening for Depression and Follow-Up Plan  |                          |                          |                          |                       |
| 12 to 17 Years <sup>H</sup>  |                          | 1.00%                    | 2.83%                    | WTSA                  |
| Weight Assessment and Counseling for Nutrition and Physic                                      | al Activity fo           | or Children              | Adolescents/             |                       |
| BMI Percentile—3 to 11 Years <sup>H</sup>  | 91.40%                   | 90.55%                   | 95.23%^                  | ≥90th                 |
| BMI Percentile—12 to 17 Years <sup>H</sup>   | 89.91%                   | 90.57%                   | 92.46%                   | ≥90th                 |
| BMI Percentile—Total <sup>H</sup>  | 90.75%                   | 90.56%                   | 94.04%^                  | ≥90th                 |
| <i>Counseling for Nutrition—3 to 11 Years<sup>H</sup></i>                                      | 93.60%                   | 91.11%                   | 95.14%^                  | ≥90th                 |
| Counseling for Nutrition—12 to 17 Years <sup>H</sup>   | 91.70%                   | 91.74%                   | 92.46%                   | ≥90th                 |
| Counseling for Nutrition—Total <sup>H</sup>  | 92.77%                   | 91.40%                   | 93.99%                   | ≥90th                 |
| Counseling for Physical Activity—3 to 11 Years <sup>H</sup>                                    | 93.88%                   | 91.44%                   | 95.06%^                  | ≥90th                 |
| Counseling for Physical Activity—12 to 17 Years <sup>H</sup>                                   | 92.14%                   | 92.13%                   | 92.91%                   | ≥90th                 |
| Counseling for Physical Activity—Total <sup>H</sup>  | 93.12%                   | 91.75%                   | 94.14%                   | ≥90th                 |
| Well-Child Visits in the First 30 Months of Life   |                          |                          |                          |                       |
| Well-Child Visits in the First 15 Months of Life—Six or<br>More Well-Child Visits <sup>H</sup> | 16.67%                   | 23.61%                   | 50.00%^                  | 10th-24th             |
| Well-Child Visits for Age 15 Months to 30 Months—Two<br>or More Well-Child Visits <sup>H</sup> | 47.55%                   | 64.20%                   | 62.35%                   | 25th-49th             |
| Maternal and Perinatal Health  |                          |                          | <u> </u>                 |                       |
| Contraceptive Care—All Women   |                          |                          |                          |                       |
| MMEC—15 to 20 Years <sup>SA</sup>  |                          | 17.62%                   | 17.93%                   | WTSA                  |
| LARC–15 to 20 Years <sup>SA</sup>  |                          | 4.13%                    | 4.10%                    | BTSA                  |
| Contraceptive Care—Postpartum Women  |                          |                          | <u> </u>                 |                       |
| MMEC—15 to 20 Years—3 Days <sup>SA</sup>   |                          | NA                       | NA                       |                       |
| MMEC—15 to 20 Years—90 Days <sup>SA</sup>  |                          | NA                       | NA                       |                       |
| LARC–15 to 20 Years–3 Days <sup>SA</sup>   |                          | NA                       | NA                       |                       |
| LARC–15 to 20 Years–90 Days <sup>SA</sup>  |                          | NA                       | NA                       |                       |
| Prenatal and Postpartum Care   |                          |                          |                          |                       |
| Timeliness of Prenatal Care—Under Age 21 <sup>H</sup>  |                          |                          | 80.00%                   | BTSA                  |
| Postpartum Care—Under Age 21 <sup>H</sup>  |                          | NA                       | 84.00%                   | BTSA                  |



| Performance Measures  | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| Care of Acute and Chronic Conditions                              |                          |                          |                          |                       |
| Asthma Medication Ratio   |                          |                          |                          |                       |
| 5 to 11 Years <sup>H</sup>  | NA                       | NA                       | NA                       |                       |
| 12 to 18 Years <sup>H</sup>                                       | NA                       | NA                       | NA                       |                       |
| 5 to 18 Years <sup>H</sup>  | 91.18%                   | 80.00%                   | NA                       | —                     |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bron       | nchiolitis               |                          |                          |                       |
| 3 Months to 17 Years <sup>H</sup>                                 |                          | NA                       | 100.00%                  | ≥90th                 |
| Behavioral Health Care  |                          |                          |                          |                       |
| Follow-Up After Emergency Department Visit for Mental Illu        | ness                     |                          |                          |                       |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>                        |                          | NA                       | NA                       |                       |
| 30-Day Follow-Up—6 to 17 Years <sup>H</sup>                       |                          | NA                       | NA                       |                       |
| Follow-Up After Emergency Department Visit for Substance          | Use                      |                          | <u> </u>                 |                       |
| 7-Day Follow-Up—13 to 17 Years <sup>H</sup>                       |                          | NA                       | NA                       |                       |
| 30-Day Follow-Up—13 to 17 Years <sup>H</sup>                      |                          | NA                       | NA                       |                       |
| Follow-Up After Hospitalization for Mental Illness                |                          |                          | LL                       |                       |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>                        | NA                       | NA                       | NA                       |                       |
| 30-Day Follow-Up—6 to 17 Years <sup>H</sup>                       | NA                       | NA                       | NA                       |                       |
| Follow-Up Care for Children Prescribed ADHD Medication            |                          |                          | <u> </u>                 |                       |
| Initiation Phase <sup>H</sup>                                     | 37.14%                   | 54.84%                   | NA                       |                       |
| Continuation and Maintenance Phase <sup>H</sup>                   | NA                       | NA                       | NA                       |                       |
| Metabolic Monitoring for Children and Adolescents on Antip        | osychotics               |                          | LL                       |                       |
| Blood Glucose Testing—1 to 11 Years <sup>H</sup>                  |                          | NA                       | NA                       |                       |
| Blood Glucose Testing—12 to 17 Years <sup>H</sup>                 | NA                       | NA                       | NA                       |                       |
| Blood Glucose Testing—Total <sup>H</sup>                          | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—1 to 11 Years <sup>H</sup>                    |                          | NA                       | NA                       |                       |
| Cholesterol Testing—12 to 17 Years <sup>H</sup>                   | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—Total <sup>H</sup>                            | NA                       | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—1 to 11 Years <sup>H</sup>  |                          | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—12 to 17 Years <sup>H</sup> |                          | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—Total <sup>H</sup>          | NA                       | NA                       | NA                       |                       |
| Use of First-Line Psychosocial Care for Children and Adoles       | cents on An              | tipsychotics             | 5                        |                       |
| 1 to 11 Years <sup>H</sup>  |                          | NA                       | NA                       |                       |
| 12 to 17 Years <sup>H</sup>                                       | NA                       | NA                       | NA                       |                       |
| Total <sup>H</sup>  | NA                       | NA                       | NA                       |                       |



| Performance Measures         | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|------------------------------|--------------------------|--------------------------|--------------------------|-----------------------|
| Use of Services              |                          |                          |                          |                       |
| Ambulatory Care: ED Visits   |                          |                          |                          |                       |
| <1 Year <sup>SA</sup>        | 28.53                    | 48.00                    | 50.75                    |                       |
| 1 to 9 Years <sup>SA</sup>   | 14.96                    | 24.33                    | 26.77                    |                       |
| 10 to 19 Years <sup>SA</sup> | 12.32                    | 14.48                    | 15.13                    |                       |
| 0 to 19 Years <sup>H</sup>   | 13.70                    | 19.04                    | 20.83                    |                       |

 $^{H}$  indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that there was no benchmark for comparison.

BTSA indicates the reported rate was better than the statewide average.

WTSA indicates the reported rate was worse than the statewide average.

Rates shaded green with one caret ( $^{\circ}$ ) indicate a statistically significant improvement in performance from the previous year.

Rates shaded red with two carets (^^) indicate a statistically significant decline in performance from the previous year.



### **RMHP Trend Table**

|  | HEDIS   | HEDIS   | HEDIS    | Percentile                            |
|--|---------|---------|----------|---------------------------------------|
| Performance Measures                             | MY 2021 | MY 2022 | MY 2023  | Ranking                               |
|  | Rate    | Rate    | Rate     | i i i i i i i i i i i i i i i i i i i |
| Primary Care Access and Preventive Care          |         |         |          |                                       |
| Child and Adolescent Well-Care Visits            | F       | 1       |          |                                       |
| 3 to 11 Years <sup>H</sup>                       | 56.45%  | 51.14%  | 47.61%^^ | 10th-24th                             |
| 12 to 17 Years <sup><math>H</math></sup>         | 46.44%  | 46.15%  | 42.48%^^ | 10th-24th                             |
| 18 to 21 Years <sup>H</sup>                      | 30.69%  | 21.83%  | 32.46%^  | 75th-89th                             |
| <i>Total</i> <sup>H</sup>                        | 50.84%  | 47.14%  | 44.46%   | 25th-49th                             |
| Childhood Immunization Status                    |         |         |          |                                       |
| $DTaP^{H}$                                       | 54.86%  | 70.55%  | 70.19%   | 25th-49th                             |
| $IPV^{H}$  | 66.29%  | 81.51%  | 87.50%   | 50th-74th                             |
| $MMR^{H}$  | 75.43%  | 83.56%  | 87.50%   | 75th-89th                             |
| HiB <sup>H</sup>                                 | 70.29%  | 82.19%  | 83.65%   | 25th-49th                             |
| Hepatitis $B^H$                                  | 68.00%  | 80.14%  | 84.62%   | 25th-49th                             |
| VZV <sup>H</sup>                                 | 74.86%  | 84.93%  | 85.58%   | 50th-74th                             |
| Hepatitis $A^H$                                  | 71.43%  | 78.08%  | 76.92%   | 10th-24th                             |
| Pneumococcal Conjugate <sup>H</sup>              | 60.57%  | 73.97%  | 73.08%   | 50th-74th                             |
| <i>Rotavirus<sup>H</sup></i>                     | 62.86%  | 73.97%  | 75.96%   | 75th-89th                             |
| Influenza <sup>H</sup>                           | 56.57%  | 45.89%  | 45.19%   | 50th-74th                             |
| Combination 3 <sup>H</sup>                       | 52.00%  | 64.38%  | 64.42%   | 50th-74th                             |
| Combination 7 <sup>H</sup>                       | 49.14%  | 61.64%  | 59.62%   | 50th-74th                             |
| Combination 10 <sup>H</sup>                      | 42.86%  | 37.67%  | 37.50%   | 50th-74th                             |
| Chlamydia Screening in Women                     |         |         |          |                                       |
| 16 to 20 Years <sup>H</sup>                      | 35.05%  | 32.12%  | 28.04%   | <10th                                 |
| Developmental Screening in the First Three Years | of Life |         |          |                                       |
| 1 Year <sup>SA</sup>                             | 66.21%  | 63.33%  | 54.03%   | WTSA                                  |
| 2 Years <sup>SA</sup>                            | 64.80%  | 65.73%  | 59.62%   | WTSA                                  |
| 3 Years <sup>SA</sup>                            | 48.87%  | 51.58%  | 49.54%   | WTSA                                  |
| Total <sup>SA</sup>                              | 57.54%  | 58.87%  | 54.30%   | WTSA                                  |
| Immunizations for Adolescents                    |         | 1       | 1        |                                       |
| Meningococcal <sup>H</sup>                       | 70.02%  | 62.24%  | 65.41%   | <10th                                 |
| Tdap <sup>H</sup>                                | 82.77%  | 85.13%  | 80.14%   | 10th-24th                             |
| HPV <sup>H</sup>                                 | 36.69%  | 26.54%  | 31.51%   | 25th-49th                             |
| Combination 1 <sup>H</sup>                       | 68.90%  | 61.33%  | 64.73%   | <10th                                 |
| Combination $2^{H}$                              | 33.11%  | 22.43%  | 28.42%   | 10th-24th                             |
| Lead Screening in Children                       | I       | 1       | 1        |                                       |
| Lead Screening in Children <sup>H</sup>          |         | 35.37%  | 37.50%   | 10th-24th                             |

#### Table B-4—RMHP Trend Table



| Performance Measures   | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|--|--------------------------|--------------------------|--------------------------|-----------------------|
| Screening for Depression and Follow-Up Plan  |                          |                          |                          |                       |
| 12 to 17 Years <sup>H</sup>  | 6.81%                    | 9.17%                    | 10.12%                   | WTSA                  |
| Weight Assessment and Counseling for Nutrition and Physical A                                  | ctivity for C            | Child                    |                          |                       |
| BMI Percentile—3 to 11 Years <sup>H</sup>  | 17.32%                   | 19.72%                   | 16.53%^^                 | <10th                 |
| BMI Percentile—12 to 17 Years <sup>H</sup>   | 19.13%                   | 21.21%                   | 19.85%                   | <10th                 |
| BMI Percentile—Total <sup>H</sup>  | 18.06%                   | 20.36%                   | 18.02%                   | <10th                 |
| Counseling for Nutrition—3 to 11 Years <sup>H</sup>  | 30.42%                   | 25.84%                   | 26.06%                   | <10th                 |
| Counseling for Nutrition—12 to 17 Years <sup>H</sup>   | 22.68%                   | 21.73%                   | 22.72%                   | <10th                 |
| Counseling for Nutrition—Total <sup>H</sup>  | 27.26%                   | 24.06%                   | 24.57%                   | <10th                 |
| Counseling for Physical Activity—3 to 11 Years <sup>H</sup>                                    | 13.59%                   | 18.01%                   | 20.69%                   | <10th                 |
| Counseling for Physical Activity—12 to 17 Years <sup>H</sup>                                   | 15.22%                   | 19.17%                   | 20.10%                   | <10th                 |
| Counseling for Physical Activity—Total <sup>H</sup>  | 14.26%                   | 18.52%                   | 20.43%                   | <10th                 |
| Well-Child Visits in the First 30 Months of Life   |                          | 1                        | L                        |                       |
| Well-Child Visits in the First 15 Months of Life—Six or More<br>Well-Child Visits <sup>H</sup> | 26.79%                   | 41.18%                   | 66.23%^                  | 75th-89th             |
| Well-Child Visits for Age 15 Months to 30 Months—Two or<br>More Well-Child Visits <sup>H</sup> | 71.43%                   | 70.00%                   | 70.54%                   | 50th-74th             |
| Maternal and Perinatal Health  |                          |                          |                          |                       |
| Contraceptive Care—All Women   |                          |                          |                          |                       |
| MMEC-15 to 20 Years <sup>SA</sup>  | 24.39%                   | 20.88%                   | 22.42%                   | BTSA                  |
| LARC-15 to 20 Years <sup>SA</sup>  | 5.49%                    | 4.52%                    | 5.04%                    | BTSA                  |
| Contraceptive Care—Postpartum Women  |                          | 1                        | L                        |                       |
| MMEC—15 to 20 Years—3 Days <sup>SA</sup>   |                          | NA                       | NA                       |                       |
| MMEC—15 to 20 Years—90 Days <sup>SA</sup>  |                          | NA                       | NA                       |                       |
| LARC-15 to 20 Years-3 Days <sup>SA</sup>   |                          | NA                       | NA                       |                       |
| LARC-15 to 20 Years-90 Days <sup>SA</sup>  |                          | NA                       | NA                       |                       |
| Prenatal and Postpartum Care   |                          |                          |                          |                       |
| Timeliness of Prenatal Care—Under Age 21 <sup>H</sup>  |                          |                          | 54.17%                   | WTSA                  |
| Postpartum Care—Under Age 21 <sup>H</sup>  |                          |                          | 51.39%                   | BTSA                  |
| Care of Acute and Chronic Conditions   |                          |                          |                          |                       |
| Asthma Medication Ratio  |                          |                          |                          |                       |
| 5 to 11 Years <sup>H</sup>   | NA                       | NA                       | NA                       |                       |
| 12 to 18 Years <sup>H</sup>  | NA                       | NA                       | NA                       |                       |
| 5 to 18 Years <sup>SA</sup>  | 82.50%                   | 77.78%                   | NA                       |                       |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchi                                 | olitis                   |                          |                          |                       |
| 3 Months to 17 Years <sup>H</sup>  |                          | 81.16%                   | 87.10%                   | ≥90th                 |
| Behavioral Health Care   |                          |                          |                          |                       |
| Follow-Up After Emergency Department Visit for Mental Illness                                  |                          |                          |                          |                       |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>   |                          | NA                       | NA                       |                       |



| Performance Measures  | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| 30-Day Follow-Up—6 to 17 Years <sup>H</sup>                       |                          | NA                       | NA                       |                       |
| Follow-Up After Emergency Department Visit for Substance U        | lse                      |                          |                          |                       |
| 7-Day Follow-Up—13 to 17 Years <sup>H</sup>                       |                          | NA                       | NA                       |                       |
| <i>30-Day Follow-Up—13 to 17 Years<sup>H</sup></i>                |                          | NA                       | NA                       |                       |
| Follow-Up After Hospitalization for Mental Illness                |                          |                          |                          |                       |
| 7-Day Follow-Up—6 to 17 Years <sup>H</sup>                        | 35.48%                   | NA                       | NA                       |                       |
| 30-Day Follow-Up—6 to 17 Years <sup>H</sup>                       | 58.06%                   | NA                       | NA                       |                       |
| Follow-Up Care for Children Prescribed ADHD Medication            | - I                      |                          |                          |                       |
| Initiation Phase <sup>H</sup>                                     | 40.91%                   | 41.86%                   | 59.38%                   | ≥90th                 |
| Continuation and Maintenance Phase <sup>H</sup>                   | NA                       | NA                       | NA                       |                       |
| Metabolic Monitoring for Children and Adolescents on Antipsy      | vchotics                 |                          |                          |                       |
| Blood Glucose Testing—1 to 11 Years <sup>H</sup>                  | NA                       | NA                       | NA                       |                       |
| Blood Glucose Testing—12 to 17 Years <sup>H</sup>                 | NA                       | NA                       | NA                       |                       |
| Blood Glucose Testing—Total <sup>H</sup>                          | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—1 to 11 Years <sup>H</sup>                    | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—12 to 17 Years <sup>H</sup>                   | NA                       | NA                       | NA                       |                       |
| Cholesterol Testing—Total <sup>H</sup>                            | NA                       | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—1 to 11 Years <sup>H</sup>  |                          | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—12 to 17 Years <sup>H</sup> |                          | NA                       | NA                       |                       |
| Blood Glucose and Cholesterol Testing—Total <sup>H</sup>          | NA                       | NA                       | NA                       |                       |
| Use of First-Line Psychosocial Care for Children and Adolesco     | ents on Antips           | sychotics                |                          |                       |
| 1 to 11 Years <sup>H</sup>  | NA                       | NA                       | NA                       |                       |
| 12 to 17 Years <sup>H</sup>                                       | NA                       | NA                       | NA                       |                       |
| Total <sup>H</sup>  | NA                       | NA                       | NA                       |                       |
| Use of Services   |                          |                          |                          |                       |
| Ambulatory Care: ED Visits <sup>*,SA</sup>                        |                          |                          |                          |                       |
| <1 Year <sup>SA</sup>   | 2.55                     | 45.02                    | 26.07                    |                       |
| 1 to 9 Years <sup>SA</sup>  | 1.06                     | 17.53                    | 17.32                    |                       |
| 10 to 19 Years <sup>SA</sup>                                      | 1.26                     | 16.29                    | 15.94                    |                       |
| 0 to 19 Years <sup>H</sup>  | 1.20                     | 17.45                    | 16.76                    |                       |

*NA* (Small Denominator) indicates that the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate. <sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that there was no benchmark for comparison.

BTSA indicates the reported rate was better than the statewide average.

WTSA indicates the reported rate was worse than the statewide average.

Rates shaded green with one caret ( $^{\circ}$ ) indicate a statistically significant improvement in performance from the previous year. Rates shaded red with two carets ( $^{\circ}$ ) indicate a statistically significant decline in performance from the previous year.



### **DentaQuest Trend Table**

| Performance Measures                      | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Percentile<br>Ranking |
|---|--------------------------|--------------------------|--------------------------|-----------------------|
| Dental and Oral Health Services           |                          |                          |                          |                       |
| Oral Evaluation, Dental Services          |                          |                          |                          |                       |
| <1 Year                                   |                          | 3.85%                    | 3.68%                    |                       |
| 1 to 2 Years                              | _                        | 24.60%                   | 25.37%                   |                       |
| 3 to 5 Years                              |                          | 38.64%                   | 39.40%                   |                       |
| 6 to 7 Years                              |                          | 44.73%                   | 45.76%                   |                       |
| 8 to 9 Years                              |                          | 45.51%                   | 45.25%                   |                       |
| 10 to 11 Years                            |                          | 43.72%                   | 45.45%                   |                       |
| 12 to 14 Years                            |                          | 41.78%                   | 41.67%                   |                       |
| 15 to 18 Years                            |                          | 32.58%                   | 33.16%                   |                       |
| 19 to 20 Years                            |                          | 22.83%                   | 21.53%                   |                       |
| Total                                     |                          | 38.25%                   | 38.61%                   |                       |
| Sealant Receipt on Permanent First Molars |                          |                          |                          | 1                     |
| At Least One Sealant                      | 24.49%                   | 43.06%                   | 54.28%                   |                       |
| All Four Molars Sealed                    | 14.30%                   | 29.27%                   | 40.60%                   |                       |
| Topical Fluoride for Children             |                          |                          |                          | 1                     |
| Dental Services—1 to 2 Years              |                          | 21.39%                   | 19.31%                   |                       |
| Dental Services—3 to 5 Years              |                          | 26.41%                   | 24.63%                   |                       |
| Dental Services—6 to 7 Years              |                          | 28.90%                   | 25.17%                   |                       |
| Dental Services—8 to 9 Years              |                          | 30.16%                   | 26.49%                   |                       |
| Dental Services—10 to 11 Years            |                          | 28.06%                   | 24.47%                   | _                     |
| Dental Services—12 to 14 Years            |                          | 24.04%                   | 21.41%                   | _                     |
| Dental Services—15 to 18 Years            |                          | 17.67%                   | 15.87%                   | _                     |
| Dental Services—19 to 20 Years            |                          | 7.14%                    | 4.91%                    |                       |
| Dental Services—Total                     |                          | 24.19%                   | 21.37%                   |                       |

#### Table B-5—DentaQuest Trend Table

- indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that there was no benchmark for comparison.



### **Colorado CHP+ Weighted Averages Trend Table**

Given that the health plans varied in membership size, the statewide average rate for each measure was weighted by each health plan's eligible population for the measure. For the health plans with rates reported as *Small Denominator* (*NA*), the numerators, denominators, and eligible populations were included in the calculations of the statewide rate. Health plan rates reported as *Biased Rate* (*BR*) or *Not Reported* (*NR*) were excluded from the statewide rate calculation.

| Performance Measures                          | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Plan Rate<br>Range |
|---|--------------------------|--------------------------|--------------------------|--------------------|
| Primary Care Access and Preventive Care       |                          |                          |                          |                    |
| Child and Adolescent Well-Care Visits         |                          |                          |                          |                    |
| 3 to 11 Years                                 | 51.70%                   | 47.20%                   | 53.64%^                  | 47.61%-61.05%      |
| 12 to 17 Years                                | 43.73%                   | 40.79%                   | 45.78%^                  | 42.48%-51.79%      |
| 18 to 21 Years                                | 28.36%                   | 23.90%                   | 31.96%^                  | 27.39%-35.63%      |
| Total   | 46.98%                   | 42.88%                   | 49.73%^                  | 44.46%-54.66%      |
| Childhood Immunization Status                 |                          |                          |                          |                    |
| DTaP  | 68.97%                   | 68.49%                   | 75.39%^                  | 66.67%-80.36%      |
| IPV   | 81.54%                   | 81.75%                   | 86.74%^                  | 67.86%-88.99%      |
| MMR   | 82.96%                   | 81.39%                   | 86.47%^                  | 77.08%-91.07%      |
| HiB   | 82.35%                   | 80.90%                   | 85.69%^                  | 73.21%-87.53%      |
| Hepatitis B                                   | 81.24%                   | 78.35%                   | 86.56%^                  | 76.79%-88.43%      |
| VZV   | 81.95%                   | 81.27%                   | 86.74%^                  | 77.08%-91.07%      |
| Hepatitis A                                   | 80.02%                   | 79.32%                   | 84.47%^                  | 76.92%-89.29%      |
| Pneumococcal Conjugate                        | 74.54%                   | 72.51%                   | 76.44%^                  | 48.21%-79.33%      |
| Rotavirus                                     | 70.99%                   | 70.44%                   | 74.78%^                  | 42.86%-76.97%      |
| Influenza                                     | 63.29%                   | 51.70%                   | 51.13%                   | 37.50%-55.21%      |
| Combination 3                                 | 64.91%                   | 61.19%                   | 69.90%^                  | 58.33%-82.14%      |
| Combination 7                                 | 57.91%                   | 55.84%                   | 63.87%^                  | 55.21%-75.00%      |
| Combination 10                                | 48.48%                   | 39.54%                   | 42.32%                   | 37.50%-51.79%      |
| Chlamydia Screening in Women                  |                          |                          |                          |                    |
| 16 to 20 Years                                | 36.58%                   | 31.44%                   | 42.70%^                  | 28.04%-76.40%      |
| Developmental Screening in the First Three Ye | ars of Life              | •                        |                          |                    |
| 1 Year  | 66.21%                   | 48.58%                   | 65.95%^                  | 54.03%-68.95%      |
| 2 Years                                       | 64.80%                   | 44.82%                   | 71.04%^                  | 59.62%-80.21%      |
| 3 Years                                       | 48.87%                   | 27.99%                   | 58.68%^                  | 49.54%-79.55%      |
| Total   | 57.54%                   | 37.84%                   | 65.03%^                  | 54.30%-73.33%      |
| Immunizations for Adolescents                 |                          |                          |                          | a                  |
| Meningococcal                                 | 74.26%                   | 72.27%                   | 69.75%                   | 65.41%-75.31%      |

#### Table B-6—Colorado CHP+ Weighted Average Trend Table



| Performance Measures  | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Plan Rate<br>Range |
|---|--------------------------|--------------------------|--------------------------|--------------------|
| Tdap  | 82.09%                   | 82.94%                   | 80.34%                   | 72.17%-85.19%      |
| HPV   | 39.50%                   | 35.53%                   | 37.11%                   | 31.51%-42.39%      |
| Combination 1   | 73.38%                   | 71.47%                   | 69.02%                   | 64.73%-75.31%      |
| Combination 2   | 37.06%                   | 33.30%                   | 34.56%                   | 28.42%-40.87%      |
| Lead Screening in Children  |                          |                          |                          |                    |
| Lead Screening in Children  |                          | 29.78%                   | 39.01%^                  | 9.47%-46.43%       |
| Screening for Depression and Follow-Up Plan                                       |                          |                          |                          |                    |
| 12 to 17 Years  | 6.81%                    | 13.41%                   | 19.25%^                  | 2.83%-25.80%       |
| Weight Assessment and Counseling for Nutrition and Physica                        | al Activity fo           | r Children/A             | <b>I</b> dolescents      |                    |
| BMI Percentile—3 to 11 Years  | 24.90%                   | 26.56%                   | 30.16%^                  | 16.53%-95.23%      |
| BMI Percentile—12 to 17 Years   | 29.07%                   | 30.37%                   | 33.66%^                  | 19.85%-92.46%      |
| BMI Percentile—Total  | 26.61%                   | 28.21%                   | 31.64%^                  | 18.02%-94.04%      |
| Counseling for Nutrition—3 to 11 Years  | 26.83%                   | 29.85%                   | 38.71%^                  | 26.06%-95.14%      |
| Counseling for Nutrition—12 to 17 Years   | 26.80%                   | 29.52%                   | 35.03%^                  | 22.72%-92.46%      |
| Counseling for Nutrition—Total  | 26.82%                   | 29.71%                   | 37.15%^                  | 24.57%-93.99%      |
| Counseling for Physical Activity—3 to 11 Years                                    | 20.44%                   | 23.69%                   | 32.26%^                  | 19.31%-95.06%      |
| Counseling for Physical Activity—12 to 17 Years                                   | 23.36%                   | 26.77%                   | 31.32%^                  | 18.39%-92.91%      |
| Counseling for Physical Activity—Total  | 21.63%                   | 25.03%                   | 31.86%^                  | 18.93%-94.14%      |
| Well-Child Visits in the First 30 Months of Life                                  |                          |                          |                          |                    |
| Well-Child Visits in the First 15 Months of Life—Six or<br>More Well-Child Visits | 47.60%                   | 46.06%                   | 61.94%^                  | 50.00%-66.23%      |
| Well-Child Visits for Age 15 Months to 30 Months—Two<br>or More Well-Child Visits | 63.58%                   | 59.14%                   | 68.11%^                  | 57.14%-70.54%      |
| Maternal and Perinatal Health   |                          |                          |                          |                    |
| Contraceptive Care—All Women  |                          |                          |                          |                    |
| MMEC—15 to 20 Years   | 24.39%                   | 16.87%                   | 18.12%                   | 17.46%-22.42%      |
| LARC-15 to 20 Years   | 5.49%                    | 3.19%                    | 3.61%                    | 3.06%-5.50%        |
| Contraceptive Care—Postpartum Women   |                          |                          |                          |                    |
| MMEC—15 to 20 Years—3 Days  |                          | 0.00%                    | NA                       |                    |
| MMEC—15 to 20 Years—90 Days   |                          | 64.86%                   | NA                       |                    |
| LARC—15 to 20 Years—3 Days  |                          | 2.70%                    | NA                       |                    |
| LARC—15 to 20 Years—90 Days   |                          | 35.14%                   | NA                       |                    |
| Prenatal and Postpartum Care  |                          |                          |                          |                    |
| Timeliness of Prenatal Care—Under Age 21  |                          |                          | 59.86%                   | 54.17%-80.00%      |
| Postpartum Care—Under Age 21  | NA                       | NA                       | 61.97%                   | 51.39%-84.00%      |



| Performance Measures  | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Plan Rate<br>Range |
|---|--------------------------|--------------------------|--------------------------|--------------------|
| Care of Acute and Chronic Conditions                        |                          |                          |                          |                    |
| Asthma Medication Ratio                                     |                          |                          |                          |                    |
| 5 to 11 Years   | 82.33%                   | 67.95%                   | 75.00%                   | 73.72%             |
| 12 to 18 Years  | 70.80%                   | 55.22%                   | 59.38%                   | 59.38%             |
| 5 to 18 Years   | 76.42%                   | 61.64%                   | 67.98%                   | 60.00%-67.25%      |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bron | nchiolitis               |                          |                          |                    |
| 3 Months to 17 Years  | —                        | 82.81%                   | 79.47%                   | 75.00%-100.00%     |
| Behavioral Health Care                                      |                          |                          |                          |                    |
| Follow-Up After Emergency Department Visit for Mental Ill   | ness                     |                          |                          |                    |
| 7-Day Follow-Up—6 to 17 Years                               |                          | 58.54%                   | 65.83%                   | 75.31%             |
| 30-Day Follow-Up—6 to 17 Years                              |                          | 71.95%                   | 77.50%                   | 83.95%             |
| Follow-Up After Emergency Department Visit for Substance    | Use                      |                          |                          |                    |
| 7-Day Follow-Up—13 to 17 Years                              |                          | 26.83%                   | 23.40%                   | 22.22%             |
| 30-Day Follow-Up—13 to 17 Years                             |                          | 31.71%                   | 40.43%                   | 41.67%             |
| Follow-Up After Hospitalization for Mental Illness          | 1                        |                          |                          |                    |
| 7-Day Follow-Up—6 to 17 Years                               | 41.15%                   | 40.36%                   | 56.40%^                  | 55.28%             |
| 30-Day Follow-Up—6 to 17 Years                              | 58.85%                   | 75.90%                   | 71.56%                   | 76.40%             |
| Follow-Up Care for Children Prescribed Attention-Deficit/H  | yperactivity I           | Disorder Me              | dication                 |                    |
| Initiation Phase  | 32.05%                   | 38.64%                   | 43.55%                   | 41.45%-59.38%      |
| Continuation and Maintenance Phase                          | 40.79%                   | 53.33%                   | 49.43%                   |                    |
| Metabolic Monitoring for Children and Adolescents on Antip  | psychotics               |                          |                          |                    |
| Blood Glucose Testing—1 to 11 Years                         | NA                       | 41.94%                   | NA                       |                    |
| Blood Glucose Testing—12 to 17 Years                        | 56.45%                   | 53.91%                   | 61.22%                   | 58.14%             |
| Blood Glucose Testing—Total                                 | 53.02%                   | 51.57%                   | 56.78%                   | 54.90%             |
| Cholesterol Testing—1 to 11 Years                           | NA                       | 35.48%                   | NA                       |                    |
| Cholesterol Testing—12 to 17 Years                          | 29.84%                   | 26.56%                   | 31.63%                   | 27.91%             |
| Cholesterol Testing—Total                                   | 28.86%                   | 28.30%                   | 30.51%                   | 28.43%             |
| Blood Glucose and Cholesterol Testing—1 to 11 Years         | NA                       | 35.48%                   | NA                       |                    |
| Blood Glucose and Cholesterol Testing—12 to 17 Years        | 29.84%                   | 25.78%                   | 30.61%                   | 26.74%             |
| Blood Glucose and Cholesterol Testing—Total                 | 28.86%                   | 27.67%                   | 29.66%                   | 27.45%             |
| Use of First-Line Psychosocial Care for Children and Adoles | scents on Ant            | tipsychotics             |                          |                    |
| 1 to 11 Years   | NA                       | NA                       | NA                       |                    |
| 12 to 17 Years  | 69.49%                   | 68.25%                   | 72.00%                   | 76.12%             |
| Total   | 71.01%                   | 66.67%                   | 71.43%                   | 76.54%             |



| Performance Measures       | HEDIS<br>MY 2021<br>Rate | HEDIS<br>MY 2022<br>Rate | HEDIS<br>MY 2023<br>Rate | Plan Rate<br>Range |
|----------------------------|--------------------------|--------------------------|--------------------------|--------------------|
| Use of Services            |                          |                          |                          |                    |
| Ambulatory Care: ED Visits |                          |                          |                          |                    |
| <1 Year                    | 40.98                    | 51.67                    | 54.37                    | 59.42-26.07        |
| 1 to 9 Years               | 18.12                    | 24.90                    | 30.57                    | 33.45-17.32        |
| 10 to 19 Years             | 16.24                    | 19.01                    | 21.40                    | 23.82-15.13        |
| 0 to 19 Years              | 17.54                    | 22.19                    | 26.21                    | 28.95-16.76        |

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that there was no benchmark for comparison.

*Rates shaded green with one caret (^) indicate a statistically significant improvement in performance from the previous year.* 



#### **Appendix C. Information Systems Findings**

#### **Information Systems Findings**

NCQA's IS standards are the guidelines used by NCQA-certified HEDIS compliance auditors to assess the health plans' HEDIS reporting capabilities.<sup>15</sup> HSAG evaluated each health plan on six IS standards. To assess the health plans' adherence to standards, HSAG reviewed several documents for the CHP+ health plans, which included the Final Audit Reports (FARs) (generated by an NCQA-licensed audit organization [LO]), custom rate reporting templates, and audit review tables. The findings indicated that all health plans were fully compliant with all of NCQA's IS standards. For the health plans that were compliant, no issues were identified that resulted in material bias to the HEDIS measure results reported for the CHP+ population. These health plans accurately reported all Department-required HEDIS performance measures.

All the health plans contracted with a software vendor to produce the measure rates. The vendors submitted programming code developed for each HEDIS measure to NCQA for the measure certification process. Through certification, NCQA tested that the source code developed for the measures within the software produced valid results and the rate calculations met the technical specifications for the measures. Additionally, all the health plans' software vendors' non-HEDIS measures underwent source code review by the health plans' NCQA HEDIS Compliance Audit Licensed Organizations. The selected source codes were reviewed and approved for measure reporting.

Each Colorado CHP+ health plan contracted with a licensed HEDIS audit organization to perform the NCQA HEDIS Compliance Audit. The following table presents NCQA's IS standards and summarizes the audit findings related to each IS standard for the CHP+ health plans.

<sup>&</sup>lt;sup>15</sup> National Committee for Quality Assurance. *HEDIS Compliance Audit Standards, Policies and Procedures, Volume 5.* Washington D.C.



| NCQA's IS Standards   | HSAG's Findings Based on<br>HEDIS MY 2023 FAR Review   |
|---|--|
| <ul> <li>IS A—Administrative Data</li> <li>Data conform with industry standards and measure requirements.</li> <li>Data are complete and accurate.</li> <li>Membership information system enables measurement.</li> </ul>   | All health plans were fully compliant with IS<br>Standard A for administrative data. No issues or<br>concerns were noted for this standard relevant to<br>the selected Colorado CHP+ measures.<br>The health plans only accepted industry standard<br>codes on industry standard forms.<br>All data elements required for HEDIS reporting<br>were adequately captured.   |
| <ul> <li>IS M—Medical Record Review Processes</li> <li>Forms capture all fields relevant to measure reporting.<br/>Electronic transmission procedures conform to industry<br/>standards and have necessary checking procedures to<br/>ensure data accuracy (logs, counts, receipts, hand-off,<br/>and sign-off).</li> <li>Retrieval and abstraction of data from medical records<br/>are reliably and accurately performed.</li> <li>Data entry processes are timely and accurate and include<br/>sufficient edit checks to ensure accurate entry of<br/>submitted data in the files for measure reporting.</li> <li>The organization continually assesses data completeness<br/>and takes steps to improve performance.</li> <li>The organization regularly monitors vendor performance<br/>against expected performance standards.</li> </ul> | All health plans were fully compliant with IS<br>Standard M for medical record review processes.<br>No issues or concerns were noted for this standard<br>relevant to the selected Colorado CHP+ measures.<br>The health plans' data collection tools were able to<br>capture all data fields necessary for HEDIS<br>reporting. Sufficient validation processes were in<br>place to ensure data accuracy. However, HSAG did<br>not review this step since the State requires<br>administrative rates only. |
| <ul> <li>IS C—Clinical and Care Delivery Data</li> <li>Data capture is complete.</li> <li>Data conform with industry standards.</li> <li>Transaction file data are accurate.</li> <li>Organization confirms ingested data meet expectations for data quality.</li> </ul>  | All health plans were fully compliant with IS<br>Standard C for clinical and care delivery data. No<br>issues or concerns were noted for this standard<br>relevant to the selected Colorado CHP+ measures.<br>The health plans appropriately captured data and<br>met expectations for data quality for HEDIS<br>reporting.  |

#### Table C-1—Summary of Compliance With IS Standards





| NCQA's IS Standards  | HSAG's Findings Based on<br>HEDIS MY 2023 FAR Review  |
|--|---|
| <ul> <li>IS R—Data Management and Reporting</li> <li>The organization's data management enables measurement.</li> <li>Data extraction and loads are complete and accurate.</li> <li>Data transformation and integration are accurate and valid.</li> <li>Data quality and governance are components of the organization's data management.</li> <li>Oversight and controls ensure correct implementation of measure reporting software.</li> </ul> | All health plans were fully compliant with IS<br>Standard R for data management and reporting. No<br>issues or concerns were noted for this standard<br>relevant to the selected Colorado CHP+ measures.<br>The HEDIS repository contained all data fields<br>required for HEDIS reporting. In addition, staff<br>members were interviewed to confirm the<br>appropriate quality processes for the data source<br>and file consolidation performed by staff members.<br>Data were verified for accuracy at each data merge<br>point. The health plans used an NCQA-certified<br>measure vendor for data production and rate<br>calculation. |



## Appendix D. CHP+ Weighted Averages

Table D-1 shows the Colorado CHP+ weighted averages for MY 2021 through MY 2023 along with the percentile ranking for each MY 2023 rate. HEDIS rates for MY 2023 shaded green with one caret (^) indicate a statistically significant improvement in performance from the previous year. HEDIS rates for MY 2023 shaded red with two carets (^^) indicate a statistically significant decline in performance from the previous year. <sup>16</sup> For measures in the Use of Services domain, HSAG did not perform significance testing; therefore, differences in rates are reported here without significance testing. In addition, higher or lower rates do not necessarily indicate better or worse performance for the measures in the Use of Services domain.

| Performance Measures                               | MY 2021<br>Rate         | MY 2022<br>Rate | MY 2023<br>Rate       | MY 2023<br>Percentile<br>Ranking |
|--|-------------------------|-----------------|-----------------------|----------------------------------|
| Primary Care Access and Preventive Care            |                         |                 |                       |                                  |
| Child and Adolescent Well-Care Visits <sup>H</sup> |                         |                 |                       |                                  |
| Total  | 46.98%                  | 42.88%          | 49.73%^               | 50th-74th                        |
| Childhood Immunization Status <sup>H</sup>         |                         |                 |                       |                                  |
| Combination 3                                      | 64.91%                  | 61.19%          | 69.90%^               | 75th-89th                        |
| Combination 7                                      | 57.91%                  | 55.84%          | 63.87%^               | 75th-89th                        |
| Combination 10                                     | 48.48%                  | 39.54%          | 42.32%                | 75th-89th                        |
| Chlamydia Screening in Women <sup>H</sup>          |                         |                 |                       |                                  |
| 16 to 20 Years                                     | 36.58%                  | 31.44%          | 42.70%^               | 10th-24th                        |
| Developmental Screening in the First Three Years o | f Life                  |                 |                       |                                  |
| Total  | 57.54%                  | 37.84%          | 65.03%^               |                                  |
| Immunizations for Adolescents <sup>H</sup>         |                         |                 |                       |                                  |
| Combination 1                                      | 73.38%                  | 71.47%          | 69.02%                | 10th-24th                        |
| Combination 2                                      | 37.06%                  | 33.30%          | 34.56%                | 50th-74th                        |
| Lead Screening in Children <sup>H</sup>            |                         |                 |                       |                                  |
| Lead Screening in Children                         |                         | 29.78%          | 39.01%^               | 10th-24th                        |
| Screening for Depression and Follow-Up Plan        |                         |                 |                       |                                  |
| 12 to 17 Years                                     | 6.81%                   | 13.41%          | 19.25%^               |                                  |
| Weight Assessment and Counseling for Nutrition an  | d Physical Activity for | Children/Ado    | lescents <sup>H</sup> | ·                                |
| BMI Percentile—Total                               | 26.61%                  | 28.21%          | 31.64%^               | <10th                            |
| Counseling for Nutrition—Total                     | 26.82%                  | 29.71%          | 37.15%^               | <10th                            |

#### Table D-1—Colorado CHP+ Weighted Averages

<sup>&</sup>lt;sup>16</sup> HEDIS measure performance comparisons are based on the Chi-square test of statistical significance with a *p* value <0.05. A change in performance is considered statistically significant in this report if there was at least a 3-percentage point difference from MY 2022 to MY 2023.</p>



| Performance Measures  | MY 2021<br>Rate       | MY 2022<br>Rate | MY 2023<br>Rate | MY 2023<br>Percentile<br>Ranking |
|---|-----------------------|-----------------|-----------------|----------------------------------|
| Counseling for Physical Activity—Total  | 21.63%                | 25.03%          | 31.86%^         | <10th                            |
| Well-Child Visits in the First 30 Months of Life <sup>H</sup>                     |                       | T               | r.              |                                  |
| Well-Child Visits in the First 15 Months of Life—Six or<br>More Well-Child Visits | 47.60%                | 46.06%          | 61.94%^         | 50th-74th                        |
| Well-Child Visits for Age 15 Months to 30 Months—Two or<br>More Well-Child Visits | 63.58%                | 59.14%          | 68.11%^         | 50th–74th                        |
| Maternal and Perinatal Health   |                       |                 |                 |                                  |
| Contraceptive Care—All Women  |                       |                 |                 |                                  |
| MMEC—15 to 20 Years   | 24.39%                | 16.87%          | 18.12%          |                                  |
| LARC—15 to 20 Years   | 5.49%                 | 3.19%           | 3.61%           |                                  |
| Contraceptive Care—Postpartum Women   |                       |                 |                 |                                  |
| MMEC—15 to 20 Years—3 Days  | —                     | 0.00%           | NA              |                                  |
| MMEC—15 to 20 Years—90 Days   | —                     | 64.86%          | NA              |                                  |
| LARC—15 to 20 Years—3 Days  | —                     | 2.70%           | NA              |                                  |
| LARC—15 to 20 Years—90 Days   |                       | 35.14%          | NA              |                                  |
| Prenatal and Postpartum Care  |                       |                 |                 |                                  |
| Timeliness of Prenatal Care—Under Age 21  |                       |                 | 59.86%          |                                  |
| Postpartum Care—Under Age 21  |                       |                 | 50.00%          |                                  |
| Care of Acute and Chronic Conditions  |                       |                 |                 |                                  |
| Asthma Medication Ratio   |                       |                 |                 |                                  |
| 5 to 18 Years   | 76.42%                | 61.64%          | 67.98%          |                                  |
| Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronch                     | hiolitis <sup>H</sup> |                 |                 |                                  |
| 3 Months to 17 Years  |                       | 82.81%          | 79.47%          | 50th-74th                        |
| Behavioral Health Care  |                       |                 |                 |                                  |
| Follow-Up After Emergency Department Visit for Mental Illnes                      | ss <sup>H</sup>       |                 |                 |                                  |
| 7-Day Follow-Up—6 to 17 Years   |                       | 58.54%          | 65.83%          | 75th-89th                        |
| 30-Day Follow-Up—6 to 17 Years  |                       | 71.95%          | 77.50%          | 75th-89th                        |
| Follow-Up After Emergency Department Visit for Substance Us                       | se <sup>H</sup>       |                 |                 |                                  |
| 7-Day Follow-Up—13 to 17 Years  |                       | 26.83%          | 23.40%          | 50th-74th                        |
| 30-Day Follow-Up—13 to 17 Years   |                       | 31.71%          | 40.43%          | 75th-89th                        |
| Follow-Up After Hospitalization for Mental Illness <sup>H</sup>                   | 1                     | 1               |                 |                                  |
| 7-Day Follow-Up—6 to 17 Years   | 41.15%                | 40.36%          | 56.40%^         | 75th-89th                        |
| 30-Day Follow-Up—6 to 17 Years  | 58.85%                | 75.90%          | 71.56%          | 25th-49th                        |
| Follow-Up Care for Children Prescribed ADHD Medication <sup>H</sup>               |                       |                 |                 |                                  |
| Initiation Phase  | 32.05%                | 38.64%          | 43.55%          | 25th-49th                        |
| Continuation and Maintenance Phase  | 40.79%                | 53.33%          | 49.43%          | 25th-49th                        |



| MY 2021<br>Rate        | MY 2022<br>Rate  | MY 2023<br>Rate   | MY 2023<br>Percentile<br>Ranking   |
|------------------------|--|---|--|
| sychotics <sup>H</sup> |  |   |  |
| 53.02%                 | 51.57%   | 56.78%  | 50th-74th  |
| 28.86%                 | 28.30%   | 30.51%  | 25th-49th  |
| 28.86%                 | 27.67%   | 31.15%  | 25th-49th  |
| cents on Antip         | sychotics <sup>H</sup>   |   |  |
| 71.01%                 | 66.67%   | 71.43%  | 75th-89th  |
|                        | ·  |   |  |
|                        |  |   |  |
| 17.5                   | 22.1   | 26.2  |  |
|                        | Rate           sychotics <sup>H</sup> 53.02%           28.86%           28.86%           cents on Antip           71.01% | Rate         Rate           sychotics <sup>H</sup> 53.02%         51.57%           28.86%         28.30%         28.86%         27.67%           cents on Antipsychotics <sup>H</sup> 71.01%         66.67% | Rate         Rate         Rate           sychotics <sup>H</sup> 53.02%         51.57%         56.78%           28.86%         28.30%         30.51%           28.86%         27.67%         31.15%           cents on Antipsychotics <sup>H</sup> 71.01%         66.67%         71.43% |

<sup>*H*</sup> indicates that the measure is a HEDIS measure and can be compared to NCQA benchmarks.

<sup>SA</sup> indicates that the measure could only be compared to the statewide average.

— indicates that a percentile ranking was not determined because the rate was not reportable or there was a break in trending. This symbol may also indicate that the denominator was too small to report the rate or there was no benchmark for comparison.

NA (Small Denominator) indicates that the health plan followed the specifications, but the denominator was too small (<30) to report a valid rate.

Rates shaded green with one caret (^) indicate a statistically significant improvement in performance from the previous year.